<SEC-DOCUMENT>0001493152-18-010603.txt : 20180730
<SEC-HEADER>0001493152-18-010603.hdr.sgml : 20180730
<ACCEPTANCE-DATETIME>20180727191315
ACCESSION NUMBER:		0001493152-18-010603
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20180727
FILED AS OF DATE:		20180730
DATE AS OF CHANGE:		20180727
EFFECTIVENESS DATE:		20180730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OncoCyte Corp
		CENTRAL INDEX KEY:			0001642380
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				271041563
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37648
		FILM NUMBER:		18975820

	BUSINESS ADDRESS:	
		STREET 1:		1010 ATLANTIC AVENUE
		STREET 2:		SUITE 102
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94501
		BUSINESS PHONE:		510-775-0515

	MAIL ADDRESS:	
		STREET 1:		1010 ATLANTIC AVENUE
		STREET 2:		SUITE 102
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94501
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>def14a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 18pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
<FONT STYLE="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SCHEDULE
14A</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt"><B>(Rule 14a-101)</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
REQUIRED IN PROXY STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
14A INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9744;</FONT></FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
    Proxy Statement</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential,
    for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9746;</FONT></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
    Proxy Statement</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
    Additional Materials</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OncoCyte
Corporation</B></FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Person(s) Filing Proxy Statement if other than the Registrant)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of Filing Fee (Check the appropriate box):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 97%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    fee required.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
    computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 5%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 92%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class of securities to which transaction applies:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    number of securities to which transaction applies:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
    the filing fee is calculated and state how it was determined):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    maximum aggregate value of transaction:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fee paid:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 97%; padding-right: 0.8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
    paid previously with preliminary materials.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
    box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
    fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date
    of its filing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    previously paid:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form,
    schedule or registration statement no.:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    party:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    filed:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.7pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 0.79in; width: 2.5in"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
27, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Shareholder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are cordially invited to attend the Annual Meeting of Shareholders of OncoCyte Corporation which will be held on Monday, August
27, 2018 at 10:00 a.m. at OncoCyte&rsquo;s principal offices, 1010 Atlantic Avenue, Suite 102, Alameda, California 94501.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notice and Proxy Statement on the following pages contain details concerning the business to come before the meeting. Management
will report on current operations, and there will be an opportunity for discussion concerning OncoCyte and its activities. Please
sign and return your proxy card in the enclosed envelope to ensure that your shares will be represented and voted at the meeting
even if you cannot attend. You are urged to sign and return the enclosed proxy card even if you plan to attend the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
look forward to personally meeting all shareholders who are able to attend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_002.jpg" ALT="http:||content.edgar-online.com|edgar_conv_img|2017|04|28|0001493152-17-004565_IMAGE_002.JPG" STYLE="height: 39px; width: 152px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judith
Segall</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt">Secretary</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="img_003.jpg" ALT="" STYLE="height: 0.79in; width: 2.5in"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTICE
OF ANNUAL MEETING OF SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
Be Held August 27, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
IS HEREBY GIVEN that the Annual Meeting of Shareholders of OncoCyte Corporation will be held at OncoCyte&rsquo;s principal offices,
1010 Atlantic Avenue, Suite 102 Alameda, California on Thursday, August 27, 2018 at 10:00 a.m. for the following purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
To elect seven (7) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors
are duly elected and qualified. The nominees of the Board of Directors are: Ronald Andrews, William Annett, Andrew Arno, Alfred
D. Kingsley, Andrew J. Last, Aditya P. Mohanty, and Cavan Redmond;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
To ratify the appointment of OUM &amp; Co. LLP as OncoCyte&rsquo;s independent registered public accountants for the fiscal year
ending December 31, 2018;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
To approve a new Equity Incentive Plan (the &ldquo;Incentive Plan&rdquo;) that, if approved, will replace our current Employee
Stock Option Plan and will make 5,000,000 shares of common stock available for the grant of stock options or other stock related
equity; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
To approve an amendment to our Articles of Incorporation to increase the total number of authorized shares of common stock, no
par value, that we may issue from 50,000,000 shares to 85,000,000 shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
To transact such other business as may properly come before the meeting or any adjournments of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has fixed the close of business on July 12, 2018 as the record date for determining shareholders entitled to
receive notice of and to vote at the meeting or any postponement or adjournment of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not you expect to attend the meeting in person, you are urged to sign and date the enclosed form of proxy and return it promptly
so that your shares may be represented and voted at the meeting. If you should be present at the meeting, your proxy will be returned
to you if you so request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHETHER
OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE SUBMIT YOUR PROXY PROMPTLY BY FOLLOWING THE INSTRUCTIONS ON THE PROXY CARD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Important
Notice Regarding the Availability of Proxy Materials</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt"><B><U>for the Shareholder Meeting to be Held August 27, 2018.</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Letter to Shareholders, Notice of Meeting and Proxy Statement, and Annual Report on Form 10-K,</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt"><B>are available at: https://materials.proxyvote.com/68235C</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
Order of the Board of Directors,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_004.jpg" ALT="http:||content.edgar-online.com|edgar_conv_img|2017|04|28|0001493152-17-004565_IMAGE_004.JPG" STYLE="height: 39px; width: 156px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judith
Segall</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alameda, California</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 27, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROXY
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
MEETING OF SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
Be Held on Monday, August 27, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUESTIONS
AND ANSWERS ABOUT THE PROXY MATERIALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND
THE ANNUAL MEETING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
Why have I received this Proxy Statement?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are holding our Annual Meeting of Shareholders (the &ldquo;Meeting&rdquo;) for the purposes stated in the accompanying Notice
of Annual Meeting, which include (1) electing directors, (2) ratifying the appointment of our independent registered public accountants,
(3) approving approve a new Equity Incentive Plan (the &ldquo;Incentive Plan&rdquo;) that, if approved, will replace our current
Employee Stock Option Plan and will make 5,000,000 shares of common stock available for the grant of stock options or other stock
related equity; and; and (4) approving an amendment to our Articles of Incorporation to increase the total number of authorized
shares of common stock, no par value, that we may issue from 50,000,000 shares to 85,000,000 shares (the &ldquo;Articles Amendment
Proposal&rdquo;). At the Meeting, our management will also report on current operations, and there will be an opportunity for
discussion concerning OncoCyte and its activities. This Proxy Statement contains information about those matters, relevant information
about the Meeting, and other information that we are required to include in a Proxy Statement under the Securities and Exchange
Commission&rsquo;s (&ldquo;SEC&rdquo;) regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
Who is soliciting my proxy?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying proxy is solicited by the Board of Directors of OncoCyte Corporation, a California corporation having its principal
offices at 1010 Atlantic Avenue, Suite 102, Alameda, California 94501, for use at the Annual Meeting of Shareholders to be held
at 10:00 a.m. on Thursday, August 27, 2018 at OncoCyte&rsquo;s principal offices, 1010 Atlantic Avenue, Suite 102 Alameda, California
94501.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
Who is entitled to vote at the Meeting?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
shareholders of record at the close of business on July 12, 2018, which has been designated as the &ldquo;record date,&rdquo;
are entitled to notice of and to vote at the Meeting. On that date, there were 39,407,566 shares of OncoCyte common stock
issued and outstanding, which constitute the only class of OncoCyte voting securities outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
What percentage of the vote is required to elect directors or to approve the other matters that are being presented for a vote
by shareholders?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
will be elected by a plurality of the votes cast at the Meeting. Approval of the Articles Amendment Proposal requires the affirmative
vote of a majority of shares of our common stock issued, outstanding and entitled to vote on the record date. All other matter
to be presented for a vote at the Meeting will require the affirmative vote of a majority of the shares of common stock present
and voting on the matter, provided that the affirmative vote cast constitutes a majority of a quorum. A quorum consists of a majority
of the outstanding shares of common stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
How many votes do my shares represent?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of OncoCyte common stock is entitled to one vote in all matters that may be acted upon at the Meeting, except that shareholders
may elect to cumulate votes in the election of directors. Under cumulative voting, each shareholder may give one candidate, or
may distribute among two or more candidates, a number of votes equal to the number of directors to be elected multiplied by the
number of shares of common stock owned. Shareholders may not cumulate votes unless at least one shareholder gives notice of his
or her intention to cumulate votes at the Meeting. The enclosed proxy confers discretionary authority to cumulate votes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
What are my choices when voting?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the election of directors, you may vote for all nominees, or you may withhold your vote from one or more nominees. For each other
proposal described in this Proxy Statement, you may vote for the proposal, vote against the proposal, or abstain from voting on
the proposal. Properly executed proxies in the accompanying form that are received at or before the Meeting will be voted in accordance
with the directions noted on the proxies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
What if I abstain from voting on a matter?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you check the &ldquo;abstain&rdquo; box in the proxy form, or if you attend the Meeting without submitting a proxy and you abstain
from voting on a matter, or if your shares are subject to a &ldquo;broker non-vote&rdquo; on a matter, your shares will be deemed
to have not voted on that matter in determining whether the matter has received an affirmative vote sufficient for approval. Please
see &ldquo;What if I do not specify how I want my shares voted?&rdquo; below for additional information about broker non-votes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
Can I change my vote after I submit my proxy form?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may revoke your proxy at any time before it is voted. If you are a shareholder of record and you wish to revoke your proxy you
must do one of the following things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deliver
    to the Secretary of OncoCyte a written revocation; or</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deliver
    to the Secretary of OncoCyte a signed proxy bearing a date subsequent to the date of the proxy being revoked; or</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attend
    the Meeting and vote in person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a &ldquo;beneficial owner&rdquo; of shares &ldquo;held in street name&rdquo; you should follow the directions provided
by your broker or other nominee regarding how to revoke your proxy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
Can I still attend and vote at the Meeting if I submit a proxy?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may attend the Meeting and vote in person whether or not you have previously submitted a proxy. If you previously gave a proxy,
your attendance at the Meeting will not revoke your proxy unless you also vote in person at the Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a shareholder of record, you may vote your shares at the Meeting by completing a ballot at the Meeting. However, if you
are a &ldquo;street name&rdquo; holder, you may vote your shares in person only if you obtain a signed proxy from your broker
or nominee giving you the right to vote your shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if you currently plan to attend the Meeting, we recommend that you also submit your proxy first so that your vote will be counted
if you later decide not to attend the Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
What are the Board of Directors&rsquo; recommendations?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors recommends that our shareholders vote <B>FOR</B> (1) each nominee for election as a director, (2) approval
of the appointment of OUM &amp; Co., LLP as our independent registered public accountants for the fiscal year ending December
31, 2018, (3) approval of the adoption of the Incentive Plan, and (4) approval of the Articles Amendment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
What if I do not specify how I want my shares voted?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholders
of Record</I>. If you are a shareholder of record and you sign and return a proxy form that does not specify how you want your
shares voted on a matter, your shares will be voted <B>FOR</B> (1) each nominee for election as a director, (2) approval of the
appointment of OUM &amp; Co., LLP as our independent registered public accountants for the fiscal year ending December 31, 2018,
(3) approval of the adoption of the Incentive Plan, and (4) approval of the Articles Amendment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Beneficial
Owners</I>. If you are a beneficial owner and you do not provide your broker or other nominee with voting instructions, the broker
or other nominee will determine if it has the discretionary authority to vote on the particular matter. Under the rules of the
various national and regional securities exchanges, brokers and other nominees holding your shares may vote on certain routine
matters, including the approval of the appointment of our independent registered public accountants, but cannot vote in the election
of directors or with respect to the adoption of the new Incentive Plan. If you hold your shares in street name and you do not
instruct your broker or other nominee how to vote on those matters as to which brokers and nominees are not permitted to vote
without your instructions, no votes will be cast on your behalf on those matters. This is generally referred to as a &ldquo;broker
non-vote.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
What is the difference between holding shares as a shareholder of record and as a beneficial owner?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
of Record.</I> You are a shareholder of record if at the close of business on the record date your shares were registered directly
in your name with American Stock Transfer &amp; Trust Company, LLC, our transfer agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Beneficial
Owner.</I> You are a beneficial owner if at the close of business on the record date your shares were held in the name of a brokerage
firm or other nominee and not in your name. Being a beneficial owner means that, like most of our shareholders, your shares are
held in &ldquo;street name.&rdquo; As the beneficial owner, you have the right to direct your broker or nominee how to vote your
shares by following the voting instructions your broker or other nominee provides. If you do not provide your broker or nominee
with instructions on how to vote your shares, your broker or nominee will be able to vote your shares with respect to some of
the proposals, but not all. Please see &ldquo;What if I do not specify how I want my shares voted?&rdquo; above for additional
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
What if any matters not mentioned in the Notice of Annual Meeting or this Proxy Statement come up for vote at the Meeting?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors does not intend to present any business for a vote at the Meeting other than the matters set forth in the accompanying
Notice of Annual Meeting of Shareholders. As of the date of this Proxy Statement, no shareholder has notified us of any other
business that may properly come before the Meeting. If other matters requiring the vote of the shareholders properly come before
the Meeting, then it is the intention of the persons named in the accompanying form of proxy to vote the proxy held by them in
accordance with their judgment on such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
enclosed proxy confers discretionary authority to vote with respect to any and all of the following matters that may come before
the Meeting: (1) matters that the Board of Directors did not know, a reasonable time before the mailing of the notice of the Meeting,
would be presented at the Meeting; and (2) matters incidental to the conduct of the Meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
Who will bear the cost of soliciting proxies for use at the Meeting?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoCyte
will bear all of the costs of the solicitation of proxies for use at the Meeting. In addition to the use of the mails, proxies
may be solicited by a personal interview, telephone, and telegram by our directors, officers, and employees, who will undertake
such activities without additional compensation. Banks, brokerage houses, and other institutions, nominees, or fiduciaries will
be requested to forward the proxy materials to the beneficial owners of the common stock held of record by such persons and entities
and will be reimbursed for their reasonable expense incurred in connection with forwarding such material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Q:
How can I attend and vote at the Meeting?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you plan on attending the Meeting in person, please read the &ldquo;How to Attend the Annual Meeting&rdquo; section of this Proxy
Statement for information about the documents you will need to bring with you to gain admission to the Meeting and to vote your
shares in person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Proxy Statement and the accompanying form of proxy are first being sent or given to our shareholders on or about July 31,
2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ELIMINATING
DUPLICATE MAILINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoCyte
has adopted a procedure called &ldquo;householding.&rdquo; Under this procedure, we may deliver a single copy of this Proxy Statement
and our Annual Report to multiple shareholders who share the same address, unless we receive contrary instructions from one or
more of the shareholders. This procedure reduces the environmental impact of our annual meetings and reduces our printing and
mailing costs. We will deliver separate copies of the Proxy Statement and Annual Report to each shareholder sharing a common address
if they notify us that they wish to receive separate copies. If you wish to receive a separate copy of the Proxy Statement, or
Annual Report, you may contact us by telephone at (510) 775-0515, or by mail at 1010 Atlantic Avenue, Suite 102, Alameda, California
94501. You may also contact us at the above phone number or address if you are presently receiving multiple copies of the Proxy
Statement, and Annual Report but would prefer to receive a single copy instead.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ELECTION
OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Meeting, seven (7) directors will be elected to hold office until the next Annual Meeting of Shareholders, and until their
successors have been duly elected and qualified. All the nominees named below, Ronald Andrews, William Annett, Andrew Arno, Alfred
D. Kingsley, Andrew Last, Aditya Mohanty, and Cavan Redmond, are incumbent directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the intention of the persons named in the enclosed proxy, unless the proxy specifies otherwise, to vote the shares represented
by such proxy <B>FOR</B> the election of the nominees listed below. In the unlikely event that any nominee should be unable to
serve as a director, proxies may be voted in favor of a substitute nominee designated by the Board of Directors. If you are a
beneficial owner of shares held in street name, your broker or other nominee will not be allowed to vote in the election of directors
unless you instruct your broker or other nominee how to vote on the form that the broker or nominee provided to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names and ages of our directors who are nominees for re-election are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ronald
Andrews</B>, 59, joined our Board of Directors in April 2018. Mr. Andrews is the founder and principal of the Bethesda
Group, a consulting firm that advises companies in the molecular diagnostics and genomics fields. Prior to founding the Bethesda
Group in 2015, Mr. Andrews served as President, Genetic Sciences Division of Thermo Fisher Scientific from September 2013 to December
2014, and as President, Medical Sciences Venture for Life Technologies from February 2012 to September 2013 when Life Technologies
was acquired by Thermo Fisher. From 2004 to December 2010, Mr. Andrews was the Chief Executive Officer and Vice Chairman of the
Board of Clarient, Inc., a cancer diagnostics company, and from December 2010 to February 2012 he served as CEO of GE Molecular
Diagnostics after Clarient was acquired by GE Healthcare. Mr. Andrews also held management positions with companies in diagnostics
and related medical fields, including Roche Molecular Diagnostics, Immucor, Inc. and Abbott Labs. Mr. Andrews also serves as a
director of Orion Health Group Ltd., Oxford ImmunoTec. Mr. Andrews is also a member of the Board of Governors of CancerLinQ LLC,
a wholly-owned non-profit subsidiary of the American Society of Clinical Oncology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Andrews has over 30 years of experience in the molecular diagnostics and genomics industries, including experience integrating
companies acquired in mergers., He also oversaw the transition of Clarient, Inc. into GE Healthcare and established a strategic
plan to integrate In Vivo and In Vitro and expand GE&rsquo;s presence in oncology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>William
Annett</B>, 64, joined OncoCyte as Chief Executive Officer in June 2015. Prior to becoming our Chief Executive Officer, Mr. Annett
was a Managing Director at Accenture from 2011 to 2014, where he founded, built, and headed Accenture&rsquo;s West Coast Life
Sciences practice with sales, marketing, and delivery responsibilities for the entire territory. His clients included most of
the major biotech and pharmaceutical companies in the western United States. At Genentech, from 2003 until 2011, Mr. Annett led
the Commercial Strategy group and managed large operational projects with several hundred team members. He also directed the Project
Finance function for research and development, which supported all development pipeline products with more than 200 clinical trials.
In 2001 Mr. Annett founded and until 2003 served as CEO of Corra Life Sciences, a prenatal diagnostics company, which worked with
a consortium of universities to develop blood tests for the major diseases of pregnancy. Mr. Annett also previously served as
Chief Executive Officer of BioFX Laboratories, Inc. from 1999 to 2000. Early in his career, Mr. Annett also founded a consumer
products company, which he led for six years as Chief Executive Officer. During his tenure, the company became publicly traded
on NASDAQ and was then acquired. Mr. Annett holds an MBA from the Harvard Business School.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Annett brings to our Board his years of senior management experience overseeing the development and commercialization of products
and services in the life sciences, pharmaceutical and diagnostics industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Andrew
Arno</B>, 59, joined our Board of Directors in June 2015 and has 30 years of experience working with emerging growth companies.
He is currently Vice Chairman of &ldquo;The Special Equities Group&rdquo; at Chardan Capital Markets, LLC, a privately held investment
banking firm, and from June 2013 until July 2015 served as Managing Director of Emerging Growth Equities, an investment bank,
and Vice President of Sabr, Inc., a family investment group. He was previously President of LOMUSA Limited, an investment banking
firm. From 2009 to 2012, Mr. Arno served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment
advisory firm that he co-founded. He was also Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment
banking firm, and served on the board of the parent company, Merriman Holdings, Inc. Mr. Arno currently serves on the boards of
directors of Smith Micro Software, Inc. and Asterias Biotherapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Arno brings over 30 years&rsquo; experience handling a wide range of corporate and financial matters and his background as an
investment banker and strategic advisor to emerging growth companies qualifies him to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alfred
D. Kingsley</B>, 75, joined the Board of Directors during September 2009 and served as Chairman of the Board from December 2010
until April 2018. Mr. Kingsley is also the Chairman of the Board of Directors of BioTime, Inc. Mr. Kingsley has been general partner
of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993.
Greenbelt Corp. served as BioTime&rsquo;s financial advisor from 1998 until June 30, 2009. Mr. Kingsley was Senior Vice-President
of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley is also a director of Asterias Biotherapeutics,
Inc. Mr. Kingsley holds a BS degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree
and LLM in taxation from New York University Law School.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Kingsley&rsquo;s long career in corporate finance and mergers and acquisitions includes substantial experience in helping companies
to improve their management and corporate governance, and to restructure their operations in order to add value for shareholders.
As Chairman of the Board of our former parent company BioTime, Mr. Kingsley has been instrumental in structuring BioTime&rsquo;s
equity and debt financings and the business acquisitions that have helped BioTime expand the scope of its business. Mr. Kingsley,
along with entities that he controls, is currently one of the largest shareholders of BioTime.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Andrew
J. Last</B>, 58, joined the Board of Directors during December 2015. In January of 2018, Dr. Last was appointed as Chief Commercial
Officer at Berkeley Lights. Berkeley Lights is enabling cell by cell selection and manipulation to empower development, antibody
discovery and engineering for personalized therapies. Previously, he served as Chief Operating Officer of Intrexon Corporation.
From 2010 to 2016, Dr. Last was Executive Vice President and Chief Operating Officer of Affymetrix. Before joining Affymetrix,
Dr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from
2004 to 2010. From 2002 to 2004, Dr. Last held management positions at Applied Biosystems, Inc., including as Vice President and
General Manager from 2003-2004 and Vice President of Marking 2002-2003. Earlier in his career, he served in a variety of management
positions at other companies, including Incyte Genomics and Monsanto. Dr. Last holds Ph. D. and MS degrees with specialization
in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences
from the University of Leicester in the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Last shares with our Board his many years of senior management experience commercializing products internationally in the genomics
and life-sciences industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aditya
P. Mohanty</B>, 51, joined the Board of Directors during April 2015. Mr. Mohanty was appointed Co-Chief Executive Officer of BioTime,
Inc. during October 2015, after serving as BioTime&rsquo;s Chief Operating Officer since December 2014. Mr. Mohanty is also a
member of BioTime&rsquo;s Board of Directors. Mr. Mohanty previously served in a number of executive positions at Shire plc, including
as President/Head Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations from 2012
to 2013, as Global Franchise Head MPS from 2010 to 2012, and as Vice President of Operations/Product General Manager from 2005
to 2012. Shire plc is a biotechnology company focused on research, development and commercialization of novel biological products
for rare diseases. Mr. Mohanty was VP of Manufacturing and Operations at Transkaryotic Therapies, Inc. from 2002 to 2005 when
it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions at Baxter
Healthcare Corporation, Bioscience Division from 1990 to 2002. Mr. Mohanty also serves as a director of Asterias Biotherapeutics,
Inc. Mr. Mohanty received an MBA degree from Saint Mary&rsquo;s College, an MS in Chemical Engineering from Clarkson University,
and a B. Tech in Chemical Engineering from REC Trichy, in India.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Mohanty brings to our Board his years of experience as an executive in the pharmaceutical industry, with particular emphasis on
product development and manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cavan
Redmond</B>, 57, joined our Board of Directors in August of 2015 and was appointed Chairman of the Board during April 2018. Since
2014, Mr. Redmond has served as Partner for Zarsy, LLC. Mr. Redmond served as Chief Executive Officer of WebMD from May 2012 until
May 2013. From August 2011 until May 2012, Mr. Redmond served as Group President, Animal Health, Consumer Healthcare and Corporate
Strategy of Pfizer Inc., a pharmaceutical company. He served as Pfizer&rsquo;s Group President, Animal Health, Consumer Healthcare,
Capsugel and Corporate Strategy from December 2010 until August 2011 and as its Senior Vice President and Group President, Pfizer
Diversified Businesses from October 2009 until December 2010. Prior to Pfizer&rsquo;s acquisition of Wyeth, a pharmaceutical company,
Mr. Redmond served as President, Wyeth Consumer Healthcare and Animal Health Business from May 2009 until October 2009. Before
that, he held the positions of President, Wyeth Consumer Healthcare from December 2007 until May 2009 and Executive Vice President
and General Manager, BioPharma, Wyeth Pharmaceuticals from 2003 until December 2007. Mr. Redmond also serves as a director of
BioTime, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Redmond brings to our Board his years of experience as a senior executive in the pharmaceutical and veterinary products industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has determined that Ronald Andrews, Andrew Arno, Andrew Last, and Cavan Redmond qualify as &ldquo;independent,&rdquo;
and that Don M. Bailey, who served as a director until November 2107, qualified as &ldquo;independent,&rdquo; in accordance with
Section 803(A) of the NYSE American Company Guide. The members of our Audit Committee meet the additional independence standards
under Section 803(B)(2) of the NYSE American Company Guide and Section 10A-3 under the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), and the members of our Compensation Committee meet the additional independence standards under
Section 805(c)(1) of the NYSE American Company Guide. Our independent directors received no compensation or remuneration for serving
as directors except as disclosed under &ldquo;CORPORATE GOVERNANCE&mdash;Compensation of Directors.&rdquo; None of these directors,
nor any of the members of their families, have participated in any transaction with us that would disqualify them as &ldquo;independent&rdquo;
directors under the standards described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
Annett does not qualify as independent because he is our full-time employee, Aditya Mohanty does not qualify as &ldquo;independent&rdquo;
because within the past three years he received compensation from our former parent BioTime as an executive officer, and Alfred
D. Kingsley does not qualify as &ldquo;independent&rdquo; because within the past three years he received compensation for serving
as our Executive Chairman.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORPORATE
GOVERNANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors&rsquo;
Meetings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal year ended December 31, 2017, our Board of Directors met 14 times. None of our current directors attended fewer than
75% of the meetings of the Board and the committees on which they served.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
are also encouraged to attend our annual meetings of shareholders, although they are not formally required to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meetings
of Non-Management Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
non-management directors meet no less frequently than quarterly in executive session, without any directors who are OncoCyte officers
or employees present. These meetings allow the non-management directors to engage in open and frank discussions about corporate
governance and about our business, operations, finances, and management performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
Communications with Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you wish to communicate with the Board of Directors or with individual directors, you may do so by following the procedure described
on our website <I><U>www.oncocyte.com</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Business Conduct and Ethics (&ldquo;Code of Ethics&rdquo;) that applies to our principal executive officers,
our principal financial officer and accounting officer, our other executive officers, and our directors. The purpose of the Code
of Ethics is to promote (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest
between personal and professional relationships; (ii) full, fair, accurate, timely, and understandable disclosure in reports and
documents that we file with or submit to the SEC and in our other public communications; (iii) compliance with applicable governmental
rules and regulations; (iv) prompt internal reporting of violations of the Code of Ethics to an appropriate person or persons
identified in the Code of Ethics; and (v) accountability for adherence to the Code of Ethics. A copy of our Code of Ethics has
been posted on our internet website and can be found at <I><U>www.oncocyte.com</U></I>. We intend to disclose any future amendments
to certain provisions of our Code of Ethics, and any waivers of those provisions granted to our principal executive officers,
principal financial officer, principal accounting officer or controller or persons performing similar functions, by posting the
information on our website within four business days following the date of the amendment or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Leadership Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
leadership structure bifurcates the roles of Chief Executive Officer and Chairman of the Board. In other words, although William
Annett is our Chief Executive Officer and is a member of our Board, Cavan Redmond currently serves as Chairman of the Board. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 9.5pt">The
Company believes that the Chairman can provide support and advice to the Chief Executive Officer, and lead the Board in fulfilling
its responsibilities.</FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairman
of the Board serves as an active liaison between the Board and our Chief Executive Officer and our other senior management. The
Chairman of the Board also interfaces with our other non-management directors with respect to matters such as the members and
chairs of Board committees, other corporate governance matters, and strategic planning. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Board&rsquo;s Role in Risk Management</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has an active role, as a whole, in overseeing management of the risks of our business. The Board regularly reviews information
regarding our credit, liquidity, and operations, as well as the risks associated with our research and development activities
and our plans to expand our business. The Audit Committee provides oversight of our financial reporting processes and the annual
audit of our financial statements. In addition, the Nominating/Corporate Governance Committee reviews and must approve any business
transactions between OncoCyte and its executive officers, directors, and shareholders who beneficially own 5% or more of our outstanding
shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has an Audit Committee, a Compensation Committee, and a Nominating/Corporate Governance Committee, the members
of which are independent in accordance with Section 803(A) of the NYSE American Company Guides and Section 10A-3 under the Exchange
Act. The members of the Audit Committee and Compensation Committee must also meet the independence tests applicable to members
of those committees under the NYSE American Company Guide. We also have a Science &amp; Technology Committee and a Finance Committee,
the members of which need not be independent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Audit
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of the Audit Committee are Andrew Arno (Chairman), Ronald Andrews, Andrew J. Last, and Cavan Redmond. Mr. Andrews joined
the Audit Committee during April 2018. During 2017, Don M. Bailey served on the Audit Committee. The Audit Committee held six
meetings during 2017. The purpose of the Audit Committee is to recommend the engagement of our independent registered public accountants,
to review their performance and the plan, scope, and results of the audit, and to review and approve the fees we pay to our independent
registered public accountants. The Audit Committee also will review our accounting and financial reporting procedures and controls.
The Audit Committee has a written charter that requires the members of the Audit Committee to be directors who are independent
in accordance with Section 803(A) and Section 803(B) of the NYSE American Company Guide and Section 10A-3 under the Exchange Act.
A copy of the Audit Committee Charter has been posted on our internet website and can be found at <I><U>www.oncocyte.com</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has determined that Andrew Arno meets the criteria of an &ldquo;audit committee financial expert&rdquo; within
the meaning of the SEC&rsquo;s regulations based on his many years of experience in the investment banking industry, and his audit
committee service at another company, including the evaluation of financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of the Compensation Committee are Ronald Andrews (Chairman), Andrew Arno, Andrew J. Last, and Cavan Redmond. Mr. Andrews
joined the Compensation Committee during April 2018. The Compensation Committee met six times during 2017. All of the members
of the Compensation Committee qualify as &ldquo;independent&rdquo; in accordance with Section 803(A) and Section 805(c)(1) of
the NYSE American Company Guide. The Compensation Committee oversees our compensation and employee benefit plans and practices,
including executive compensation arrangements and incentive plans and awards of stock options and other equity-based awards under
our Option Plan. The Compensation Committee will determine or recommend to the Board of Directors the terms and amount of executive
compensation and grants of equity-based awards to executives, key employees, consultants, and independent contractors. The Chief
Executive Officer may make recommendations to the Compensation Committee concerning executive compensation and performance, but
the Compensation Committee makes its own determination or recommendation to the Board of Directors with respect to the amount
and components of compensation, including salary, bonus and equity awards to executive officers, generally taking into account
factors such as company performance, individual performance, and compensation paid by peer group companies. A copy of the Compensation
Committee Charter has been posted on our internet website and can be found at <I><U>www.oncocyte.com</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoCyte
has engaged Barney &amp; Barney to provide compensation consulting services and advice to management and the Compensation Committee,
which has generally included market survey information and competitive market trends in employee, executive and directors&rsquo;
compensation programs. Barney &amp; Barney has also made recommendations to the Compensation Committee with respect to pay mix
components such as salary, bonus, equity awards and the target market pay percentiles in which executive compensation should fall
so OncoCyte can be competitive in executive hiring and retention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Report
of the Audit Committee on the Audit of Our Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following is the report of the Audit Committee with respect to OncoCyte&rsquo;s audited financial statements for the year ended
December 31, 2017.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Don
M. Bailey also served on the Audit Committee during 2017. Mr. Bailey resigned from the Board and the Audit Committee during November
2017. Ronald Andrews jointed the Audit Committee during April 2018 when he became a member of our Board of Directors. Accordingly,
Mr. Andrews did not participate in the review of our financial statements included in our Annual Report on Form 10-K for the year
ended December 31, 2107, and did not participate in discussions with our independent registered public accountants concerning
those financial statements or other matters as described below.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
information contained in this report shall not be deemed &ldquo;soliciting material&rdquo; or otherwise considered &ldquo;filed&rdquo;
with the SEC, and such information shall not be incorporated by reference into any future filing under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), or the Exchange Act, except to the extent that OncoCyte specifically incorporates
such information by reference in such filing.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of the Audit Committee held discussions with our management and representatives of OUM &amp; Co., LLP, our independent
registered public accountants, concerning the audit of our financial statements for the year ended December 31, 2017. The independent
public accountants are responsible for performing an independent audit of our financial statements and issuing an opinion on the
conformity of those audited financial statements with generally accepted accounting principles in the United States. The Audit
Committee does not itself prepare financial statements or perform audits, and its members are not auditors or certifiers of OncoCyte&rsquo;s
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee members reviewed and discussed with management and representatives of the auditors the audited financial statements
contained in our Annual Report on Form 10-K for the year ended December 31, 2017. Our auditors also discussed with the Audit Committee
the adequacy of OncoCyte&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee members discussed with the auditors the matters required to be discussed by Statement on Auditing Standards No.
61 (Communications with Audit Committees). Our auditors submitted to the Audit Committee the written disclosures and the letter
mandated by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant&rsquo;s
communications with the Audit Committee concerning independence. Based on the reviews and discussions referred to above, the Audit
Committee unanimously approved the inclusion of the audited financial statements in our Annual Report on Form 10-K for the year
ended December 31, 2017, filed with the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee also met on a quarterly basis with the auditors during 2017 to review and discuss our financial statements for
the quarter and the adequacy of internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
Audit Committee: Andrew Arno (<I>Chairman</I>), Ronald Andrews, Andrew J. Last, and Cavan Redmond.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nomination
of Candidates for Election as Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nominating
and Corporate Governance Committee and Nominating Policies and Procedures</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of the Nominating/Corporate Governance Committee are Andrew J. Last (Chairman), Andrew Arno, and Cavan Redmond. Don M.
Bailey also served on the Nominating/Corporate Governance Committee during 2017. The Nominating/Corporate Governance Committee
held two meetings during 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the Nominating/Corporate Governance Committee is to recommend to the Board of Directors individuals qualified to serve
as directors and on committees of the Board, and to make recommendations to the Board on issues and proposals regarding corporate
governance matters. The Nominating/Corporate Governance Committee also overseas compliance with, and all requests for waivers
of, our Code of Conduct, and under our Interested Persons Transaction Policy reviews for approval transactions between us and
our executive officers, directors, and shareholders who beneficially own 5% or more of our outstanding shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating/Corporate Governance Committee will consider nominees for election as directors proposed by shareholders, provided
that they notify the Nominating/Corporate Governance Committee of the nomination in writing at least 120 days before the date
of the next annual meeting and they and the nominee provide the Nominating/Corporate Governance Committee with all information
that the Nominating/Corporate Governance Committee may reasonably request regarding the nominee, no later than 90 days prior to
the annual meeting. A copy of the Nominating/Corporate Governance Committee Charter has been posted on our internet website and
can be found at <I><U>www.oncocyte.com</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board and the Nominating/Corporate Governance Committee have not set any specific minimum qualifications that a prospective nominee
would need in order to be nominated to serve on the Board of Directors. Rather, in evaluating any new nominee or incumbent director,
the Nominating/Corporate Governance Committee will consider whether the particular person has the knowledge, skills, experience,
and expertise needed to manage our affairs in light of the skills, experience, and expertise of the other members of the Board
as a whole. The Committee will also consider whether a nominee or incumbent director has any conflicts of interest with OncoCyte
that might conflict with our Code of Ethics or that might otherwise interfere with their ability to perform their duties in a
manner that is in the best interest of OncoCyte and its shareholders. The Committee will also consider whether including a prospective
director on the Board will result in a Board composition that complies with (a) applicable state corporate laws, (b) applicable
federal and state securities laws, and (c) the rules of the SEC and each stock exchange on which our shares are listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors and the Nominating/Corporate Governance Committee have not adopted specific policies with respect to a particular
mix or diversity of skills, experience, expertise, perspectives, and background that nominees should have. However, the present
Board was assembled with a focus on attaining a Board comprised of people with substantial experience in bioscience, the pharmaceutical
or diagnostic industry, corporate management, and finance. The Board believes that this interdisciplinary approach will best suit
our needs as we work to develop and commercialize cancer diagnostic tests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the factors considered by the Committee and the Board in selecting the Board&rsquo;s nominees for election at the Meeting are
discussed in this Proxy Statement under &ldquo;ELECTION OF DIRECTORS&mdash;Directors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
Annett, Mitchell Levine, Lyndal K. Hesterberg, and Kristine C. Mechem are our only executive officers. Russell L. Skibsted served
as Chief Financial Officer through November 2017. Dr. Mechem is presently on an unpaid sabbatical that is scheduled to end on
September 10, 2018 but which may be extended by OncoCyte for up to an additional three months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mitchell
Levine</B> joined OncoCyte as Chief Financial Officer in November 2017. Prior to joining OncoCyte, Mr. Levine was the Managing
Partner of Kirby Cove Capital Advisors, which provides consulting services to international life sciences investment funds regarding
collaboration and investment in US-based life sciences companies. Mr. Levine was the founder and from 2002 to 2017 the managing
member of Enable Capital Management, LLC, the general partner of, Enable Growth Partners, L.P. provided growth capital to technology,
life sciences, consumer products, and energy companies. Prior to founding Enable, Mr. Levine was a founding member of The Shemano
Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies. He has also worked
at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lyndal
K. Hesterberg, Ph.D.</B> was appointed Senior Vice President-Research and Development during November 2016. Dr. Hesterberg began
providing consulting services to OncoCyte in 2015 and was named Vice President of Development in February of 2016. Dr. Hesterberg
continues to provide counsel on clinical trial design, product development and corporate strategy as a consultant to medical and
biotech companies. Until 2012, Dr. Hesterberg was the Chief Technology Officer of Crescendo Biosciences where he was responsible
for clinical trial, laboratory operations, manufacturing and quality systems and helped bring to market Vectra DA. Previously,
he was the president and Chief Executive Officer of Barofold, Inc., where he led the company from product conception through its
clinical stage, and recruited a senior leadership team that developed a pipeline of proprietary drug candidates. Dr. Hesterberg
received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kristine
C. Mechem, Ph.D.</B> joined OncoCyte Corporation as Vice President of Marketing in August 2015 after serving as a commercialization
consultant assisting in the areas of portfolio management, launch planning and forecasting from April 2015 until joining OncoCyte.
Dr. Mechem served as a Director of Business Insights and Analytics at Abbott Diabetes Care, from 2011 until 2014, leading a team
of analysts and forecasters supporting the business planning process and developing monthly key performance indicators for its
senior management. Dr. Mechem brings to OncoCyte extensive experience within the biotechnology and diagnostics industry. Dr. Mechem&rsquo;s
leadership and industry experience includes: marketing, planning and analytic roles. Her experience spans from smaller early stage
diagnostic companies such as Corra Life Sciences, to larger biopharma companies like Abbott Laboratories and Genentech. At Corra
Life Sciences, a prenatal diagnostics company, she was a co-founder and served as Vice President of Business Development and Marketing
from 2006 until 2007. Dr. Mechem provided business development and marketing support working to secure co-development partners
and license intellectual property from three prominent universities. At Genentech from 2009 until 2010, Dr. Mechem supported the
portfolio management and led the business planning process for a $400 million annual revenue product. Her increasing roles of
responsibility included long range planning, commercial opportunity assessments, and target product profile market research. Dr.
Mechem holds a Ph.D. from the University of Chicago, where she was a National Institute of Child Health and Human Development
(NICHD) fellow. She also completed the Stanford Business School Executive Program in Strategy and Organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Key Management Team Members</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lyssa
Friedman</B> joined OncoCyte as a consultant in April 2014 and was named Vice President of Clinical and Regulatory Affairs in
September 2015. Ms. Friedman started her career as a registered nurse specializing in oncology, and has led clinical research
operations teams for more than 15 years. Ms. Friedman was a founding team member at Veracyte, Inc. and worked there from 2008
to 2014, where she executed a 49-site, 4000-subject clinical validation study that resulted in the launch of the <I>Afirma</I><SUP>&reg;
</SUP>Gene Expression Classifier. She later oversaw clinical utility studies that contributed to positive coverage decision from
the Centers for Medicare and Medicaid Services and major U.S private insurers. Ms. Friedman is an author of about a dozen peer-reviewed
publications and is a frequent speaker on diagnostic development, clinical and regulatory affairs, and reimbursement. Ms. Friedman
received her masters in Public Administration from the University of San Francisco.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>William
K. Seltzer, Ph.D.</B> began providing consulting services to OncoCyte in September 2014 and has since been appointed Vice President
of Clinical Services. Dr. Seltzer provides consulting services to companies in the diagnostic industry and is a board certified
clinical molecular geneticist with 30 years commercial and academic experience in clinical diagnostic services, clinical diagnostic
products development and commercialization, quality assurance and regulatory compliance. As an Associate Professor of Pediatrics
at Colorado, he founded and directed the University&rsquo;s DNA Diagnostic Laboratory. Later, as a member of the executive management
team at Athena Diagnostics, Inc. and as senior Laboratory Director, Dr. Seltzer was responsible for the successful launch and
oversight of clinical services for over 100 laboratory diagnostic tests in the fields of neurology, endocrinology and nephrology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Seltzer established the clinical diagnostic laboratory at Veracyte, Inc. which developed and launched the first molecular cytology
test in the country and later served as laboratory director and site director at Counsyl, Inc. a health technology company. He
has published more than 50 articles in peer-reviewed scientific journals and is co-inventor on patents for molecular diagnostics
and methods. Dr. Seltzer received his Ph.D. in Pharmacology and Nutrition from the University of Southern California and completed
a clinical fellowship in molecular genetics at the University of Colorado School of Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and members of committees of the Board of Directors who are salaried employees of OncoCyte or BioTime are entitled to receive
compensation as employees but are not compensated for serving as directors or attending meetings of the Board or committees of
the Board. All directors are entitled to reimbursements for their out-of-pocket expenses incurred in attending meetings of the
Board or committees of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-employee
directors, other than the Chairman of the Board of Directors, received an annual fee of $30,000 in cash during 2017, plus $1,000
for each regular or special meeting of the Board of Directors attended or $500 for each meeting attended by telephone conference
call. In addition to cash fees, non-employee directors received options to purchase 26,520 shares of common stock under our Employee
Stock Option Plan (the &ldquo;Option Plan&rdquo;) during 2017. In 2017, our Chairman received an annual cash fee of $65,000, plus
$1,000 for each regular or special meeting of the Board of Directors attended or $500 for each meeting attended by telephone conference
call, and an annual award of options to purchase 66,300 shares of OncoCyte common stock. Per meeting fees were eliminated as of
April 24, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual fee of cash was paid, and the stock options granted vested and became exercisable, in four equal quarterly installments,
provided that the non-employee director remained a director on the last day of the applicable quarter. The options will expire
if not exercised five years from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the Meeting, the annual grant of stock options to non-employee directors, other than the Chairman, will be increased to 45,000
stock options that will vest annually. Non-employee directors who are appointed or elected to the Board of Directors for the first
time after the Meeting will also receive a one-time grant of 52,500 stock options that will vest over a period of three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
who served on the Audit Committee, the Compensation Committee, the Nominating/Corporate Governance Committee, Science and Technology
Committee or the Finance Committee during 2017, received, in addition to other fees payable to them as directors, the following
annual fees:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Committee Chairman: $10,000 in the first quarter and increased to $15,000 effective April 24, 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Committee Member other than Chairman: $7,000 in the first quarter and increased to $7,500 effective April 24, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    Committee Chairman: $7,500 in the first quarter and increased to $10,000 effective April 24, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    Committee Member other than Chairman: $5,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating/Corporate
    Governance Committee Chairman: $7,500 in the first quarter and increased to $10,000 effective April 24, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating/Corporate
    Governance Committee Member other than Chairman: $5,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Science
    and Technology Committee Chairman: $7,500 in the first quarter and increased to $10,000 effective April 24, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Science
    and Technology Committee Member other than Chairman: $5,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    Committee Chairman: $10,000 effective July 15, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    Committee Member other than Chairman: $5,000 effective July 15, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of those committees formerly received $1,000 for each committee meeting attended in person, and $500 for each committee
meeting attended by telephone. Per meeting fees were eliminated as of April 24, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes certain information concerning the compensation paid during the past fiscal year to each of the persons
who served as directors during the year ended December 31, 2017 and who were not our employees on the date the compensation was
earned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    Earned<BR> Or Paid in Cash</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt"><B>Awards <SUP>(1)</SUP></B></FONT></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Andrew
    Arno</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">65,750</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">83,281</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">149,031</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Don
    M. Bailey</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,250</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">83,281</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">124,531</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alfred
    D. Kingsley</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">210,344</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(4)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">278,344</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Andrew
    J. Last</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">70,875</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">83,281</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">154,156</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cavan
    Redmond</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,750</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">83,281</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">146,031</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted will vest and become exercisable in equal quarterly installments over a one-year period or other vesting periods,
    but must be reported here at the aggregate grant date fair value, as if all options were fully vested and exercisable at the
    date of grant. Values are computed in accordance with FASB Accounting Standards Codification (ASC) Topic 718. We used the
    Black-Sholes-Merton Pricing Model to compute option fair values based on applicable exercise and stock prices, an expected
    option term, volatility assumptions, and risk-free interest rates.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Messrs.
    Arno, Bailey, Last, and Redmond each received 26,520 stock options. We used the following variables to compute the value of
    the options: stock price and exercise price of $5.10, expected option term of 5.3 years, volatility of 73.42%, and risk-free
    interest rate of 1.79%.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Bailey resigned from the Board of Directors during November 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Kingsley received 66,300 stock options. We used the following variables to compute the value of the options: stock price and
    exercise price of $5.10, expected option term of 5.3 years, volatility of 73.42%, and risk-free interest rate of 1.79%.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012. As an emerging growth
company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general,
to public companies that are not emerging growth companies. Accordingly, this Proxy Statement includes reduced disclosure about
our executive compensation arrangements and does not include a non-binding shareholder advisory vote on executive compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee Interlocks and Insider Participation in Compensation Decisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Compensation Committee are Ronald Andrews, Andrew Arno, Andrew J. Last, and Cavan Redmond, each of whom qualify
as &ldquo;independent&rdquo; in accordance with Section 803(A) and Section 805(c) of the NYSE American Company Guide. Mr. Andrews,
Mr. Arno, Mr. Last and Mr. Redmond are not current or former officers or employees of OncoCyte or BioTime or any of BioTime&rsquo;s
subsidiaries, nor did any of them have any relationship with OncoCyte, BioTime or any of BioTime&rsquo;s subsidiaries requiring
disclosure under Item 404 of SEC Regulation S-K except as reported in this proxy statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
last fiscal year, none of our executive officers served as (a) a member of the compensation committee (or other board committee
performing equivalent functions or, in the absence of any such committee, the entire board of directors) of another entity, one
of whose executive officers served on our Compensation Committee, (b) a director of another entity, one of whose executive officers
served on our Compensation Committee, or (c) a member of the compensation committee (or other board committee performing equivalent
functions or, in the absence of any such committee, the entire board of directors) of another entity, one of whose executive officers
served on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Employment Agreements and Change of Control Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into Employment Agreements with our Chief Executive Officer William Annett, our Chief Financial Officer Mitchell
Levine, our Senior Vice President of Research and Development Lyndal Hesterberg, and our Vice President of Marketing Kristine
C. Mechem.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March 2017, the Compensation Committee reviewed the base salaries of Mr. Annett and Dr. Mechem. The Compensation Committee determined,
and recommended to the Board of Directors, that during 2017 the base salaries for Mr. Annett and Dr. Mechem should increase from
$380,000 and $210,000 to $400,000 and $228,000, respectively, and the Board of Directors approved those salary increases. The
Board of Directors, in consultation with the Compensation Committee, awarded limited bonuses to our executive officers for 2017,
as shown in the Summary Compensation Table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Mr. Annett&rsquo;s Employment Agreement, he is eligible to receive annual cash incentive bonus awards determined by the Board
of Directors, with a target bonus of not less than 35% of his base salary, based on his achievement of specific, objectively determinable,
performance goals at target levels for the year. If the specified performance goals are achieved at maximum levels, the amount
of the annual bonus will be up to 150% of Mr. Annett&rsquo;s base salary as determined by the Board of Directors in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Annett&rsquo;s employment agreement contains provisions entitling him to severance benefits under certain circumstances. If we
terminate Mr. Annett&rsquo;s employment without &ldquo;cause&rdquo; or if he resigns for &ldquo;good reason&rdquo; as those terms
are defined in his employment agreement, he will be entitled to receive as a severance benefit six months base salary, a pro rated
portion of the target bonus for the year, payable on the date that annual bonuses would otherwise be payable to executives, and
any unvested stock options that would have vested during the six months following termination of his employment (the &ldquo;Severance
Period&rdquo;) will vest, and the period during which his vested options may be exercised will be extended to earlier of the date
twelve months after termination of his employment or the expiration date of the option. If Mr. Annett&rsquo;s employment is terminated
without &ldquo;cause&rdquo; or if he resigns for &ldquo;good reason&rdquo; within twelve months following a &ldquo;Change of Control,&rdquo;
he will be entitled to twelve months base salary and the Severance Period will be twelve months rather than six months. In addition,
if Mr. Annett elects continued health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (&ldquo;COBRA&rdquo;)
we will reimburse him for or we will directly pay the premiums for that coverage until the earlier of the end of the Severance
Period or the date on which he receives equivalent health care insurance in connection with new employment. In order to receive
the severance benefits, Mr. Annett must execute a general release of all claims against us and must return all our property in
his possession.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Change
of Control&rdquo; means (A) the acquisition of our voting securities by a person or an Affiliated Group entitling the holder to
elect a majority of our directors; provided, that an increase in the amount of voting securities held by a person or Affiliated
Group who on the date of the Employment Agreement beneficially owned (as defined in Section 13(d) of the Exchange Act, and the
regulations thereunder) more than 10% of our voting securities shall not constitute a Change of Control; and provided, further,
that an acquisition of voting securities by one or more persons acting as an underwriter in connection with a sale or distribution
of voting securities shall not constitute a Change of Control, (B) the sale of all or substantially all of our assets; or (C)
a merger or consolidation in which we merge or consolidate into another corporation or entity in which our shareholders immediately
before the merger or consolidation do not own, in the aggregate, voting securities of the surviving corporation or entity (or
the ultimate parent of the surviving corporation or entity) entitling them, in the aggregate (and without regard to whether they
constitute an Affiliated Group) to elect a majority of the directors or persons holding similar powers of the surviving corporation
or entity (or the ultimate parent of the surviving corporation or entity). A Change of Control shall not be deemed to have occurred
if all of the persons acquiring our voting securities or assets, or merging or consolidating with us, are one or more of our direct
or indirect subsidiaries or parent corporations. &ldquo;Affiliated Group&rdquo; means (A) a person and one or more other persons
in control of, controlled by, or under common control with, such person; and (B) two or more persons who, by written agreement
among them, act in concert to acquire voting securities entitling them to elect a majority of our directors. &ldquo;Person&rdquo;
includes both people and entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Annett&rsquo;s Employment Agreement also provides that if any of the payments to him would constitute &ldquo;parachute payments&rdquo;
under applicable provisions of the Internal Revenue Code and would be subject to excise tax, we will use our best efforts to obtain
shareholder approval of the payment, or Mr. Annett may elect to accept a reduced amount that would not be subject to the excise
tax on parachute payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Mr. Levine&rsquo;s Employment Agreement entered into on November 15, 2017, he is eligible to receive annual cash incentive
bonus awards determined by the Board of Directors, with a target bonus of not less than 40% of his base salary, based on his achievement
of specific, objectively determinable, performance goals at target levels for the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Levine&rsquo;s employment agreement contains provisions entitling him to severance benefits under certain circumstances. If we
terminate Mr. Levine&rsquo;s employment on or after August 1, 2018 without &ldquo;cause&rdquo; he will be entitled to six months
base salary. If we terminate Mr. Levine on or after August 1, 2018 following a &ldquo;Change of Control,&rdquo; he will be entitled
to twelve months base salary. The severance compensation may be paid in a lump sum or, at our election, in installments consistent
with the payment of his salary while employed by us. In order to receive the severance benefits, Mr. Levine must execute a general
release of all claims against us and must return all our property in his possession.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to his Employment Agreement, Dr. Hesterberg received a base annual salary of $210,750 for 2017. He is eligible to receive annual
cash incentive bonus awards determined by the Board of Directors, with a target bonus of 35% of his base salary, based on his
performance and achievement of goals or milestones set by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to her Employment Agreement, Dr. Mechem is eligible to receive annual cash incentive bonus awards determined by the Board of Directors,
with a target bonus of not less than 30% of her base salary, based on her achievement of objectively determinable performance
goals for the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we terminate the employment of Dr. Hesterberg or Dr. Mechem without &ldquo;cause&rdquo; as defined in their respective Employment
Agreements, the terminated employee will be entitled to receive, as a severance benefit, payment of three months base salary if
he or she has been employed by us for one year or less, or six months base salary, if he or she has been employed by us for more
than one year. The severance compensation may be paid in a lump sum or, at our election, in installments consistent with the payment
of his or her salary while employed by us. In order to receive the severance benefits, the terminated employee must execute a
general release of all claims against us and must return all our property in his or her possession. If Dr. Hesterberg&rsquo;s
employment is terminated by OncoCyte without &ldquo;cause&rdquo; or if he resigns for &ldquo;good reason&rdquo; within twelve
months following a &ldquo;Change of Control,&rdquo; he will be entitled to twelve months base salary and accelerated vesting of
100% of any then unvested stock options as may have been granted to him by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables show certain information relating to the compensation of our Chief Executive Officer and the three highest paid
individuals who were serving as executive officers at year end and in each case whose total compensation exceeded $100,000 during
2017. We refer to such executive officers referred to as our &ldquo;Named Executive Officers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
COMPENSATION TABLE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name and principal position</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salary</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bonus</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All other</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 32%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Annett</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">397,308</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">740,276(3)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 13%; text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,500</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,191,084</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">380,000</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,000</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">481,518(4)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,108</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,044,626</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">173,333</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,333</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">852,206(5)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,262(6)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,140,134</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mitchell Levine <SUP>(7)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,885</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,864</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">578,991(7)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">627,740</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristine C. Mechem</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">225,577</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,132</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">222,083(8)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,490</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">488,282</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP of Marketing</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">210,000</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,150</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,565(9)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,750</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">403,465</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83,333</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201,633(10)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,333</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313,299</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lyndal K. Hesterberg <SUP>(11)</SUP></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">210,750</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,720</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,378(12)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,521</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">299,369</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior VP of Research and Development</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,125</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,625</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">414,873(13)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">208,837(14)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">671,460</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%; padding-right: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,441(14)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,441</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    awards were granted under the Option Plan and are valued at the aggregate grant date fair value, as if all options were fully
    vested and exercisable at the date of grant. Except as otherwise indicated below, one quarter of the options will vest upon
    completion of 12 full months of continuous employment measured from the grant date, and the balance of the options shall vest
    in 36 equal monthly installments commencing on the first anniversary of the date of grant, based upon the completion of each
    month of continuous employment. Option awards are accounted for in accordance with FASB Accounting Standards Codification
    (ASC) Topic 718. We used the Black-Sholes-Merton Pricing Model to compute option fair values based on applicable exercise
    and stock prices, an expected option term of six to nine years, volatility ranging from 55.12% to 76.58%, and risk-free interest
    rate ranging from 1.38% to 2.12%, depending on the date of the grant and based upon observed interest rates on United States
    government securities appropriate for the expected term.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise indicated below, other compensation consists entirely of employer contributions to employee accounts under BioTime&rsquo;s
    401(k) plan in which employees of BioTime subsidiaries, including OncoCyte, are entitled to participate.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Annett was granted 225,000 stock options exercisable at an exercise price of $4.85 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Annett was granted 250,000 stock options exercisable at an exercise price of $3.06 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Annett was appointed as our Chief Executive Officer on June 16, 2015. Mr. Annett was granted 605,000 stock options exercisable
    at an exercise price of $2.20 per share of which 5,000 options vested on the date of grant.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    compensation also includes 10,000 stock options, with a fair market value of $13,262, granted as partial compensation for
    serving on the Board of Directors of which 5,000 options were forfeited before Mr. Annett was appointed President and Chief
    Executive Officer.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Levine was appointed as our Chief Financial Officer on November 15, 2017. Mr. Levine was granted 200,000 stock options exercisable
    at an exercise price of $5.90 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Mechem was granted 67,500 stock options exercisable at an exercise price of $4.70 per share</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(9)</FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dr.
    Mechem was granted 60,000 stock options exercisable at an exercise price of $3.06 per share.</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(10)</FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dr.
    Mechem was granted 100,000 stock options exercisable at an exercise price of $3.16 per share.</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Hesterberg was appointed Senior Vice President-Research and Development during November 2016. Dr. Hesterberg began providing
    consulting services to OncoCyte in 2015 and was named Vice President of Development in February of 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Hesterberg was granted 14,400 stock options exercisable at an exercise price of $4.70 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    February 2016, Dr. Hesterberg in the capacity of a consultant received 25,000 stock options exercisable at an exercise price
    of $3.06 per share. In November 2016, Dr. Hesterberg received 125,000 stock options exercisable at an exercise price of $4.05
    per share as part of his employment.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    compensation entirely represents cash compensation paid to Dr. Hesterberg for consulting services prior to the date he became
    an OncoCyte employee.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Options Outstanding at Year End</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes certain information concerning stock options granted by us under the Option Plan, and held as of December
31, 2017 by our Named Executive Officers:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OUTSTANDING
EQUITY AWARDS AT YEAR-END</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Securities<BR> Underlying<BR> Unexercised Options<BR> Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underlying</B></FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercised Options</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercisable<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> <FONT STYLE="font-size: 10pt"><B>Date</B></FONT></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 38%; text-align: left">William Annett</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right; padding-right: 10pt">5,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right; padding-right: 12pt">&mdash;</TD><TD STYLE="width: 2%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: right">$</TD><TD STYLE="width: 5%; text-align: right; padding-right: 4pt">2.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 22%; text-align: center; padding-left: 1.5pt">January 8, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">2.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">June 15, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">375,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">225,000(2)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">2.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">June 15, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">114,583</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">135,417(3)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">3.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">February 15, 2026</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">225,000(4)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">4.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">February 16, 2027</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 4pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mitchell Levine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">200,000(5)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">5.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">November 15, 2027</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 4pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Kristine C. Mechem</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">58,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">41,667(6)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">3.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">August 3, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">27,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">32,5000(3)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">3.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">February 15, 2026</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">67,500(4)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">4.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">February 16, 2027</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 4pt">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Lyndal K. Hesterberg</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">6,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">18,750(7)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">3.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">February 15, 2026</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">33,854</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">91,146(8)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">4.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">October 31, 2026</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 10pt">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; padding-right: 12pt">14,400(4)</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD><TD STYLE="text-align: right; padding-right: 4pt">4.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 1.5pt">February 16, 2027</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as otherwise indicated below, one quarter of the options shall vest upon completion of 12 full months of continuous employment
    measured from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the
    first anniversary of the date of grant, based upon the completion of each month of continuous employment.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    date of grant was June 15, 2015.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    date of grant was February 16, 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    date of grant was February 17, 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    options were granted to Mr. Levine upon his appointment as Chief Financial Officer on November 16, 2017. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    date of grant was August 4, 2015.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    options were granted to Dr. Hesterberg in the capacity of a consultant on February 16, 2016. One quarter of the options shall
    vest upon completion of 12 full months of continuous service provided to the company measured from the date of grant, the
    second and third quarterly installment vest upon achievement of certain milestones, and the last one quarter shall vest on
    the second anniversary from the option grant date.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    date of grant was November 1, 2016 at which time Dr. Hesterberg became an employee of OncoCyte.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Option Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted the Option Plan pursuant to which we may grant options to purchase, or we may sell as restricted stock, up to a total
of 5,200,000 shares of common stock. The following summary of the Option Plan is qualified in all respects by reference to the
full text of the Option Plan, a copy of which has been filed as an exhibit to our registration statement on Form 10. The Option
Plan will expire if the new Incentive Plan is approved by our shareholders at the Meeting, but stock options issued under the
Option Plan will continue in effect in accordance with their terms and the terms of the Option Plan until the exercise or expiration
of the individual options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Administration
of the Option Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Option Plan is administered by the Compensation Committee, which recommends to the Board of Directors which of our officers, directors,
employees, consultants, and independent contractors should be awarded options or restricted stock, the number of shares subject
to the options granted or shares of restricted stock to be sold, the exercise price of the options or purchase price of restricted
stock, and certain other terms and conditions of the options and restricted stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
options may be granted under the Option Plan more than ten years after the date the Option Plan was adopted by the Board of Directors,
and no options granted under the Option Plan may be exercised after the expiration of ten years from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Terms
of the Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the Option Plan may be either &ldquo;incentive stock options&rdquo; within the meaning of Section 422(b) of the
Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), or non-qualified stock options. Incentive stock options may
be granted only to our employees and employees any parent or subsidiary company. The exercise price of incentive stock options
granted under the Option Plan must be equal to not less than 85% of the fair market of our common stock on the date the option
is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of our capital stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common
stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of the common
stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the
first time by an optionee in any calendar year may not exceed $100,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
options&rsquo; exercise price may be payable in cash or in shares of common stock having a fair market value equal to the exercise
price, or in a combination of cash and common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the Option Plan are nontransferable (except by will or the laws of descent and distribution) and may vest upon the
satisfaction of reasonable conditions determined by the Board of Directors or Compensation Committee. Incentive stock options
may be exercised only during employment or within three months after termination of employment, subject to certain exceptions
in the event of the death or disability of the optionee, provided, that the Board of Directors or Compensation Committee may waive
this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
Adjustments to Number of Shares and Exercise Price</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock covered by the Option Plan, and the number of shares of common stock and the exercise price per
share of each outstanding option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding
shares of common stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other
increase or decrease in the number of issued and outstanding shares of common stock effected without receipt of consideration
by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Corporate
Reorganization or Liquidation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the dissolution or liquidation of OncoCyte, or in the event of a reorganization, merger, or consolidation of OncoCyte
as a result of which OncoCyte common stock is changed into or exchanged for cash or property or securities not issued by us, or
upon a sale of substantially all of our property to, or the acquisition of stock representing more than eighty percent 80% of
the voting power of our capital stock then outstanding by, another corporation or person, the Option Plan and all options granted
under the Option Plan shall terminate, unless provision can be made in writing in connection with such transaction for either
the continuance of the Option Plan or for the assumption of options granted under the Option Plan, or the substitution for such
options by options covering the stock of a successor corporation, or a parent or a subsidiary of a successor corporation, with
appropriate adjustments as to the number and kind of shares and prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock Sales</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of granting options, we may enter into restricted stock purchase agreements with employees under which they may purchase
common stock subject to certain vesting and repurchase restrictions. We have the right to repurchase unvested shares at the shareholder&rsquo;s
cost upon the occurrence of specified events, such as termination of employment. The price at which shares may be sold under restricted
stock purchase agreements will be not less than 85% of fair market value, or 100% of fair market value in the case of stock sold
to a person who owns capital stock representing more than 10% of the combined voting power of all classes of our capital stock.
We may permit employees or consultants, but not executive officers or directors, who purchase stock under restricted stock purchase
agreements to pay for their shares by delivering a promissory note that is secured by a pledge of their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Compensation Plans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any pension plans, defined benefit plans, or non-qualified deferred compensation plans. We do make contributions to
401(k) plans for participating executive officers and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risk
Considerations and Recoupment Policies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee considers, in establishing and reviewing the executive compensation program, whether the program encourages
unnecessary or excessive risk taking. Our executive compensation arrangements include a fixed salary that provides a steady income
so that executives do not feel pressured to focus exclusively on stock price performance or short term financial targets to the
detriment of our long-term operational and strategic objectives. We supplement fixed salaries with discretionary bonus awards
based on the executive&rsquo;s performance as well as the performance of OncoCyte. Most of the stock options that we have granted
to our executive officers under our Option Plan vest over four years, assuring that the executives take a long-term perspective
in viewing their equity ownership.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have not adopted compensation plans, or made incentive awards, based on quantified financial performance measures, we have
not adopted specific policies regarding the adjustment or recovery of awards or payments if the relevant performance measures
are restated or otherwise adjusted in a manner that would reduce the size of an award or payment. We may adopt such policies,
however, if we adopt incentive compensation plans or grant incentive bonuses based on financial performance measures or if we
are required to do by the rules of any national securities exchange or interdealer quotation system on which our common stock
or other equity securities are listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of July 10, 2018 concerning beneficial ownership of our common stock by each
shareholder known by us to be the beneficial owner of 5% or more of our outstanding shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
Ownership of Certain Beneficial Owners</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholder</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                         of </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent
    of<BR> Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 80%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioTime,
    Inc. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> <FONT STYLE="font-size: 10pt">1010 Atlantic Avenue,
    Suite 102</FONT><BR> <FONT STYLE="font-size: 10pt">Alameda, California 94501</FONT></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,674,244</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">37.24</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broadwood
    Partners, L.P. <SUP>(1)</SUP></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> <FONT STYLE="font-size: 10pt">724
    Fifth Avenue, 9<SUP>th</SUP> Floor</FONT><BR> <FONT STYLE="font-size: 10pt">New York, New York 10019</FONT></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,624,041</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.31</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Karfunkel </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">126 East 56<SUP>th</SUP> Street/15<SUP>th</SUP> Floor</FONT><BR> <FONT STYLE="font-size: 10pt">New
    York, New York 10022</FONT></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,828,114</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.25</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GKarfunkel
    Family LLC <SUP>(2)</SUP></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> <FONT STYLE="font-size: 10pt">126
    East 56<SUP>th </SUP>Street/15<SUP>th</SUP> Floor</FONT><BR> <FONT STYLE="font-size: 10pt">New York, New York 10022</FONT></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.42</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Karfunkel</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">126 East 56<SUP>th</SUP> Street/15<SUP>th</SUP> Floor</FONT><BR> <FONT STYLE="font-size: 10pt">New
    York, New York 10022</FONT></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,551,666</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.48</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,055,961 shares that may be acquired upon the exercise of certain warrants.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,000,000 shares that may be acquired upon the exercise of certain warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
Ownership of Management</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of July 10, 2018 concerning beneficial ownership of our common stock by each
member of the Board of Directors, all Named Executive Officers, and all executive officers and directors as a group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of<BR> Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent
    of<BR> Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 80%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Annett <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">725,625</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.81</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mitchell
    Levine <SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristine
    C. Mechem <SUP>(3)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">139,895</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lyndal
    K. Hesterberg <SUP>(4)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">75,191</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred
    D. Kingsley <SUP>(5)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">701,064</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.77</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    Andrews <SUP>(6)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Arno <SUP>(7)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,520</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    J. Last <SUP>(8)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,520</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cavan
    Redmond <SUP>(9)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,520</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aditya
    Mohanty</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    executive officers and directors as a group (10 persons) <SUP>(10)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,816,335</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.45</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Less
than 1%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    680,833 shares that may be acquired through the exercise of stock options that are presently exercisable and 44,792 shares
    that may be acquired upon the exercise of certain stock options that may become exercisable within 60 days. Excludes 539,375
    shares that may be acquired upon the exercise of certain stock options that are not presently exercisable and that will not
    become exercisable within 60 days. </FONT> In addition to the shares shown in the table, on July 26, 2018 Mr. Annett agreed
    to purchase from OncoCyte an additional 3,500 shares of common stock and warrants to purchase 3,500 shares of common stock
    pursuant to a Securities Purchase Agreement, in a transaction that is expected to close on or around July 31, 2018. </TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
    375,000 shares that may be acquired upon the exercise of certain stock options that are not presently exercisable and that
    will not become exercisable within 60 days.</FONT> In addition to the shares shown in the table, on July 26, 2018 Mr. Levine
    agreed to purchase from OncoCyte an additional 3,500 shares of common stock and warrants to purchase 3,500 shares of common
    stock pursuant to a Securities Purchase Agreement, in a transaction that is expected to close on or around July 31, 2018.



<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    130,416 shares that may be acquired through the exercise of stock options that are presently exercisable and 9,479
    shares that may be acquired upon the exercise of certain stock options that may become exercisable within 60 days. Excludes
    262,605 shares that may be acquired upon the exercise of certain stock options that are not presently exercisable and
    that will not become exercisable within 60 days.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    69,383 shares that may be acquired through the exercise of stock options that are presently exercisable and 5,808 shares that
    may be acquired upon the exercise of certain stock options that may become exercisable within 60 days. Excludes 239,209 shares
    that may be acquired upon the exercise of certain stock options that are not presently exercisable and that will not become
    exercisable within 60 days. </FONT> In addition to the shares shown in the table, on July 26, 2018 Mr. Hesterberg agreed
    to purchase from OncoCyte an additional 8,74 shares of common stock and warrants to purchase 874 shares of common stock pursuant
    to a Securities Purchase Agreement, in a transaction that is expected to close on or around July 31, 2018.



<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    290,350 shares that may be acquired through the exercise of stock options that are presently exercisable and 19,700
    shares that may be acquired upon the exercise of certain stock options that may become exercisable within 60 days. Excludes
    6,250 shares that may be acquired upon the exercise of certain stock options that are not presently exercisable and
    that will not become exercisable within 60 days.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    5,000 shares that may be acquired through the exercise of stock options that are presently exercisable. Excludes 15,000 shares
    that may be acquired upon the exercise of certain stock options that are not presently exercisable and that will not become
    exercisable within 60 days.  In addition to the shares shown in the table, on July 26, 2018 Mr. Andrews agreed to purchase
    from OncoCyte an additional 17,482 shares of common stock and warrants to purchase 17,482 shares of common stock pursuant
    to a Securities Purchase Agreement, in a transaction that is expected to close on or around July 31, 2018.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    49,890 shares that may be acquired through the sale of options that are presently exercisable and 6,630 shares that may be
    acquired upon the exercise of certain stock options that may become exercisable within 60 days.  In addition to the shares
    shown in the table, on July 26, 2018 Mr. Arno agreed to purchase from OncoCyte an additional 52,447 shares of common stock
    and warrants to purchase 52,447 shares of common stock pursuant to a Securities Purchase Agreement, in a transaction that
    is expected to close on or around July 31, 2018.</FONT></TD></TR>


<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; text-indent: 0in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-indent: 0in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    49,890 shares that may be acquired through the sale of options that are presently exercisable and 6,630 shares that may be
    acquired upon the exercise of certain stock options that may become exercisable within 60 days. In addition to the shares
    shown in the table, on July 26, 2018 Mr. Last agreed to purchase from OncoCyte an additional 6,993 shares of common stock
    and warrants to purchase 6,993 shares of common stock pursuant to a Securities Purchase Agreement, in a transaction that is
    expected to close on or around July 31, 2018.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="text-indent: 0in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    49,890 shares that may be acquired through the sale of options that are presently exercisable and 6,630 shares that may be
    acquired upon the exercise of certain stock options that may become exercisable within 60 days. In addition to the shares
    shown in the table, on July 26, 2018 Mr. Redmond agreed to purchase from OncoCyte an additional 52,447 shares of common stock
    and warrants to purchase 52,447 shares of common stock pursuant to a Securities Purchase Agreement, in a transaction that
    is expected to close on or around July 31, 2018.</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,425,321 shares that may be acquired upon the exercise of certain stock options that are presently exercisable or that may
    become exercisable within 60 days. Excludes 1,437,439 shares that may be acquired upon the exercise of certain stock options
    that are not presently exercisable and that will not become exercisable within 60 days.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Relationships and Related Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shared
Facilities Agreement and Relationship with BioTime</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, BioTime has provided us with the use of office and laboratory facilities, laboratory and office equipment and supplies,
utilities, insurance, and the services of its employees and contractors, for which we have reimbursed BioTime, either through
cash payments, shares of our common stock, or delivering convertible promissory notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a Shared Facilities Agreement with BioTime through which BioTime will continue to provide us with the use of
its facilities, equipment and supplies, utilities, and personnel at its cost plus 5%. However, BioTime did not charge us the 5%
markup until the 2016 fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioTime
is not required to hire any additional personnel or to acquire any additional equipment or supplies for our use. We expect to
hire our own personnel and to acquire our own equipment and supplies for our own exclusive use as the need arises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shared Facilities Agreement will remain in effect from year to year, unless either party gives the other party written notice
stating that this agreement shall terminate on December 31 of that year, or unless the agreement is otherwise terminated under
another provision of the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate the Shared Facilities Agreement immediately upon the occurrence of a default by the other party. A default
will be deemed to have occurred if a party (i) fails to pay any sum due under the Shared Facilities Agreement, or fails to perform
any other obligation under the agreement, and the failure continues for a period of 5 days after written notice from the party
seeking to terminate the agreement; (ii) becomes the subject of any order for relief in a proceeding under any Debtor Relief Law;
(iii) becomes unable to pay, or admits in writing the party&rsquo;s inability to pay, its debts as they mature; (iv) makes an
assignment for the benefit of creditors; (v) applies for or consents to the appointment of any receiver, trustee, custodian, conservator,
liquidator, rehabilitation, or similar officer for the party or for all or any part of the party&rsquo;s property or assets, or
any such officer is appointed for such party or any part of its assets without the party&rsquo;s consent and such appointment
is not dismissed or discharged within 60 calendar days; (vi) institutes or consents to any proceeding under any Debtor Relief
Law with respect to the party or all or any part of the party&rsquo;s property or assets, (vii) becomes subject to any proceeding
under any Debtor Relief Law without the consent of the party if such case or proceeding continues undismissed or unstayed for
60 calendar days; or (viii) dissolves or liquidates or takes any action to dissolve or liquidate. As used in the Shared Facilities
Agreement, the term Debtor Relief Law means the Bankruptcy Code of the United States of America, as amended, or any other similar
debtor relief law affecting the rights of creditors generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Shared Facilities Agreement, we have agreed to defend, indemnify, and hold harmless BioTime, BioTime&rsquo;s shareholders,
directors, officers, employees, and agents against and from any and all claims arising from our use of BioTime&rsquo;s office
and laboratory facilities, and from any of our work or other activities there, including all activities, work, and services performed
by BioTime employees, contractors, and agents for us. The scope of our indemnification obligations also includes any and all claims
arising from any breach or default on our part in the performance of any of our obligations under the terms of the Shared Facilities
Agreement, or arising from any act or omission (including, but not limited to negligent acts or omissions) of us or any of our
officers, agents, employees, contractors, guests, or invitees acting in that capacity. We are also assuming all risk of damage
to property or injury to persons in, upon, or about the BioTime&rsquo;s office and laboratory facilities, from any cause other
than BioTime&rsquo;s willful malfeasance or sole gross negligence. BioTime will not be liable to us for any loss or damages of
any kind caused by, arising from, or in connection with (i) the performance of services by BioTime personnel for us, or the failure
of any BioTime employee, contractor, or agent to perform any services for us, or (ii) any delay, error, or omission by any BioTime
employee, contractor, or agent in the performance of services for us, except to the extent the loss or damage is the result of
fraud, gross negligence or willful misconduct by a BioTime employee, contractor, or agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2017, OncoCyte had $2.1 million outstanding and payable to BioTime and affiliates in connection with the costs
incurred under the Shared Facilities Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cavan
Redmond, Alfred D. Kingsley, and Adi Mohanty, who are members of our Board of Directors, are directors of BioTime, and Mr. Mohanty
is the Co-Chief Executive Officer of BioTime. Broadwood Partners, L.P. and Mr. Kingsley each beneficially own more than 5% of
the outstanding common stock of BioTime. All of our directors and executive officers, and beneficial owners of more than 5% of
our outstanding common stock (&ldquo;5% Shareholders&rdquo;) as reported in this </FONT>proxy statement, in the aggregate
beneficially own more than 30% of the outstanding common shares of BioTime. The fact that certain of our executive officers and
directors and 5% Shareholders own BioTime common shares should not be considered to mean that they constitute or are acting in
concert as a &ldquo;group&rdquo; with respect to those shares or that they otherwise share power or authority to vote or dispose
of the shares that each of them own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
Sales of Equity Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
August 2016, we sold an aggregate of 3,246,153 immediately separable &ldquo;units,&rdquo; with each unit consisting of one share
of our common stock and one warrant to purchase one share of our common stock, at a price of $3.25 per unit (the &ldquo;Units&rdquo;).
George Karfunkel and Broadwood Partners, L.P. (&ldquo;Broadwood&rdquo;) who each beneficially own more than 5% of our outstanding
common stock, purchased 1,000,000 Units, and purchased 1,538,461 Units. During February 2017, certain investors who purchased
Units, including Broadwood, entered into Warrant Exercise Agreements pursuant to which they exercised some of the warrants that
were included in the Units, and purchased shares of our common stock earlier than the expiration date of the warrants. Under the
Warrant Exercise Agreements, we issued new warrants to those investors. Broadwood exercised 425,000 warrants and was issued 212,500
new warrants with exercise of $3.25 per warrant share in addition to the 425,000 shares of common stock purchased through the
exercise of the warrants. The new warrants are exercisable at any time for five years from the date of issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2017, OncoCyte entered into three forms of Warrant Exercise Agreements (each, an &quot;Exercise Agreement&quot;) with
certain holders of the 2016 Warrants, including Broadwood and George Karfunkel, providing for the cash exercise of their 2016
Warrants and the issuance of new warrants (the &quot;July 2017 Warrants&quot;) to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to one form of Exercise Agreement, two investors exercised 2016 Warrants to purchase 226,923 shares of OncoCyte's common stock
at the exercise price of $3.25 per share, and OncoCyte issued to them July 2017 Warrants expiring five years from the date of
issue, to purchase 226,923 shares of common stock at an exercise price of $5.50 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a second form of Exercise Agreement, Broadwood exercised 2016 Warrants to purchase 540,000 shares of common stock at the exercise
price of $3.25 per share, and OncoCyte issued to Broadwood a July 2017 Warrant, expiring five years from the date of issue, to
purchase 270,000 shares of common stock at an exercise price of $3.25 per share. In this alternative form of Exercise Agreement,
OncoCyte also agreed to use commercially reasonable efforts to file with the SEC a registration statement covering the resale
of the shares of common stock issuable upon exercise of the July 2017 Warrant and to keep it continuously effective for up to
five years, subject to conditions set forth in the Exercise Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a third form of Exercise Agreement, George Karfunkel exercised 2016 Warrants to purchase 1,000,000 shares of common stock at
the exercise price of $3.25 per share, and OncoCyte issued to the investor (i) a July 2017 Warrant, expiring two years from the
date of issue, to purchase 500,000 shares of common stock at an exercise price of $5.50 per share, and (ii) a July 2017 Warrant,
expiring two years from the date of issue, to purchase 500,000 shares of common stock at an exercise price of $3.25 per share.
In this alternative form of Exercise Agreement, OncoCyte also agreed to use commercially reasonable efforts to file with the SEC
a registration statement covering the resale of the shares of common stock issuable upon exercise of the July 2017 Warrant and
to keep it continuously effective for up to five years, subject to conditions set forth in the Exercise Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March 2018, OncoCyte entered into securities purchase agreements with Broadwood and George Karfunkel pursuant to which Broadwood
purchased 3,968,254 shares of common stock, and Mr. Karfunkel purchased 3,968,254 shares of common stock in two installments,
for $1.26 per share. Under the securities purchase agreements, we have agreed to register the shares for resale under the Securities
Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 26, 2018, Cavan
Redmond and Andrew Arno, who are members of our Board of Directors, each agreed to purchase from OncoCyte 52,447 shares of common
stock and warrants to purchase 52,447 shares of common stock for $150,000 pursuant to a Securities Purchase Agreement, in a transaction
that is expected to close on or around July 31, 2018. The shares of common stock and warrants were sold in a registered direct
offering in &ldquo;units,&rdquo; with each unit consisting of one share of common stock and one warrant, at a price of $2.86 per
unit. Each warrant entitles the warrant holder to purchase one share of common stock at an exercise price of $3.00 per share,
<FONT STYLE="background-color: white">will become exercisable six months after the date of issue, and will expire five years after
the date it becomes exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Approval
by the Board of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the transactions described above were reviewed directly by the Board of Directors, and the Board of Directors or a designated
committee of the Board determined whether to approve or withhold approval of each transaction. The Board of Directors or committee
considered such factors as they deemed relevant to the particular transaction and applied such criteria as it determined to be
appropriate in connection with its evaluation of each proposed transaction on a transaction by transaction basis. The Board of
Directors does not have any written guidelines governing the exercise of its discretion other than the Related Person Transaction
Policy with respect to transactions with officers, directors, beneficial owners of more than 5% of our outstanding shares of common
stock, or any member of their immediate family.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Related
Person Transaction Policy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Related Person Transaction Policy that applies to transactions exceeding $120,000 in which any of our officers,
directors, beneficial owners of more than 5% of our outstanding shares of common stock, or any member of their immediate family,
has a direct or indirect material interest, determined in accordance with the policy (a &ldquo;Related Person Transaction&rdquo;).
A Related Person Transaction must be reported to our outside legal counsel, our Chief Operating Officer, and our Chief Financial
Officer, and will be subject to review and approval by our Nominating/Corporate Governance Committee prior to effectiveness or
consummation, to the extent practical. In addition, any Related Person Transaction that is ongoing in nature will be reviewed
by the Nominating/Corporate Governance Committee annually to ensure that the transaction has been conducted in accordance with
any previous approval and that all required disclosures regarding the transaction are made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
appropriate for the circumstances, the Nominating/Corporate Governance Committee will review and consider:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    interest of the officer, director, beneficial owner of more than 5% of our common stock, or any member of their immediate
    family (&ldquo;Related Person&rdquo;) in the Related Person Transaction;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approximate dollar value of the amount involved in the Related Person Transaction;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approximate dollar value of the amount of the Related Person&rsquo;s interest in the transaction without regard to the amount
    of any profit or loss;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the transaction was undertaken in the ordinary course of our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the transaction with the Related Person is proposed to be, or was, entered into on terms no less favorable to us than terms
    that could have been reached with an unrelated third party;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purpose of, and the potential benefits to the transaction to us; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other information regarding the Related Person Transaction or the Related Person in the context of the proposed transaction
    that would be material to investors in light of the circumstances of the particular transaction.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating/Corporate Governance Committee will review all relevant information available to it about a Related Person Transaction.
The Nominating/Corporate Governance Committee may approve or ratify the Related Person Transaction only if it determines that,
under all of the circumstances, the transaction is in, or is not in conflict with, our best interests. The Nominating/Corporate
Governance Committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the Related Person in
connection with approval of the Related Person Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of our Related Person Transaction Policy can be found on our website at <I><U>www.oncocyte.com</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPLIANCE
WITH SECTION 16(a)</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt"><B>OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of Exchange Act, requires our directors and executive officers and persons who own more than ten percent (10%) of a registered
class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common
stock and other OncoCyte equity securities. Officers, directors and greater than ten percent beneficial owners are required by
SEC regulations to furnish us with copies of all reports they file under Section 16(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, based solely on our review of the copies of such reports furnished to us, all Section 16(a) filing requirements
applicable to our officers, directors, and greater than ten percent beneficial owners were complied with during the fiscal year
ended December 31, 2017, except that a Form 4 was filed late by Andrew Last.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RATIFICATION
OF THE SELECTION OF OUR INDEPENDENT REGISTERED</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt"><B>PUBLIC ACCOUNTANTS</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has selected OUM &amp; Co., LLP (&ldquo;OUM&rdquo;) as our independent registered public accountants. OUM has
served as our independent registered public accountants since the fourth quarter of 2015. The Board of Directors proposes and
recommends that the shareholders ratify the selection of the firm of OUM to serve as our independent registered public accountants
for the fiscal year ending December 31, 2018. Approval of the selection of OUM to serve as our independent registered public accountants
requires the affirmative vote of a majority of the shares of common stock present and voting on the matter at the Meeting, provided
that the affirmative vote cast constitutes a majority of a quorum. Unless otherwise directed by the shareholders, proxies will
be voted <B>FOR</B> approval of the selection of OUM to audit our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that a representative of OUM will be present at the Meeting, in person or by conference telephone, and will have an opportunity
to make a statement if he or she so desires and may respond to appropriate questions from shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Board of Directors Recommends a Vote &ldquo;FOR&rdquo; Ratification of the Selection of OUM as Our</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent
Registered Public Accountants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OUM
audited our annual financial statements for the fiscal years ended December 31, 2017 and 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit
Fees, Audit Related Fees, Tax Fees and Other Fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate fees billed to us during the fiscal years ended December 31, 2017 and 2016 by OUM:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 80%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Fees <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">201,228</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 7%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">248,435</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Related Fees <SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Fees <SUP>(3)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Fees</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">201,228</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">248,435</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Fees consist of fees billed for professional services rendered for the audit of OncoCyte&rsquo;s annual financial statements
    included in our Registration Statement on Form 10 and in our Annual Report on Form 10-K, and review of the interim financial
    statements included in our Registration Statement on Form 10 and our Quarterly Reports on Form 10-Q, as applicable, and services
    that are normally provided by our independent registered public accountants in connection with statutory and regulatory filings
    or engagements.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related
    Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit
    or review of our financial statements and are not reported under &ldquo;Audit Fees.&rdquo; This category includes fees related
    to non-routine SEC filings.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Fees were billed for services including assistance with tax compliance and the preparation of tax returns, tax consultation
    services, assistance in connection with tax audits and tax advice related to mergers, acquisitions and dispositions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Approval
of Audit and Permissible Non-Audit Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee requires pre-approval of all audit and non-audit services. Other than <I>de minimis</I> services incidental to
audit services, non-audit services shall generally be limited to tax services such as advice and planning and financial due diligence
services. All fees for such non-audit services must be approved by the Audit Committee, except to the extent otherwise permitted
by applicable SEC regulations. The Committee may delegate to one or more designated members of the Committee the authority to
grant pre-approvals, provided such approvals are presented to the Committee at a subsequent meeting. During 2017, 100% of the
fees paid to OUM were approved by the Audit Committee or by our Board of Directors prior to the appointment of our Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADOPTION
OF EQUITY INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are asking the shareholders to approve our new Equity Incentive Plan (the &ldquo;Incentive Plan&rdquo;) that our Board of Directors
adopted during July 2018 to replace our Option Plan. In adopting the Incentive Plan, our Board of Directors determined to terminate
the Option Plan effective on the date that our shareholders approve the new Incentive Plan. Upon termination of the Option Plan,
we will not grant any additional stock options or sell any stock under restricted stock purchase agreements under the Option Plan
but stock options issued under the Option Plan will continue in effect in accordance with their terms and the terms of the Option
Plan until the exercise or expiration of the individual options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Incentive Plan will reserve 5,000,000 shares of our common stock for the grant of stock options or the sale of restricted stock
(&ldquo;Restricted Stock&rdquo;) or for the settlement of hypothetical units issued with reference to common stock (&ldquo;Restricted
Stock Units&rdquo;). We may also grant stock appreciation rights (&ldquo;SARs&rdquo;) under the Incentive Plan. The Incentive
Plan also permits us to issue such other securities as our Board of Directors or the Compensation Committee (the &ldquo;Committee&rdquo;)
administering the Incentive Plan may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
of stock options, Restricted Stock, SARs, and Restricted Stock Units (&ldquo;Awards&rdquo;) may be granted under the Incentive
Plan to our employees, directors, and consultants, and those of any of our subsidiaries, including any subsidiaries that we may
form or acquire in the future. The Incentive Plan will be administered by our Board of Directors or by the Committee, who will
make all determinations with regard to the grant and terms of Awards, subject to the terms of the Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of the Incentive Plan requires the affirmative vote of a majority of the shares present and voting at the Meeting, provided that
the affirmative vote cast constitutes a majority of a quorum. Unless otherwise directed by the shareholders, proxies will be voted
<B>FOR</B> approval of the Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Board of Directors Recommends A Vote &ldquo;FOR&rdquo; the approval of the Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reasons
for the Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options and other equity-based Awards are an important part of employee and director compensation packages. The Board strongly
believes that our ability to attract and retain the services of employees, consultants, and directors depends in great measure
upon our ability to provide the kind of incentives that are derived from the ownership of stock, stock options, and other equity
based incentives that are offered by other diagnostic companies. This is especially true for us since the salaries we pay our
employees may be lower than the compensation packages offered by competing companies. We believe that we will be placed at a serious
competitive disadvantage in attracting and retaining capable employees, consultants, and directors at a critical time in our corporate
development, unless the Incentive Plan is approved by the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board believes that the 5,000,000 shares of common stock available for the grant of Awards under the Incentive Plan will fulfill
our needs for the near future. Any future increase in the number of shares under the Incentive Plan would be submitted to the
shareholders for approval. Although the Incentive Plan has been adopted by our Board of Directors, the Incentive Plan has not
yet been approved by our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of the Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the Incentive Plan is qualified in all respects by reference to the full text of the Incentive Plan, a copy
of which is attached to this proxy statement as Appendix A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
may be granted under the Incentive Plan to our employees, directors, and consultants, and those of any subsidiaries that we may
form or acquire in the future. The Incentive Plan will be administered by our Board of Directors or by the Committee, who will
make all determinations with regard to the grant and terms of Awards, subject to the terms of the Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic installments
or upon the attainment of performance goals, or upon the occurrence of specified events as determined by the Board or the Committee.
Awards may not vest, in whole or in part, earlier than one year from the date of grant. Vesting of an Award after the date of
grant may be accelerated by the Committee or the Board, or under the terms of any Award agreement or employment agreement or other
agreement, only in the following limited circumstances: (a) the death or disability of the Award holder; (b) termination of employment
or &ldquo;continuous service,&rdquo; as defined in the Incentive Plan, of the Award holder by OncoCyte without &ldquo;cause,&rdquo;
as defined in the Incentive Plan, or by the Award holder for &ldquo;good reason,&rdquo; as defined in the Incentive Plan; or (c)
termination of the employment or &ldquo;continuous service&rdquo; of the Award holder by OncoCyte or a successor in interest without
&ldquo;cause,&rdquo; or by the Award holder for &ldquo;good reason,&rdquo; following a &ldquo;change in control&rdquo; of OncoCyte,
as defined in the Incentive Plan. In the case of the acceleration of vesting of any performance-based Award, acceleration of vesting
shall be limited to actual performance achieved, pro rata achievement of the performance goal(s) on the basis for the elapsed
portion of the performance period (as determined by the Committee or the Board), or a combination of actual and pro rata achievement
of performance goals.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 1,000,000 shares
in the aggregate, or any Awards of Restricted Stock or Restricted Stock Units with respect to more than 500,000 shares in the
aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual
share limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Awards may be granted under the Incentive Plan more than ten years after the date upon which the Incentive Plan was adopted by
the Board of Directors, and no options or SARS granted under the Incentive Plan may be exercised after the expiration of ten years
from the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the Incentive Plan may be either &ldquo;incentive stock options&rdquo; within the meaning of Section 422(b) of the
Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), or &ldquo;non-qualified&rdquo; stock options that do not qualify
incentive stock options. Incentive stock options may be granted only to our employees and employees of our subsidiaries. The exercise
price of stock options granted under the Incentive Plan must be equal to the fair market of our common stock on the date the option
is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of our stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of our common stock
on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of our common
stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the
first time by an optionee in any calendar year may not exceed $100,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of an option may be payable in cash or in common stock having a fair market value equal to the exercise price,
or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board of Directors
or Committee may approve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter
as approved by the Board or Committee, but in the case of the termination of an employee, director, or consultant&rsquo;s services
due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination
or the expiration date of the option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares covered by the Incentive Plan, and the number of shares and the exercise price per share of each outstanding
option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding shares of common
stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other increase or decrease
in the number of issued and outstanding shares of common stock effected without receipt of consideration by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock and Restricted Stock Units</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of granting options, we may enter into purchase agreements with employees under which they may purchase or otherwise acquire
Restricted Stock or Restricted Stock Units subject to such vesting, transfer, and repurchase terms and restrictions as the Board
or Committee may determine. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market
value. We may permit employees or consultants, but not executive officers or directors, who purchase Restricted Stock to pay for
their shares by delivering a promissory note or an installment payment agreement that may be secured by a pledge of their Restricted
Stock. We may also issue Restricted Stock for services actually performed by the recipient prior to the issuance of the Restricted
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors or Committee may require that Restricted Stock shall be held by us or in escrow pending the expiration or release
of the applicable restrictions. Unvested Restricted Stock for which we have not received payment may be forfeited to us, or we
may have the right to repurchase unvested shares upon the occurrence of specified events, such as termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the restrictions set by the Board of Directors or Committee, a recipient of Restricted Stock generally shall have the rights
and privileges of a shareholder, including the right to vote the Restricted Stock and the right to receive dividends; provided
that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld by us for the recipient&rsquo;s
account, and interest may be credited on the amount of the cash dividends withheld at a rate and subject to such terms as determined
by the Board or Committee. The cash dividends or stock dividends so withheld and attributable to any particular share of Restricted
Stock (and earnings thereon, if applicable) shall be distributed to the recipient in cash or, at the discretion of the Board of
Directors or Committee, in shares of common stock having a fair market value equal to the amount of such dividends, if applicable,
upon the release of restrictions on the Restricted Stock and, if the Restricted Stock is forfeited, the recipient shall have no
right to the dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms and conditions of a grant of Restricted Stock Units shall be determined by the Board or Committee. No shares of common stock
shall be issued at the time a Restricted Stock Unit is granted, and we will not be required to set aside a fund for the payment
of any such award. A recipient of Restricted Stock Units shall have no voting rights with respect to the Restricted Stock Units.
Upon the expiration of the restrictions applicable to a Restricted Stock Unit, we will either issue to the recipient, without
charge, one common share per Restricted Stock Unit or cash in an amount equal to the fair market value of one common share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the discretion of the Board of Directors or Committee, each Restricted Stock Unit (representing one common share) may be credited
with cash and stock dividends paid in respect of one common share (&ldquo;Dividend Equivalents&rdquo;). Dividend Equivalents shall
be withheld by us for the recipient&rsquo;s account, and interest may be credited on the amount of cash Dividend Equivalents withheld
at a rate and subject to such terms as determined by the Board or Committee. Dividend Equivalents credited to a recipient&rsquo;s
account and attributable to any particular Restricted Stock Unit (and earnings thereon, if applicable) shall be distributed in
cash or, at the discretion of the Board or Committee, in shares of common stock having a fair market value equal to the amount
of the Dividend Equivalents and earnings, if applicable, upon settlement of the Restricted Stock Unit. If a Restricted Stock Unit
is forfeited, the recipient shall have no right to the related Dividend Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>SARs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
SAR is the right to receive, upon exercise, an amount payable in cash or shares or a combination of shares and cash, as determined
by the Board or Committee, equal to the number of shares subject to the SAR that is being exercised, multiplied by the excess
of (a) the fair market value of a common share on the date the SAR is exercised, over (b) the exercise price specified in the
SAR Award agreement. SARs may be granted either as free standing SARs or in tandem with options, and with such terms and conditions
as the Board or Committee may determine. No SAR may be exercised later than 10 years after the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of an SAR will be determined by the Board or Committee, but shall not be less than 100% of the fair market value
of one common share on the date of grant. An SAR granted in conjunction with an option shall have the same exercise price as the
related option, shall be transferable only upon the same terms and conditions as the related option, and shall be exercisable
only to the same extent as the related option; provided, however, that the SAR by its terms shall be exercisable only when the
fair market value per share exceeds the exercise price per share of the SAR or related option. Upon any exercise of an SAR granted
in tandem with an option, the number of shares for which the related option shall be exercisable shall be reduced by the number
of shares for which the SAR has been exercised. The number of shares for which an SAR issued in tandem with an option shall be
exercisable shall be reduced by the number of shares for which the related option has been exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Withholding</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent provided by the terms of an Award Agreement or as may be approved by the Board or Committee, an optionee or recipient
of a Restricted Stock or Restricted Stock Unit Award or SAR may satisfy any federal, state or local tax withholding obligation
relating to the Award by any of the following means (in addition to our right to withhold from any compensation paid to the Award
recipient) or by a combination of such means: (a) tendering a cash payment; (b) authorizing us to withhold shares of common stock
from the shares otherwise issuable to the recipient as a result of the exercise or acquisition of shares under the Award, provided,
however, that no shares are withheld with a value exceeding the minimum amount of tax required to be withheld by law; or (c) delivering
to us previously owned and unencumbered shares of OncoCyte common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Changes
in Shares Under the Incentive Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of changes in the outstanding common stock or in our capital structure by reason of any stock or extraordinary cash
dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization,
merger, consolidation, combination, exchange, or other relevant change in capitalization, the terms of Awards granted under the
Incentive Plan, and the maximum number of shares subject to all Awards under the Incentive Plan or with respect to which any one
person may be granted Awards during any one year period, will be equitably adjusted or substituted, as to the number, price or
kind of shares or other consideration subject to the Awards to the extent necessary to preserve the economic intent of the Awards.
In making such adjustments, the Board or Committee shall generally ensure that the adjustments will not constitute a modification,
extension or renewal of an incentive stock option within the meaning of Section 424(h)(3) of the Code, and in the case of non-qualified
options, ensure that any adjustments will not constitute a modification of such non-qualified options within the meaning of Section
409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restrictions
on Transfers of Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Incentive Plan, stock options may be transferred to a limited class of defined &ldquo;permitted transferees,&rdquo; such as
the option holder&rsquo;s immediate family members, family trusts and family controlled companies. In addition, options may be
transferred to a securities broker/dealer to exercise the options on the option holder&rsquo;s behalf as a means of the option
holder obtaining the funds needed to exercise the option, provided that the fair market value of the shares being acquired exceeded
the exercise price of the option at the close of the market on the trading day preceding the exercise date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Repricing
                                         Prohibition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Incentive Plan prohibits any modification of the purchase price or exercise price of an outstanding option or other Award if the
change would effect a &ldquo;repricing&rsquo; without shareholder approval. As defined in the Incentive Plan, &ldquo;repricing&rdquo;
means a reduction in the exercise price of an outstanding option or SAR or cancellation of an &ldquo;underwater&rdquo; or &ldquo;out-of-the-money&rdquo;
Award in exchange for other Awards or cash. An &ldquo;underwater&rdquo; or &ldquo;out-of-the-money&rdquo; Award is defined to
mean an Award for which the exercise price is less than the &ldquo;fair market value&rdquo; of OncoCyte common stock. The fair
market value is generally determined by the closing price of OncoCyte common stock on the NYSE American or any other national
securities exchange or inter-dealer quotation system on which OncoCyte common stock is traded.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
on Share Recycling</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
subject to an Award shall not again be made available for issuance or delivery under the Incentive Plan if those shares are (a)
shares tendered in payment of an option, (b) shares delivered or withheld by OncoCyte to satisfy any tax withholding obligation,
(c) shares covered by a stock-settled SAR or other Award that were not issued upon the settlement of the Award, or (d) shares
repurchased by OncoCyte using the proceeds from option exercises. Only shares subject to an Award that is cancelled or forfeited
or expires prior to exercise or realization may be regranted under the Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Future
Option Plan Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than with respect to certain stock options to be granted to our non-employee directors as described in &ldquo;CORPORATE GOVERNANCE&mdash;Compensation
of Directors,&rdquo; the Equity Awards under the Incentive Plan are within the discretion of our Compensation Committee and the
exercise price and value of the Equity Awards will reflect the market price of our common stock at the time of the Equity Award.
As a result, the benefits that will be awarded under the Incentive Plan, including to our non-employee directors, are not determinable
at this time. Our Compensation Committee and Board of Directors have guidelines for determining option awards based upon the professional
level of each employee in the organization, but the ultimate decision to grant Equity Awards will also be based on each employee&rsquo;s
annual performance. According, the number and value of options that might be granted to our executive officers and other employees
is not presently determinable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows certain information concerning the options outstanding and available for issuance under all of our compensation
plans and agreements as of December 31, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plan
    Category</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares to be Issued upon Exercise of Outstanding Options, Warrants, and Rights</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price of the Outstanding Options, Warrants, and Rights</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares Remaining Available for Future Issuance under Equity Compensation Plans</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 64%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    Compensation Plans Approved by Shareholders*</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,390,287</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.25</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,384,198</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    Compensation Plans Not Approved by Shareholders</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not include information concerning the Incentive Plan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Federal
Income Tax Consequence of Participation in the Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion summarizes certain federal income tax consequences of participation in the Incentive Plan. Although we believe
the following statements are correct based on existing provisions of the Code and the regulations thereunder, the Code or regulations
may be amended from time to time, and future judicial interpretations may affect the veracity of the discussion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Incentive
Stock Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 422(a) of the Code, the grant and exercise of an incentive stock option pursuant to the Incentive Plan is entitled to
the benefits of Section 421(a) of the Code. Under Section 421(a), an optionee will not be required to recognize income at the
time the option is granted or at the time the option is exercised, except to the extent that the optionee is subject to the alternative
minimum tax. If the applicable holding periods described below are met, when the shares of stock received upon exercise of an
incentive stock option are sold or otherwise disposed of in a taxable transaction, the option holder will recognize compensation
income (taxed as a long term capital gain), for the taxable year in which disposition occurs, in an amount equal to the excess
of the fair market value of the common stock at the time of such disposition over the amount paid for the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not be entitled to any business expense deduction with respect to the grant or exercise of an incentive stock option, except
in connection with a disqualifying disposition as discussed below. No portion of the amount received by the optionee upon the
sale of common stock acquired through the exercise of an incentive stock option will be subject to withholding for federal income
taxes, or be subject to FICA or state disability taxes, except in connection with a disqualifying disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for a participant to receive the favorable tax treatment provided in Section 421(a) of the Code, Section 422 requires that
the participant make no disposition of the option shares within two years from the date the option was granted, nor within one
year from the date the option was exercised and the shares were transferred to the participant. In addition, the participant must,
with certain exceptions for death or disability, be an employee of OncoCyte (or of a parent or subsidiary of OncoCyte, as defined
in Section 424(e) and (f) of the Code, or a corporation, or parent or subsidiary thereof, issuing or assuming the option in a
merger or other corporate reorganization transaction to which Section 424(a) of the Code applies) at all times within the period
beginning on the date of the grant of the option and ending on a date within three months before the date of exercise. In the
event of the death of the participant, the holding periods will not apply to a disposition of the option or option shares by the
participant&rsquo;s estate or by persons receiving the option or shares under the participant&rsquo;s will or by intestate succession.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a participant disposes of stock acquired pursuant to the exercise of an incentive stock option before the expiration of the holding
period requirements set forth above, the participant will realize, at the time of the disposition, ordinary income to the extent
the fair market value of the common stock on the date the shares were purchased exceeded the purchase price. The difference between
the fair market value of the common stock on the date the shares were purchased and the amount realized on disposition is treated
as long-term or short-term capital gain or loss, depending on the participant&rsquo;s holding period of the shares of common stock.
The amount treated as ordinary income may be subject to the income tax withholding requirements of the Code and FICA withholding
requirements. The participant will be required to reimburse us, either directly or through payroll deduction, for all withholding
taxes that we are required to pay on behalf of the participant. At the time of the disposition, we will be allowed a corresponding
business expense deduction under Section 162 of the Code to the extent of the amount of the participant&rsquo;s ordinary income.
We may adopt procedures to assist us in identifying such deductions, and may require a participant to notify us of his or her
intention to dispose of any such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of whether a participant satisfies the requisite holding period for his or her option and shares, the participant may be subject
to the alternative minimum tax with respect to the amount by which the fair market value of the common stock acquired exceeded
the exercise price of the option on the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Incentive Plan also permits us to grant options that do not qualify as incentive stock options. These &ldquo;non-qualified&rdquo;
stock options may be granted to employees or non-employees, such as persons performing consulting or professional services for
us. An Incentive Plan participant who receives a non-qualified option will not be taxed at the time of receipt of the option,
provided that the option does not have an ascertainable value or an exercise price below fair market value of the common stock
on the date of grant, but the participant will be taxed at the time the option is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of taxable income that will be earned upon exercise of a non-qualified option will be the difference between the fair market
value of the common stock on the date of the exercise and the exercise price of the option. We will be allowed a business expense
deduction to the extent of the amount of the participant&rsquo;s taxable income recognized upon the exercise of a non-qualified
option. Because the option holder is subject to tax immediately upon exercise of the option, there are no applicable holding periods
for the stock. The option holder&rsquo;s tax basis in the common stock purchased through the exercise of a non-qualified option
will be equal to the exercise price paid for the stock plus the amount of taxable gain recognized upon the exercise of the option.
The option holder may be subject to additional tax on sale of the stock if the price realized exceeds his or her tax basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>SARs;
Restricted Stock; and Restricted Stock Units</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
recipient of an SAR will not recognize taxable income upon the grant of the SAR. The recipient of the SAR will recognize ordinary
income upon exercise of the SAR in an amount equal to the difference between the fair market value of the shares and the exercise
price on the date of exercise. Any gain or loss recognized upon any later disposition of the shares generally will be a capital
gain or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
recipient of a Restricted Stock Award will not have taxable income upon the grant, unless the Restricted Stock is then vested,
or unless the recipient elects under Section 83(b) of the Code to be taxed at the time of grant. Otherwise, upon vesting of the
shares, the recipient will recognize ordinary income equal to the fair market value of the shares at the time of vesting less
the amount paid for such shares, if any. Any gain or loss recognized upon any later disposition of the shares generally will be
a capital gain or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
recipient of a Restricted Stock Unit does not recognize taxable income when the Award is granted. When vested Restricted Stock
Unit (and dividend equivalents, if any) is settled and distributed, the participant will recognize ordinary income equal to the
amount of cash or the fair market value of shares received, less the amount paid for the Restricted Stock Unit, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ERISA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Incentive Plan is not subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended, and is not
qualified under Code Section 401(a).</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLES
AMENDMENT PROPOSAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are asking our shareholders to approve an amendment (the &ldquo;Amendment&rdquo;) to our Articles of Incorporation that, if approved,
will increase the authorized number of shares of our common stock, no par value, to 85,000,000, from the currently authorized
number of 50,000,000 shares. We refer to this proposal as the Articles Amendment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operative provision of the proposed Amendment would read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Article
THREE of the Articles of Incorporation of the corporation is amended to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THREE:
The corporation is authorized to issue two classes of shares, which shall be designated &ldquo;Common Stock&rdquo; and &ldquo;Preferred
Stock.&rdquo; The number of shares of Common Stock which the corporation is authorized to issue is 85,000,000, and the number
of shares of Preferred Stock which the corporation is authorized to issue is 5,000,000. The Preferred Stock may be issued in one
or more series as the board of directors may by resolution designate. The board of directors is authorized to fix the number of
shares of any series of Preferred Stock and to determine or alter the rights, preferences, privileges, and restrictions granted
to or imposed upon the Preferred Stock as a class, or upon any wholly unissued series of Preferred Stock. The board of directors
may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares
of any series of Preferred Stock subsequent to the issue of shares of that series.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
text of the proposed Amendment is subject to modification to include such changes as our Board determines to be necessary or advisable
to effect the Articles Amendment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vote
Required; Effect of Abstentions and Broker Non-Votes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Articles Amendment Proposal to be approved in accordance with the requirements of California law, the affirmative vote of
the holders of not less than a majority of our outstanding shares entitled to vote is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker
non-votes occur when a beneficial owner of outstanding shares held in &ldquo;street name&rdquo; fails to provide instructions
to the broker or nominee holding the shares as to how to vote on matters deemed &ldquo;non-routine.&rdquo; If you as beneficial
owner do not provide voting instructions, the broker or nominee cannot vote the shares with respect to &ldquo;non-routine&rdquo;
matters, but can vote the shares with respect to &ldquo;routine&rdquo; matters. Typically, when brokers are able to vote the shares,
they vote in favor of the matter. We believe the Articles Amendment Proposal is a &ldquo;routine&rdquo; matter and, as a result,
we do not expect there to be any broker non-votes for this proposal. As long as one of the matters submitted for approval is deemed
to be routine, as is the case with this proxy, any proxies reflecting broker non-votes (if any) will be counted towards the quorum
requirement. If you do not vote your shares for this routine matter, your broker will have the discretion to vote your shares
and broker non-votes will have the effect of a vote against the Articles Amendment Proposal. Accordingly, we strongly encourage
you to submit your proxy and exercise your right to vote as a stockholder to ensure that your shares are voted in the manner in
which you want them to be voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you check the &ldquo;abstain&rdquo; box for the Articles Amendment Proposal on the proxy card or if you attend the Meeting without
submitting a proxy and you abstain from voting on the Articles Amendment Proposal, your shares will be counted for purposes of
determining the presence or absence of a quorum but will not be counted for purposes of determining whether the Articles Amendment
Proposal has received an affirmative vote sufficient for approval. Because the vote to approve the Articles Amendment Proposal
requires the affirmative vote of a majority of our outstanding shares of common stock, an abstention on the Articles Amendment
Proposal has the effect of a vote against the Articles Amendment Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Board of Directors Recommends A Vote &ldquo;FOR&rdquo; the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approval
of the Articles Amendment Proposal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reasons
for the Amendment </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors believes that the proposed increase in the number of authorized shares of Common Stock is desirable in order
to enhance our flexibility in taking possible future actions, such as raising additional equity capital, making acquisitions using
our equity as consideration, awarding equity compensation or pursuing other corporate purposes. As of July 12, 2018, the record
date for determining shareholders entitled to notice of and to vote at the Meeting, we had 39,407,566 shares of Common Stock issued
and outstanding, 4,383,967 shares of Common Stock reserved for issuance upon the exercise of outstanding stock options,
and 2,779,221 shares of Common Stock reserved for issuance upon the exercise of outstanding stock purchase warrants, leaving only
3,429,246 shares of Common Stock available to OncoCyte for use in raising capital, making acquisitions, awarding equity
compensation, or pursuing other corporate purposes. OncoCyte has not yet commercialized any of the cancer diagnostic tests that
it is developing and, until such time as it is able to do so and to generate sufficient revenue to finance its operations, it
will need to raise additional capital, which may occur through the sale of Common Stock, preferred stock, and securities convertible
into or exercisable for shares of Common Stock or preferred stock. OncoCyte may also issue or sell shares of Common Stock to acquire
businesses or assets to expand its technology and product portfolios. OncoCyte considers potential sources of financing and potential
acquisition candidates from time to time when opportunities arise; however, OncoCyte is not presently a party of any financing
or acquisition agreements, and OncoCyte may not be able to raise capital or consummate acquisitions on terms it deems acceptable,
or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved by our shareholders, the Articles Amendment will allow OncoCyte to issue shares of Common Stock to accommodate its foreseeable
needs and objectives without further approval by OncoCyte shareholders. By increasing the authorized number of shares of Common
Stock in advance of any specific transactions, we will be able to act in a timely manner when an opportunity involving the issuance
of Common Stock arises, or when our Board of Directors believes it is in the best interests of OncoCyte and our shareholders to
take action, without the delay, uncertainty and expense that could be involved in obtaining shareholder approval in the midst
of that opportunity. The additional shares of Common Stock being authorized by the Articles Amendment will be unreserved and available
for issuance. No further shareholder authorization would be required prior to the issuance of those shares of Common Stock by
us, except where approval by our shareholders is required under NYSE American rules or the California Corporations Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
additional shares of Common Stock authorized by adoption of the Articles Amendment have rights identical to the currently outstanding
shares of Common Stock. Adoption of the Articles Amendment and issuance of any newly authorized shares of Common Stock will not
affect the rights of the holders of the currently outstanding shares of Common Stock, except for effects incidental to increasing
the number of our shares of Common Stock outstanding, such as dilution of the earnings (loss) per share and voting rights of current
holders of shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in authorized shares of Common Stock could make more difficult or discourage attempts to obtain control of OncoCyte,
thereby having an anti-takeover effect. The increase in the authorized Common Stock was not proposed by our Board of Directors
in response to any known threat to acquire control of OncoCyte.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles of Incorporation currently provide our Board of Directors with the authority to issue up to 5,000,000 shares of preferred
stock and to determine the preferences, limitations and relative rights of shares of preferred stock and to fix the number of
shares of preferred stock constituting any series and the designation of such series, without any further vote or action by our
shareholders. This authority of the Board of Directors will not be changed by the Articles Amendment, and the Articles Amendment
will not increase the total number of shares of preferred stock that the Board of Directors may determine to issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSALS
OF SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
who intend to present a proposal for action at our 2019 Annual Meeting of Shareholders must notify our management of such intention
by notice received at our principal executive offices not later than February 17, 2019 for such proposal to be included in our
proxy statement and form of proxy relating to such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2017, without exhibits, may be obtained by
a shareholder without charge, upon written request to the Secretary of OncoCyte.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
Order of the Board of Directors,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_005.jpg" ALT="http:||content.edgar-online.com|edgar_conv_img|2017|04|28|0001493152-17-004565_IMAGE_005.JPG" STYLE="height: 43px; width: 150px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judith
Segall</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt">Secretary</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
27, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOW
TO ATTEND THE ANNUAL MEETING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a &ldquo;shareholder of record&rdquo; (meaning that you have a stock certificate registered in your own name), your name
will appear on our shareholder list. You will be admitted to the Meeting upon showing your proxy card, driver&rsquo;s license,
or other identification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a &ldquo;street name&rdquo; shareholder (meaning that your shares are held in an account at a broker-dealer firm) your
name will not appear on our shareholder list. If you plan to attend the Meeting, you should ask your broker for a &ldquo;legal
proxy.&rdquo; You will be admitted to the Meeting by showing your legal proxy. You probably received a proxy form from your broker
along with your Proxy Statement, but that form can only be used by your broker to vote your shares, and it is not a &ldquo;legal
proxy&rdquo; that will permit you to vote your shares directly at the Meeting. If you cannot obtain a legal proxy in time, you
will be admitted to the Meeting if you bring a copy of your most recent brokerage account statement showing that you own OncoCyte
shares. However, if you do not obtain a legal proxy, you can only vote your shares by returning to your broker, before the Meeting,
the proxy form that accompanied your Proxy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APPENDIX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018
EQUITY INCENTIVE PLAN</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ONCOCYTE
CORPORATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Purpose; Eligibility</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>General Purpose</U>. The name of this plan is the OncoCyte Corporation 2018 Equity Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;).
The purposes of the Plan are to (a) enable the Company, to attract and retain the types of Employees, Consultants and Directors
who will contribute to the Company&rsquo;s long range success; (b) provide incentives that align the interests of Employees, Consultants
and Directors with those of the shareholders of the Company; and (c) promote the success of the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
<U>Eligible Award Recipients</U>. The persons eligible to receive Awards are the Employees, Consultants and Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
<U>Available Awards</U>. Awards that may be granted under the Plan include: (a) Incentive Stock Options, (b) Non-qualified Stock
Options, (c) Stock Appreciation Rights, and (d) Stock Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Laws</B>&rdquo; means the requirements related to or implicated by the administration of the Plan under applicable state corporate
law, United States federal and state securities laws, the Code, any stock exchange or quotation system on which the shares of
Common Stock are listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are granted under
the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Award</B>&rdquo;
means any right granted under the Plan, including an Incentive Stock Option, a Non-qualified Stock Option, a Stock Appreciation
Right, or a Stock Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Award
Agreement</B>&rdquo; means a written agreement, contract, certificate or other instrument or document evidencing the terms and
conditions of an individual Award granted under the Plan which may, in the discretion of the Company, be transmitted electronically
to any Participant. Each Award Agreement shall be subject to the terms and conditions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Board</B>&rdquo;
means the Board of Directors of OncoCyte, as constituted at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Cause</B>&rdquo;
means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to any Employee or Consultant: (a) If the Employee or Consultant is a party to an employment or service agreement with
the Company or its Affiliates and such agreement provides for a definition of Cause, the definition contained therein; or (b)
If no such agreement exists, or if such agreement does not define Cause: (i) the commission of, or plea of guilty or no contest
to, a felony or a crime involving moral turpitude or the commission of any other act involving wilful malfeasance or material
fiduciary breach with respect to the Company or an Subsidiary; (ii) conduct that results in or is reasonably likely to result
in harm to the reputation or business of the Company or any of its Affiliates; (iii) wilful conversion or misappropriation of
corporate funds; (iv) gross negligence or wilful misconduct with respect to the Company or an Subsidiary; or (v) material violation
of any state or federal securities law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to any Director, a determination by a majority of the disinterested Board members that the Director has engaged in any
of the following:(a) malfeasance in office; (b) gross misconduct or neglect; (c) false or fraudulent misrepresentation inducing
the director&rsquo;s appointment; (d) wilful conversion or misappropriation of corporate funds; or (e) repeated failure to participate
in Board meetings on a regular basis despite having received proper notice of the meetings in advance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to whether a Participant
has been discharged for Cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Change
in Control</B>&rdquo; (a) the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger
or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the
Company and its subsidiaries, taken as a whole, to any Person that is not a subsidiary of the Company; (b) the date which is 10
business days prior to the consummation of a complete liquidation or dissolution of the Company; (c) the acquisition by any Person
of Beneficial Ownership of 50% or more (on a fully diluted basis) of either (i) the then outstanding shares of Common Stock of
the Company, taking into account as outstanding for this purpose such Common Stock issuable upon the exercise of options or warrants,
the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock (the &ldquo;Outstanding
Company Common Stock&rdquo;) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled
to vote generally in the election of directors (the &ldquo;Outstanding Company Voting Securities&rdquo;); provided, however, that
for purposes of this Plan, the following acquisitions shall not constitute a Change in Control: (A) any acquisition by the Company
or any Subsidiary, (B) any acquisition by any employee benefit plan sponsored or maintained by the Company or any subsidiary,
(C) any acquisition which complies with clauses, (i), (ii) and (iii) of subsection (d) of this definition or (D) in respect of
an Award held by a particular Participant, any acquisition by the Participant or any group of persons including the Participant
(or any entity controlled by the Participant or any group of persons including the Participant); or (d) the consummation of a
reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company
that requires the approval of the Company&rsquo;s shareholders, whether for such transaction or the issuance of securities in
the transaction (a &ldquo;Business Combination&rdquo;), unless immediately following such Business Combination: (i) more than
50% of the total voting power of (A) the entity resulting from such Business Combination (the &ldquo;Surviving Company&rdquo;),
or (B) if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of sufficient voting securities
eligible to elect a majority of the members of the board of directors (or the analogous governing body) of the Surviving Company
(the &ldquo;Parent Company&rdquo;), is represented by the Outstanding Company Voting Securities that were outstanding immediately
prior to such Business Combination (or, if applicable, is represented by shares into which the Outstanding Company Voting Securities
were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the
same proportion as the voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to
the Business Combination; (ii) no Person (other than any employee benefit plan sponsored or maintained by the Surviving Company
or the Parent Company) is or becomes the Beneficial Owner, directly or indirectly, of 50% or more of the total voting power of
the outstanding voting securities eligible to elect members of the board of directors of the Parent Company (or the analogous
governing body) (or, if there is no Parent Company, the Surviving Company); and (iii) at least a majority of the members of the
board of directors (or the analogous governing body) of the Parent Company (or, if there is no Parent Company, the Surviving Company)
following the consummation of the Business Combination were Board members at the time of the Board&rsquo;s approval of the execution
of the initial agreement providing for such Business Combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Code</B>&rdquo;
means the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section of the Code shall
be deemed to include a reference to any regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Committee</B>&rdquo;
means a committee of the Board appointed by the Board to administer the Plan in accordance with <B><I>Section </I> 3.3</B> and
<B><I>Section </I> 3.4</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Common
Stock</B>&rdquo; means the common shares, no par value per share, of OncoCyte, or such other securities of the OncoCyte as may
be designated by the Board or Committee from time to time in substitution thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
means OncoCyte and any or all of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Consultant</B>&rdquo;
means any individual who is engaged by the Company to render consulting or advisory services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Continuous
Service</B>&rdquo; means that the Participant&rsquo;s service with the Company, whether as an Employee, Consultant or Director,
is not interrupted or terminated. The Participant&rsquo;s Continuous Service shall not be deemed to have terminated merely because
of a change in the capacity in which the Participant renders service to the Company as an Employee, Consultant or Director or
a change in the entity for which the Participant renders such service (such as a change of employment from one Subsidiary to another
Subsidiary), <I>provided that</I> there is no interruption or termination of the Participant&rsquo;s Continuous Service; <I>provided
further that</I> if any Award is subject to Section 409A of the Code, this sentence shall only be given effect to the extent consistent
with Section 409A of the Code. For example, a change in status from an Employee to a Director will not constitute an interruption
of Continuous Service. The Board or Committee, in its sole discretion, may determine whether Continuous Service shall be considered
interrupted in the case of any leave of absence approved by the Board or Committee, such as sick leave, military leave, or any
other personal or family leave of absence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Director</B>&rdquo;
means a member of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Disability</B>&rdquo;
means that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical
or mental impairment; <I>provided, however,</I> for purposes of determining the term of an Incentive Stock Option pursuant to
<B><I>Section </I> 6.10</B> hereof, the term Disability shall have the meaning ascribed to it under Section 22(e)(3) of the Code.
The determination of whether an individual has a Disability shall be determined by the Board or Committee or under procedures
adopted by the Board or Committee. Except for a determination of Disability within the meaning of Section 22(e)(3) of the Code
for purposes of an Incentive Stock Option, the Board or Committee may rely on any determination that a Participant is disabled
for purposes of benefits under any long-term disability plan maintained by the Company in which a Participant participates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effective
Date</B>&rdquo; shall mean the date as of which this Plan is adopted by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Employee</B>&rdquo;
means any person employed by the Company; <I>provided, that, </I>for purposes of determining eligibility to receive Incentive
Stock Options, an Employee shall mean an employee of the Company or a parent corporation within the meaning of Code Section 424.
Mere service as a Director or payment of a director&rsquo;s fee by the Company shall not be sufficient to constitute &ldquo;employment&rdquo;
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Fair
Market Value</B>&rdquo; means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed
on any national stock exchange, inter-dealer quotation system, or over-the-counter market that reports closing prices, including
without limitation, the New York Stock Exchange, NYSE MKT, or the OTC Bulletin Board, the Fair Market Value shall be the closing
price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date)
as quoted on such exchange or system on the day of determination, as reported in the <I>Wall Street Journal</I> or such other
source as the Board or Committee deems reliable. In the absence of an established market for the Common Stock, the Fair Market
Value shall be determined in good faith by the Board or Committee, using such methods as the Board or Committee determines to
be reasonable under the circumstances, and such determination shall be conclusive and binding on all persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Free
Standing Rights</B>&rdquo; has the meaning set forth in <B><I>Section </I> 7.1(a)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Good
Reason</B>&rdquo; means: (a) if an Employee or Consultant is a party to an employment or service agreement with the Company and
such agreement provides for a definition of Good Reason, the definition contained therein; or (b) if no such agreement exists
or if such agreement does not define Good Reason, the occurrence of one or more of the following without the Participant&rsquo;s
express written consent, which circumstances are not remedied by the Company within thirty (30) days of its receipt of a written
notice from the Participant describing the applicable circumstances (which notice must be provided by the Participant within ninety
(90) days of the Participant&rsquo;s knowledge of the applicable circumstances): (i) any material increase in the Participant&rsquo;s
duties (other than by way of promotion attendant with additional responsibilities, authority or title and an increase in salary
commensurate therewith), (ii) any material diminution of responsibilities, authority, title, status or reporting structure; (iii)
a material reduction in the Participant&rsquo;s base salary or bonus opportunity; or (iv) a geographical relocation of the Participant&rsquo;s
principal office location by more than fifty (50) miles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Grant
Date</B>&rdquo; means the date on which the Board or Committee adopts a resolution, or takes other appropriate action, expressly
granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in
such resolution, then such date as is set forth in such resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Incentive
Stock Option</B>&rdquo; means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of
the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Non-Employee
Director</B>&rdquo; means a Director who is a &ldquo;non-employee director&rdquo; within the meaning of Rule 16b-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Non-qualified
Stock Option</B>&rdquo; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock
Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Officer</B>&rdquo;
means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations
promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;OncoCyte&rdquo;
</B>means OncoCyte Corporation, a California corporation, and any successor company or any parent company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Option</B>&rdquo;
means an Incentive Stock Option or a Non-qualified Stock Option granted pursuant to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Optionholder</B>&rdquo;
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding
Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Option
Exercise Price</B>&rdquo; means the price at which a share of Common Stock may be purchased upon the exercise of an Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Participant</B>&rdquo;
means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding
Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Performance
Goals</B>&rdquo; means one or more goals established by the Board or Committee that must be attained by OncoCyte or a Subsidiary,
or a division, business unit or operational unit of OncoCyte or a Subsidiary in order for an Award to vest or for the determination
of the amount of an Award. A Performance Goal may be based on financial results or performance or upon the attainment of any other
goal or milestone designated by the Board or Committee such as, by way of example only and not by way of limitation, the attainment
of a specified amount of sales, revenues, or net income, an increase in the Fair Market Value of the Common Stock, or the commencement
or successful completion of a clinical trial of a new drug, biological product, or medical device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Permitted
Transferee</B>&rdquo; means: (a) a member of the Optionholder&rsquo;s immediate family (child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including adoptive relationships), any person sharing the Optionholder&rsquo;s household (other
than a tenant or employee), a trust in which these persons have more than 50% of the beneficial interest, a foundation in which
these persons (or the Optionholder) control the management of assets, and any other entity in which these persons (or the Optionholder)
own more than 50% of the voting interests; and (b) in conjunction with the exercise of an Option, and for the purpose of obtaining
financing for such exercise, the option holder may arrange for a securities broker/dealer to exercise an option on the option
holder&rsquo;s behalf, to the extent necessary to obtain funds required to pay the exercise price of the option, provided that
the Fair Market Value of the Common Stock determined as of the date immediately before the date of such transfer exceeded the
exercise price of the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Plan</B>&rdquo;
means this OncoCyte 2018 Equity Incentive Plan, as amended and/or amended and restated from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Related
Rights</B>&rdquo; has the meaning set forth in <B><I>Section </I> 7.1(a)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Restricted
Period</B>&rdquo; has the meaning set forth in <B><I>Section </I> 7.2(a)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Rule
16b-3</B>&rdquo; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Stock
Appreciation Right</B>&rdquo; means the right pursuant to an Award granted under <B><I>Section </I> 7.1</B> to receive, upon exercise,
an amount payable in cash or shares equal to the number of shares subject to the Stock Appreciation Right that is being exercised
multiplied by the excess of (a) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (b)
the exercise price specified in the Stock Appreciation Right Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Stock
Award</B>&rdquo; means any Award granted pursuant to <B><I>Section </I> 7.2(a)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Stock
for Stock Exchange</B>&rdquo; has the meaning set forth in <B><I>Section </I> 6.4</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>&ldquo;Subsidiary&rdquo;
</B>means (i) any corporation or other entity in which the Company possesses directly or indirectly equity interests representing
at least 50% of the total ordinary voting power or at least 50% of the total value of all classes of equity interests of such
corporation or other entity and (ii) any other entity in which the Company has a direct or indirect economic interest that is
designated as a Subsidiary by the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Ten
Percent Shareholder</B>&rdquo; means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing
more than 10% of the total combined voting power of all classes of stock of the Company or of any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Voting
Securities&rdquo;</B> means any class or series of stock or other securities entitling the holder vote for the election of Directors
generally, but shall exclude any such security that entitles the holder to designate, appoint, or vote for the election of a minority
of the Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Administration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Authority of Committee</U>. The Plan shall be administered by the Board or, in the Board&rsquo;s sole discretion, by a Committee.
Subject to the terms of the Plan, the Board or Committee shall have the authority:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
to construe and interpret the Plan and apply its provisions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
to determine when Awards are to be granted under the Plan and the applicable Grant Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
from time to time to select those Participants to whom Awards shall be granted;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
to determine the number of shares of Common Stock to be made subject to each Award;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
to determine whether each Option is to be an Incentive Stock Option or a Non-qualified Stock Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of payment,
and vesting provisions (subject to <B><I>Section 3.5</I></B>), and to specify the provisions of the Award Agreement relating to
such grant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding
Award; <I>provided, however</I>, that no such amendment shall accelerate the vesting date of any Award except as otherwise permitted
by the Plan; and <I>provided, further, </I>that if any such amendment impairs a Participant&rsquo;s rights or increases a Participant&rsquo;s
obligations under his or her Award or creates or increases a Participant&rsquo;s federal income tax liability with respect to
an Award, such amendment shall also be subject to the Participant&rsquo;s consent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination
of their employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees
under the Company&rsquo;s employment policies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
to make decisions with respect to outstanding Awards that may become necessary upon a Change in Control or an event that triggers
anti-dilution adjustments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
to interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any
instrument or agreement relating to, or Award granted under, the Plan; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration
of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board or Committee also may modify the purchase price or the exercise price of any outstanding Award, <I>provided that</I> if
the modification effects a repricing, shareholder approval shall be required before the repricing is effective. As used in this
paragraph, repricing means (i) reduction in the exercise price of an outstanding Option or SAR, and (ii) cancellation of an &ldquo;underwater&rdquo;
or &ldquo;out-of-the money&rdquo; Award in exchange for other Awards or cash. An &ldquo;underwater&rdquo; or &ldquo;out-of-the
money&rdquo; Award is one for which the exercise price is greater than the Fair Market Value of the underlying Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Decisions Final</U>. All decisions made by the Board or Committee pursuant to the provisions of the Plan shall be final and
binding on the Company and the Participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<U>Delegation</U>. The Board may delegate administration of the Plan to a committee or committees of the Board, and the term &ldquo;<B>Committee</B>&rdquo;
shall apply to any such committee. The Board may abolish the Committee at any time and revest in the Board the administration
of the Plan. The members of the Committee shall be appointed by and serve at the pleasure of the Board. From time to time, the
Board may increase or decrease the size of the Committee, add additional members to, remove members (with or without cause) from,
appoint new members in substitution therefor, and fill vacancies, however caused, in the Committee. The Committee shall act pursuant
to a vote of the majority of its members or, in the case of a Committee comprised of only two members, the unanimous consent of
its members, whether present or not, or by the written consent of the majority of its members and minutes shall be kept of all
of its meetings and copies thereof shall be provided to the Board. Subject to the limitations prescribed by the Plan and the Board,
the Committee may establish and follow such rules and regulations for the conduct of its business as it may determine to be advisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<U>Committee Composition</U>. Except as otherwise determined by the Board, the Committee shall consist solely of two or more Non-Employee
Directors. The Board shall have discretion to determine whether or not it intends to comply with the exemption requirements of
Rule 16b-3. However, if the Board intends to satisfy such exemption requirements, with respect to Awards to any insider subject
to Section 16 of the Exchange Act, the Committee shall be a compensation committee of the Board that at all times consists solely
of two or more Non-Employee Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
<U>Acceleration of Vesting</U>. The Committee or the Board of Directors shall not approve the acceleration of vesting of any Award,
or provide for the acceleration of vesting of any Award in any Award Agreement, employment agreement or other agreement with a
Participant, except in connection with the termination of Continuous Service of a Participant as a result of (a) death or Disability
of the Participant, (b) termination of the employment or Continuous Service of a Participant by the Company without Cause, or
by the Participant for Good Reason, or (c) termination of the employment or Continuous Service of a Participant by the Company
or a successor in interest without Cause, or by the Participant for Good Reason, following a Change in Control. In the case of
the acceleration of vesting of any performance-based Award, acceleration of vesting shall be limited to actual performance achieved,
pro rata achievement of the performance goal(s) on the basis for the elapsed portion of the performance period (as determined
by the Committee or the Board), or a combination of actual and pro rata achievement of performance goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Shares Subject to the Plan</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
Subject to adjustment in accordance with <B><I>Section </I> 11</B>, a total of 5,000,000 shares of Common Stock shall be available
for the grant of Awards under the Plan. Any shares of Common Stock granted in connection with Options and Stock Appreciation Rights
shall be counted against this limit as one share for every one Option or Stock Appreciation Right awarded. Any shares of Common
Stock granted in connection with Awards other than Options and Stock Appreciation Rights shall be counted against this limit as
two (2) shares of Common Stock for every one (1) share of Common Stock granted in connection with such Award. During the terms
of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
Subject to adjustment in accordance with <B><I>Section </I> 11</B>, no Participant shall be granted, during any one (1) year period,
Options to purchase Common Stock and Stock Appreciation Rights with respect to more than 1,000,000 shares of Common Stock in the
aggregate or any other Awards with respect to more than 500,000 shares of Common Stock in the aggregate. If an Award is to be
settled in cash, the number of shares of Common Stock on which the Award is based shall not count toward the individual share
limit set forth in this <B><I>Section</I> 4</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
Any shares of Common Stock subject to an Award that is cancelled, forfeited or expires prior to exercise or realization, either
in full or in part, shall again become available for issuance under the Plan. Any shares of Common Stock that again become available
for future grants pursuant to this Section shall be added back as one share if such shares were subject to Options or Stock Appreciation
Rights and as two (2) shares if such shares were subject to other Awards. Notwithstanding anything to the contrary contained herein:
shares subject to an Award under the Plan shall not again be made available for issuance or delivery under the Plan if such shares
are (a) shares tendered in payment of an Option, (b) shares delivered or withheld by the Company to satisfy any tax withholding
obligation, (c) shares covered by a stock-settled Stock Appreciation Right or other Awards that were not issued upon the settlement
of the Award, or (d) shares repurchased by the Company using Option proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Eligibility</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Eligibility for Specific Awards</U>. Incentive Stock Options may be granted only to Employees. Awards other than Incentive
Stock Options may be granted to Employees, Consultants and Directors. Awards may be granted to individuals whom the Committee
determines are reasonably expected to become Employees, Consultants and Directors; provided that such grant and the Grant Date
shall become effective only the individual becoming an Employee, Consultant or Director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Ten Percent Shareholders</U>. A Ten Percent Shareholder shall not be granted an Incentive Stock Option unless the Option Exercise
Price is at least 110% of the Fair Market Value of the Common Stock at the Grant Date and the Option is not exercisable after
the expiration of five years from the Grant Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Option Provisions</U>. Each Option granted
under the Plan shall be evidenced by an Award Agreement. Each Option so granted shall be subject to the conditions set forth in
this <B><I>Section</I> 6</B>, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable
Award Agreement. All Options shall be separately designated Incentive Stock Options or Non-qualified Stock Options at the time
of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased
on exercise of each type of Option. Notwithstanding the foregoing, the Company shall have no liability to any Participant or any
other person if an Option designated as an Incentive Stock Option fails to qualify as such at any time or if an Option is determined
to constitute &ldquo;nonqualified deferred compensation&rdquo; within the meaning of Section 409A of the Code and the terms of
such Option do not satisfy the requirements of Section 409A of the Code. The provisions of separate Options need not be identical,
but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance
of each of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Term</U>. An Option shall expire, and thereafter no longer be exercisable, on such date as the Board or Committee may designate;
<I>provided, however</I>, no Option shall be exercisable after the expiration of 10 years from the Grant Date, and no Incentive
Stock Option granted to a Ten Percent Shareholder shall be exercisable after the expiration of 5 years from the Grant Date. The
expiration date of each Option shall be stated in the Award Agreement pertaining to the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Exercise Price of An Incentive Stock Option</U>. Subject to the provisions of <B><I>Section </I> 5.2</B> pertaining to Incentive
Stock Options granted to Ten Percent Shareholders, the Option Exercise Price of each Incentive Stock Option shall be not less
than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing,
an Incentive Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if
such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section
424(a) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Exercise Price of a Non-qualified Stock Option</U>. The Option Exercise Price of each Non-qualified Stock Option shall be not
less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing,
a Non-qualified Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence
if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of
Section 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Consideration</U>. The Option Exercise Price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted
by applicable statutes and regulations, either (a) in cash or by certified or bank check at the time the Option is exercised or
(b) to the extent approved by the Board or Committee, the Option Exercise Price may be paid: (i) by delivery to the Company of
other Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date of delivery equal to the Option
Exercise Price (or portion thereof) due for the number of shares being acquired (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);
(ii) a &ldquo;cashless&rdquo; exercise program established with a broker pursuant to which the broker exercises or arranges for
the coordination of the exercise of the Option with the sale of some or all of the underlying Common Stock; (iii) any combination
of the foregoing methods; or (iv) in any other form of consideration that is legal consideration for the issuance of Common Stock
and that may be acceptable to the Board or Committee. Unless otherwise specifically provided in the Option, the exercise price
of Common Stock acquired pursuant to an Option that is paid by delivery to the Company of other Common Stock acquired, directly
or indirectly from the Company, shall be paid only by shares of the Common Stock of the Company that have been held for more than
six months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes).
Notwithstanding the foregoing, during any period for which the Common Stock is publicly traded (i.e., the Common Stock is listed
on any national securities exchange or an interdealer quotation system, or is traded in an over-the-counter market that reports
closing prices) an exercise by a Director or Officer that involves or may involve a direct or indirect extension of credit or
arrangement of an extension of credit by the Company, directly or indirectly, in violation of Section 402(a) of the Sarbanes-Oxley
Act of 2002 shall be prohibited with respect to any Award under this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5
<U>Transferability of An Incentive Stock Option</U>. An Incentive Stock Option shall not be transferable except by will or by
the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6
<U>Transferability of a Non-qualified Stock Option</U>. A Non-qualified Stock Option may, in the sole discretion of the Board
or Committee, be transferable to a Permitted Transferee, upon approval by the Board or Committee, to the extent provided in the
Award Agreement or by subsequent consent granted by the Board or Committee. If the Non-qualified Stock Option does not provide
for transferability or consent to transfer to a Permitted Transferee is not granted by the Board or Committee, then the Non-qualified
Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during
the lifetime of the Optionholder only by the Optionholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7
<U>Vesting of Options</U>. Each Option shall vest and therefore become exercisable in periodic instalments as determined by the
Board or Committee or based upon the attainment of a Performance Goal or the occurrence of a specified event; provided, however,
that no Option shall vest, in whole or in part, earlier than one year from the date of grant, except as permitted by <B><I>Section
3.5</I></B>. The vesting provisions of individual Options may vary. No Option may be exercised for a fraction of a share of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8
<U>Termination of Continuous Service</U>. Unless otherwise provided in an Award Agreement or in an employment agreement the terms
of which have been approved by the Board or Committee, in the event an Optionholder&rsquo;s Continuous Service terminates (other
than upon the Optionholder&rsquo;s death or Disability), the Optionholder may exercise his or her Option (to the extent that the
Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on
the earlier of (a) the date three months following the termination of the Optionholder&rsquo;s Continuous Service or (b) the expiration
of the term of the Option as set forth in the Award Agreement. If, after termination, the Optionholder does not exercise his or
her Option within the time specified in the Award Agreement, the Option shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9
<U>Extension of Termination Date</U>. An Optionholder&rsquo;s Award Agreement may also provide that if the exercise of the Option
following the termination of the Optionholder&rsquo;s Continuous Service for any reason would be prohibited at any time because
the issuance of shares of Common Stock would violate the registration requirements under the Securities Act or any other state
or federal securities law or the rules of any securities exchange or interdealer quotation system, then the Option shall terminate
on the earlier of (a) the expiration of the term of the Option in accordance with <B><I>Section </I> 6.1</B> or (b) the expiration
of a period after termination of the Participant&rsquo;s Continuous Service that is three months after the end of the period during
which the exercise of the Option would be in violation of such registration or other securities law requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10
<U>Disability of Optionholder</U>. Unless otherwise provided in an Award Agreement, in the event that an Optionholder&rsquo;s
Continuous Service terminates as a result of the Optionholder&rsquo;s Disability, the Optionholder may exercise his or her Option
(to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such
period of time ending on the earlier of (a) the date 12 months following such termination or (b) the expiration of the term of
the Option as set forth in the Award Agreement. If, after termination, the Optionholder does not exercise his or her Option within
the time specified herein or in the Award Agreement, the Option shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11
<U>Death of Optionholder</U>. Unless otherwise provided in an Award Agreement, in the event an Optionholder&rsquo;s Continuous
Service terminates as a result of the Optionholder&rsquo;s death, then the Option may be exercised (to the extent the Optionholder
was entitled to exercise such Option as of the date of death) by the Optionholder&rsquo;s estate, executor, or personal representative,
by a person who acquired the right to exercise the Option by bequest, but only within the period ending on the earlier of (a)
the date 12 months following the date of death or (b) the expiration of the term of such Option as set forth in the Award Agreement.
If, after the Optionholder&rsquo;s death, the Option is not exercised within the time specified herein or in the Award Agreement,
the Option shall terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12
<U>Incentive Stock Option $100,000 Limitation</U>. To the extent that the aggregate Fair Market Value (determined at the time
of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder
during any calendar year (under all plans of the Company) exceeds $100,000, the Options or portions thereof which exceed such
limit (according to the order in which they were granted) shall be treated as Non-qualified Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Provisions of Awards Other Than Options</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Stock Appreciation Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Stock Appreciation Right granted under the Plan shall be evidenced by an Award Agreement. Each Stock Appreciation Right so granted
shall be subject to the conditions set forth in this <B><I>Section</I> 7.1</B>, and to such other conditions not inconsistent
with the Plan as may be reflected in the applicable Award Agreement. Stock Appreciation Rights may be granted alone (&ldquo;<B>Free
Standing Rights</B>&rdquo;) or in tandem with an Option granted under the Plan (&ldquo;<B>Related Rights</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Grant Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Related Right that relates to a Non-qualified Stock Option may be granted at the same time the Option is granted or at any time
thereafter but before the exercise or expiration of the Option. Any Related Right that relates to an Incentive Stock Option must
be granted at the same time the Incentive Stock Option is granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Term of Stock Appreciation Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of a Stock Appreciation Right granted under the Plan shall be determined by the Board or Committee; <I>provided, however</I>,
no Stock Appreciation Right shall be exercisable later than the tenth anniversary of the Grant Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Vesting of Stock Appreciation Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Stock Appreciation Right shall vest and therefore become exercisable in periodic instalments as determined by the Board or Committee
or based upon the attainment of a Performance Goal or the occurrence of a specified event; provided, however, that no Stock Appreciation
Right shall vest, in whole or in part, earlier than one year from the date of grant, except as permitted by <B><I>Section 3.5</I></B>.
The vesting provisions of individual Stock Appreciation Rights may vary. No Stock Appreciation Right may be exercised for a fraction
of a share of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Exercise and Payment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
exercise of a Stock Appreciation Right, the holder shall be entitled to receive from the Company an amount equal to the number
of shares of Common Stock subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (i) the
Fair Market Value of a share of Common Stock on the date the Award is exercised, over (ii) the exercise price specified in the
Stock Appreciation Right or related Option. Payment with respect to the exercise of a Stock Appreciation Right shall be made on
the date of exercise. Payment shall be made in the form of shares of Common Stock (with or without restrictions as to substantial
risk of forfeiture and transferability, as determined by the Board Committee in its sole discretion), cash or a combination thereof,
as determined by the Board or Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Exercise Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of a Free Standing Stock Appreciation Right shall be determined by the Board or Committee, but shall not be less
than 100% of the Fair Market Value of one share of Common Stock on the Grant Date of the Stock Appreciation Right. A Related Right
granted simultaneously with or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto
shall have the same exercise price as the related Option, shall be transferable only upon the same terms and conditions as the
related Option, and shall be exercisable only to the same extent as the related Option; <I>provided, however</I>, that a Stock
Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per share of Common Stock subject to the
Stock Appreciation Right and related Option exceeds the exercise price per share thereof. No Stock Appreciation Rights may be
granted in tandem with an Option unless the Board or Committee determines that the requirements of <B><I>Section </I> 7.1(b)</B>
are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>Reduction in the Underlying Option Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any exercise of a Related Right, the number of shares of Common Stock for which any related Option shall be exercisable shall
be reduced by the number of shares for which the Stock Appreciation Right has been exercised. The number of shares of Common Stock
for which a Related Right shall be exercisable shall be reduced upon any exercise of any related Option by the number of shares
of Common Stock for which such Option has been exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Stock Awards</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Stock Award is an Award of actual shares of Common Stock (&ldquo;<B>Restricted Stock</B>&rdquo;) or hypothetical Common Stock
units (&ldquo;<B>Restricted Stock Units</B>&rdquo;) having a value equal to the Fair Market Value of an identical number of shares
of Common Stock. A Stock Award may, but need not, provide that such Stock Award may not be sold, assigned, transferred or otherwise
disposed of, or pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any
other purpose for such period as the Board or Committee shall determine (the &ldquo;<B>Restricted Period</B>&rdquo;). Each Stock
Award granted under the Plan shall be evidenced by an Award Agreement. Each Stock Award so granted shall be subject to the conditions
set forth in this <B><I>Section</I> 7.2</B>, and to such other conditions not inconsistent with the Plan as may be reflected in
the applicable Award Agreement.</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Restricted Stock and Restricted Stock Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    Participant granted Restricted Stock shall execute and deliver to the Company an Award Agreement with respect to the Restricted
    Stock setting forth the applicable payment terms, if any, for the Restricted Stock, and restrictions and other terms and conditions
    applicable to such Restricted Stock. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    Stock may be issued to a Participant without payment or without the delivery of a promissory note or instalment payment agreement
    only for services actually performed by the Participant prior to the issuance of the Restricted Stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the case of Restricted Stock sold to a Participant on an instalment payment basis, the Company may require, as a condition
    of the grant, that the Participant execute and deliver to the Company a promissory note or instalment payment agreement and
    a stock pledge or security agreement, and a blank stock power with respect to the Restricted Stock, in such form and containing
    such terms as the Board or Committee may require. No Restricted Stock shall be sold to an Officer or Director on instalment
    payment terms that would constitute an extension of credit in violation of in violation of Section 402(a) of the Sarbanes-Oxley
    Act of 2002. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the Committee determines that the Restricted Stock shall be held by the Company or in escrow rather than delivered to the
    Participant pending the release of the applicable restrictions, the Committee may require the Participant to additionally
    execute and deliver to the Company (A) an escrow agreement satisfactory to the Committee, if applicable and (B) the appropriate
    blank stock power with respect to the Restricted Stock covered by such agreement. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a Participant fails to execute an agreement evidencing an Award of Restricted Stock and, if applicable, a promissory note
    or instalment payment agreement, stock pledge or security agreement, escrow agreement, and stock power, the Award shall be
    null and void. Subject to the restrictions set forth in the Award, the Participant generally shall have the rights and privileges
    of a shareholder as to such Restricted Stock, including the right to vote such Restricted Stock and the right to receive dividends;
    <I>provided that</I>, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld by the
    Company for the Participant&rsquo;s account, and interest may be credited on the amount of the cash dividends withheld at
    a rate and subject to such terms as determined by the Board or Committee. The cash dividends or stock dividends so withheld
    and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to
    the Participant in cash or, at the discretion of the Board or Committee, in shares of Common Stock having a Fair Market Value
    equal to the amount of such dividends, if applicable, upon the release of restrictions on such share and, if such share is
    forfeited, the Participant shall have no right to such dividends.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    terms and conditions of a grant of Restricted Stock Units shall be reflected in an Award Agreement. No shares of Common Stock
    shall be issued at the time a Restricted Stock Unit is granted, and the Company will not be required to set aside a fund for
    the payment of any such Award. A Participant shall have no voting rights with respect to any Restricted Stock Units granted
    hereunder. At the discretion of the Committee, each Restricted Stock Unit (representing one share of Common Stock) may be
    credited with cash and stock dividends paid by the Company in respect of one share of Common Stock (&ldquo;<B>Dividend Equivalents</B>&rdquo;).
    Dividend Equivalents shall be withheld by the Company for the Participant&rsquo;s account, and interest may be credited on
    the amount of cash Dividend Equivalents withheld at a rate and subject to such terms as determined by the Board or Committee.
    Dividend Equivalents credited to a Participant&rsquo;s account and attributable to any particular Restricted Stock Unit (and
    earnings thereon, if applicable) shall be distributed in cash or, at the discretion of the Board or Committee, in shares of
    Common Stock having a Fair Market Value equal to the amount of such Dividend Equivalents and earnings, if applicable, to the
    Participant upon settlement of such Restricted Stock Unit and, if such Restricted Stock Unit is forfeited, the Participant
    shall have no right to such Dividend Equivalents.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    Stock awarded to a Participant shall be subject to the following restrictions until the expiration of the Restricted Period,
    and to such other terms and conditions as may be set forth in the applicable Award Agreement: (A) if an escrow arrangement
    is used, the Participant shall not be entitled to delivery of the stock certificate; (B) the shares shall be subject to the
    restrictions on transferability set forth in the Award Agreement; (C) the shares shall be subject to forfeiture to the extent
    provided in the applicable Award Agreement; and (D) to the extent such shares are forfeited, the stock certificates shall
    be returned to the Company, and all rights of the Participant to such shares and as a shareholder with respect to such shares
    shall terminate without further obligation on the part of the Company. </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    Stock Units awarded to any Participant shall be subject to (A) forfeiture until the expiration of the Restricted Period, and
    satisfaction of any applicable Performance Goals during such period, to the extent provided in the applicable Award Agreement,
    and to the extent such Restricted Stock Units are forfeited, all rights of the Participant to such Restricted Stock Units
    shall terminate without further obligation on the part of the Company and (B) such other terms and conditions as may be set
    forth in the applicable Award Agreement. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Board or Committee shall have the authority to remove any or all of the restrictions on the Restricted Stock and Restricted
    Stock Units whenever it may determine that, by reason of changes in Applicable Laws or other changes in circumstances arising
    after the date the Restricted Stock or Restricted Stock Units are granted, such action is appropriate; provided, that the
    removal of such restrictions shall not occur earlier than one year from the date of grant of the Award except as permitted
    by <B><I>Section 3.5</I></B>. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Restricted Period</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Stock Awards, the Restricted Period shall commence on the Grant Date and end at the time or times set forth on a schedule
established by the Board or Committee in the applicable Award Agreement; provided, however, that the Restricted Period shall not
expire earlier than one year from the date of grant, except as permitted by <B><I>Section 3.5</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>Delivery of Restricted Stock and Settlement of Restricted Stock Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in <B><I>Section
</I> 7.2(c)</B> and the applicable Award Agreement shall be of no further force or effect with respect to such shares, except
as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver
to the Participant, or his or her beneficiary, without charge, the stock certificate evidencing the shares of Restricted Stock
which have not then been forfeited and with respect to which the Restricted Period has expired (provided, that no fractional shares
shall be issued) and any cash dividends or stock dividends credited to the Participant&rsquo;s account with respect to such Restricted
Stock and the interest thereon, if any. Upon the expiration of the Restricted Period with respect to any outstanding Restricted
Stock Units, the Company shall deliver to the Participant, or his or her beneficiary, without charge, one share of Common Stock
for each such outstanding Restricted Stock Unit (&ldquo;<B>Vested Unit</B>&rdquo;); <I>provided, however</I>, that, if explicitly
provided in the applicable Award Agreement, the Company may, in its sole discretion, elect to pay cash or part cash and part Common
Stock in lieu of delivering only shares of Common Stock for Vested Units. If a cash payment is made in lieu of delivering shares
of Common Stock, the amount of such payment shall be equal to the Fair Market Value of the Common Stock as of the date on which
the Restricted Period lapsed with respect to each Vested Unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<B>Stock Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
certificate representing Restricted Stock awarded under the Plan shall, in addition to any other legends as may be required by
law or by the Board or Committee, bear a legend to the following effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THESE
SHARES MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF
WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Securities Law Compliance</U>. All Awards,
including all Options, Stock Appreciation Rights, and Stock Awards granted under the Plan shall be subject to the requirement
that, if at any time the Board or the Committee shall determine, in its discretion, that the listing upon any securities exchange,
or the registration under the Securities Act, or registration or qualification under any state law is required for the grant,
exercise, issue , or sale of any Options, Stock Appreciation Rights, Common Stock, or Restricted Stock Units under the Plan, or
the consent or approval of any government regulatory body, is necessary or desirable as a condition of, or in connection therewith,
such Option, Stock Appreciation Rights, or Stock Award may not be exercised in whole or in part unless such listing, registration,
qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board or
the Committee. Furthermore, if the Board or the Committee determines that any amendment to any Award (including, but not limited
to, an increase in the exercise price of any Option or Stock Award) is necessary or desirable in connection with the registration
or qualification of any of its shares under any state securities or &ldquo;blue sky&rdquo; law, then the Board or the Committee
shall have the unilateral right to make such changes without the consent of the Participant to whom the Award was granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Each Award Agreement shall provide that no shares of Common Stock shall be purchased or sold thereunder unless and until (i) any
then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction
of the Company and its counsel and (i) if required to do so by the Company, the Participant has executed and delivered to the
Company a letter of investment intent in such form and containing such provisions as the Committee may require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 43pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except as may otherwise be required by the Securities Act, the Company shall not be required to register under the Securities
Act the Plan, any Award or any Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, or any Common Stock
issued or issuable pursuant to any such Award, and the Company shall have no liability for any delay in issuing or failure to
issue or sell any Option, Stock Appreciation Right, Common Stock, or Restricted Stock Unit prior to the date on which a registration
statement under the Securities Act becomes effective with respect to the offer, sale, and issuance of such Award, Option, Stock
Appreciation Right, Restricted Stock, Restricted Stock Unit, or Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Use of Proceeds from Stock</U>. Proceeds from
the sale of Common Stock pursuant to Awards, or upon exercise thereof, shall constitute general funds of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
<U>Acceleration of Exercisability and Vesting</U>. The Board or Committee shall have the power to accelerate the time at which
an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding
the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
<U>Shareholder Rights</U>. Except as provided in the Plan or an Award Agreement, no Participant shall be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until
such Participant has satisfied all requirements for exercise of the Award pursuant to its terms and no adjustment shall be made
for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for
which the record date is prior to the date such Common Stock certificate is issued, except as provided in <B><I>Section </I> 11
</B>hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3
<U>No Employment or Other Service Rights</U>. Nothing in the Plan or any instrument executed or Award granted pursuant thereto
shall confer upon any Participant any right to continue to serve the Company in the capacity in effect at the time the Award was
granted or shall affect the right of the Company to terminate (a) the employment of an Employee with or without notice and with
or without Cause, except as may otherwise be provided in a written employment agreement between the Company and the Participant,
or (b) the service of a Director pursuant to the By-laws of OncoCyte or an Subsidiary, and any applicable provisions of the corporate
law of the state in which OncoCyte or the Subsidiary is incorporated, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4
<U>Withholding Obligations</U>. To the extent provided by the terms of an Award Agreement or as may be approved by the Board or
Committee, a Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition
of Common Stock under an Award by any of the following means (in addition to the Company&rsquo;s right to withhold from any compensation
paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company
to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise
or acquisition of Common Stock under the Award, <I>provided, however</I>, that no shares of Common Stock are withheld with a value
exceeding the minimum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered
shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">11.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustments Upon Changes in Stock</U>. In
the event of changes in the outstanding Common Stock or in the capital structure of the Company by reason of any stock or extraordinary
cash dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization,
merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any
Award, Awards granted under the Plan and any Award Agreements, including the exercise price of Options and Stock Appreciation
Rights and the number of shares of Common Stock subject to such Options, Stock Appreciation Rights, or Stock Awards, the maximum
number of shares of Common Stock subject to all Awards stated in <B><I>Section </I> 4</B>, and the maximum number of shares of
Common Stock with respect to which any one person may be granted Awards during any period stated in <B><I>Section </I> 4</B> will
be equitably adjusted or substituted, as to the number, price or kind of a share of Common Stock or other consideration subject
to such Awards to the extent necessary to preserve the economic intent of such Award. In the case of adjustments made pursuant
to this <B><I>Section</I> 11</B>, unless the Board or Committee specifically determines that such adjustment is in the best interests
of the Company, Board or the Committee shall, in the case of Incentive Stock Options, ensure that any adjustments under this <B><I>Section
</I>11</B> will not constitute a modification, extension or renewal of the Incentive Stock Options within the meaning of Section
424(h)(3) of the Code and in the case of Non-qualified Stock Options, ensure that any adjustments under this <B><I>Section</I>
11</B> will not constitute a modification of such Non-qualified Stock Options within the meaning of Section 409A of the Code.
Any adjustments made under this <B><I>Section</I> 11</B> shall be made in a manner which does not adversely affect the exemption
provided pursuant to Rule 16b-3 under the Exchange Act. The Company shall give each Participant notice of an adjustment hereunder
and, upon notice, such adjustment shall be conclusive and binding for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">12.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effect of Change in Control</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1
In the discretion of the Board and the Committee, any Award Agreement may provide, or the Board or the Committee may provide by
amendment of any Award Agreement or otherwise (including in a written employment agreement), notwithstanding any provision of
the Plan to the contrary, that in the event of a Change in Control, Options and/or Stock Appreciation Rights shall become immediately
exercisable with respect to all or a specified portion of the shares subject to such Options or Stock Appreciation Rights, and/or
the Restricted Period shall expire immediately with respect to all or a specified portion of the shares of Restricted Stock or
Restricted Stock Units, if after such Change in Control the employment or Continuous Service of the Participant is terminated
by the Company or its successor in interest without Cause or is terminated by the Participant for Good Reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2
In addition, in the event of a Change in Control, the Committee may in its discretion and upon at least 10 days&rsquo; advance
notice to the affected Participant, cancel any outstanding Awards and pay to the holders thereof, in cash or stock, or any combination
thereof, the value of such vested Awards based upon the price per share of Common Stock received or to be received by other shareholders
of the Company in the event. In the case of any Option or Stock Appreciation Right with an exercise price (or SAR Exercise Price
in the case of a Stock Appreciation Right) that equals or exceeds the price paid for a share of Common Stock in connection with
the Change in Control, the Committee may cancel the Option or Stock Appreciation Right without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3
The obligations of the Company under the Plan shall be binding upon any successor corporation or organization resulting from the
merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to
all or substantially all of the assets and business of the Company and its Subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">13.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment of the Plan and Awards</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1
<U>Amendment of Plan</U>. The Board at any time, and from time to time, may amend or terminate the Plan. However, except as provided
in <B><I>Section </I> 11</B> relating to adjustments upon changes in Common Stock, and <B><I>Section</I> 13.3</B>, no amendment
shall be effective unless approved by the shareholders of the Company to the extent shareholder approval is necessary to satisfy
any Applicable Laws. At the time of such amendment, the Board shall determine, upon advice from counsel, whether such amendment
will be contingent on shareholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2
<U>Shareholder Approval</U>. The Board may, in its sole discretion, submit any amendment to the Plan or any Award for shareholder.
If any Award is granted under the Plan prior to the date that the Plan has been approved by the shareholders of OncoCyte, such
Award shall be contingent upon the approval of the Plan by the shareholders of OncoCyte. Further, the Board or Committee may make
the payment of any Award contingent upon shareholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3
<U>No Impairment of Rights</U>. Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment
of the Plan unless (a) the Company requests the consent of the Participant and the Participant consents in writing, or (b) the
Award was granted subject to the terms of the amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">14.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1
<U>Forfeiture Events</U>. The Committee may specify in an Award Agreement that the Participant&rsquo;s rights, payments and benefits
with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain
events, in addition to applicable vesting conditions of an Award. Such events may include, without limitation, breach of non-competition,
non-solicitation, confidentiality, or other restrictive covenants that are contained in the Award Agreement or otherwise applicable
to the Participant, a termination of the Participant&rsquo;s Continuous Service for Cause, or other conduct by the Participant
that is detrimental to the business or reputation of the Company and/or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2
<U>Clawback</U>. Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government
regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made
pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant
to any such law, government regulation or stock exchange listing requirement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3
<U>Other Compensation Arrangements</U>. Nothing contained in this Plan shall prevent the Board or Committee from adopting other
or additional compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may
be either generally applicable or applicable only in specific cases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4
<U>Sub-plans</U>. The Committee may from time to time establish sub-plans under the Plan for purposes of satisfying blue sky,
securities, tax or other laws of various jurisdictions in which the Company intends to grant Awards. Any sub-plans shall contain
such limitations and other terms and conditions as the Committee determines are necessary or desirable. All sub-plans shall be
deemed a part of the Plan, but each sub-plan shall apply only to the Participants in the jurisdiction for which the sub-plan was
designed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5
<U>Deferral of Awards</U>. The Committee may establish one or more programs under the Plan to permit selected Participants the
opportunity to elect to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other
event that absent the election would entitle the Participant to payment or receipt of shares of Common Stock or other consideration
under an Award. The Committee may establish the election procedures, the timing of such elections, the mechanisms for payments
of, and accrual of interest or other earnings, if any, on amounts, shares or other consideration so deferred, and such other terms,
conditions, rules and procedures that the Committee deems advisable for the administration of any such deferral program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.6
<U>Unfunded Plan</U>. The Plan shall be unfunded. Neither the Company, the Board nor the Committee shall be required to establish
any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7
<U>Recapitalizations</U>. Each Award Agreement shall contain provisions required to reflect the provisions of <B><I>Section </I>
11</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.8
<U>Delivery</U>. Subject to <B><I>Section</I> 8</B> and <B><I>Section</I> 7.2(c)</B>, upon exercise of an Option or Stock Appreciation
Right or Restricted Stock Unit granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable
period of time thereafter. A period of 30 days shall be considered a reasonable period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.9
<U>No Fractional Shares</U>. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Board
or Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of
fractional shares of Common Stock or whether any fractional shares should be rounded down, forfeited, or otherwise eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.10
<U>Other Provisions</U>. The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with
this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Committee may deem advisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.11
<U>Section 409A</U>. The Plan is intended to comply with Section 409A of the Code to the extent subject thereto, and, accordingly,
to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described
in the Plan that are due within the &ldquo;short-term deferral period&rdquo; as defined in Section 409A of the Code shall not
be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the
Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A of the Code, amounts that would
otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately
following the Participant&rsquo;s termination of Continuous Service shall instead be paid on the first payroll date after the
six-month anniversary of the Participant&rsquo;s separation from service (or the Participant&rsquo;s death, if earlier). Notwithstanding
the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of
any excise tax or penalty on any Participant under Section 409A of the Code and neither the Company nor the Committee will have
any liability to any Participant for such tax or penalty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.12
<U>Disqualifying Dispositions</U>. Any Participant who shall make a &ldquo;disposition&rdquo; (as defined in Section 424 of the
Code) of all or any portion of shares of Common Stock acquired upon exercise of an Incentive Stock Option within two years from
the Grant Date of such Incentive Stock Option or within one year after the issuance of the shares of Common Stock acquired upon
exercise of such Incentive Stock Option shall be required to immediately advise the Company in writing as to the occurrence of
the sale and the price realized upon the sale of such shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.13
<U>Section 16</U>. It is the intent of the Company that the Plan satisfy, and be interpreted in a manner that satisfies, the applicable
requirements of Rule 16b-3 as promulgated under Section 16 of the Exchange Act so that Participants will be entitled to the benefit
of Rule 16b-3, or any other rule promulgated under Section 16 of the Exchange Act, and will not be subject to short-swing liability
under Section 16 of the Exchange Act. Accordingly, if the operation of any provision of the Plan would conflict with the intent
expressed in this <B><I>Section</I> 14.13</B>, such provision to the extent possible shall be interpreted and/or deemed amended
so as to avoid such conflict.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.14
<U>Expenses</U>. The costs of administering the Plan shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.15
<U>Severability</U>. If any of the provisions of the Plan or any Award Agreement is held to be invalid, illegal or unenforceable,
whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity,
illegality or unenforceability and the remaining provisions shall not be affected thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.16
<U>Plan Headings</U>. The headings in the Plan are for purposes of convenience only and are not intended to define or limit the
construction of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.17
<U>Non-Uniform Treatment</U>. The determinations of the Board or Committee under the Plan need not be uniform and may be made
selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing,
the Board and Committee shall be entitled to make non-uniform and selective determinations, amendments and adjustments, and to
enter into non-uniform and selective Award Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">15.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effective Date of Plan</U>. The Plan shall
become effective as of the Effective Date, but no Award shall be exercised (or, in the case of a stock Award, shall be granted)
unless and until the Plan has been approved by the shareholders of the Company, which approval shall be within twelve (12) months
before or after the date the Plan is adopted by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">16.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination or Suspension of the Plan</U>.
The Plan shall terminate automatically on July 2, 2028 which is ten years from the date the Plan was approved by the Company&rsquo;s
Board of Directors. No Award shall be granted pursuant to the Plan after such date, but Awards theretofore granted may extend
beyond that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">17.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effect of Dissolution, Merger or Other </U>Reorganization.
Upon the dissolution or liquidation of OncoCyte, or upon a reorganization, merger or consolidation of OncoCyte as a result of
which the outstanding Common Stock or other securities of the class then subject to Awards are changed into or exchanged for cash
or property or securities not of OncoCyte&rsquo;s issue, or upon a sale of substantially all the property of OncoCyte to, or the
acquisition of more than eighty percent (80%) of the Voting Securities of OncoCyte then outstanding by, another corporation or
person, this Plan shall terminate, and all unexercised Awards theretofore granted hereunder shall terminate, unless provision
can be made in writing in connection with such transaction for the continuance of the Plan and/or for the assumption of Awards
theretofore granted, or the substitution for Awards options or other rights covering the shares of a successor corporation, or
a parent or a subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices, in which event
the Plan and Awards theretofore granted shall continue in the manner and under the terms so provided, subject to such adjustments.
The grant of an Award pursuant to the Plan shall not affect in any way the right or power of OncoCyte or any Subsidiary or parent
corporation to make adjustments, reclassifications, reorganizations or changes or its capital or business structure or to merge
or to consolidate or to dissolve, liquidate or sell, or transfer all or any part of its business or assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">18.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Choice of Law</U>. The law of the State of
California shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to
such state&rsquo;s conflict of law rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>
<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 779; width: 650"></FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&nbsp;<IMG SRC="image_002.jpg" ALT="" STYLE="height: 626; width: 650"></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !Z 8(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4ZUJ?M&CRXX3FQ#HIG;AMW0BFO(L2EI'51ZL<5YEH^M2:0UQ)&IDED0*FXY
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M26<$[P:G;)(;V6,X:-8NX]-YVX]B:7*%SNZ*CM6+VD+,<ED4D_A12 X'QO\
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M*]=?PSY_J>VT4@.:6N<L***3- '%?%G_ )$T?]?4?]:\V\#_ /([:3_UV_\
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M8R3N.FX]A[ <5MV]O#;1*D$21)C[J*%'Y"I:RG-RT&D HHHK,84444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img_002.jpg
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G )@# 2(  A$! Q$!_\0
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>  #/WFP"3T ** .EHHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_003.jpg
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 8(# 2(  A$! Q$!_\0
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MU4+J-ZMU'TJJ%-TX69ECJ\*]9U*>QN"EI%&% ].]+6QQA1110 4444 %%%%
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M1Z4N?E%HY ]]U8GPQU30M&UZYOM<ECB,<(%L\BEL.3SC'?%;/QO_ .1FTO\
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MI)0.9K5P W_ 3TJ;4/CC#Y)&FZ-*9>S7,@"C\!UJ.3X%MN_<Z_\ +_MVW/\
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M'!^[;(/Z5O22>Y+.1'QH\4 <VVG$^NP_XU0U'XK^*[^%HA=PVD;#!-M%@_\
M?1SBLN6TM@3BWB_[X%=YX-T72I[N/SM,LY./XX%/\Q6CA!:V \RTS2=4\0WI
MBTZUGO)W;+N,D9/4NW]:^BO ?A0>$O#RV4D@ENI7,MS(.F\]A[ <5T4%M!:1
MK%;01PQX^Y&@4?D*L5A4J.2L-(!11168PHHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img_004.jpg
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G )P# 2(  A$! Q$!_\0
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MS8_M!7:9E25T5R/5E4-^-=/0 44V22.)-\CJBY W,<#).!^M.H **YB[\?\
MAZU\36WAY;P3ZA-+Y3K$5V0,> '8D $G"A02V2!CFNGH *Q;GQ);0^*[/PY#
M#)/?3P-<RE,!;>$<!W)_O-\H SWS@5/K^O:?X:T>?5-2F\N")2<#EI#@D*H[
MDX/\S@ FN=^'=E<W5I>^+=2B$>HZ^ZW'EYSY-L!B&//^[\Q.!DMR* .UHHHH
M ***XOQ/XHFVWMGI-[;V$-D,:EK5P T5EG^! ?\ 63'(^7H,C/) (!I>(O&^
MA^&6,-Y<-->^6THLK9?,F* 9+$#A% !.YBJX!YJ3PWXBEUOP]_;=[8'2K1P9
M81<2C=Y(&?,?@!,\G&3Q@YYP/.;/2]$M=*EUO5XI=/\ "JR"4C4"7O=<F'*R
M7&?F*9&5B_B/S$ <5/:OKOQ4/V]K,6VB!\V<%XN;? /$DB @W+]PF5B7CYG8
M$4 :?B+XJF&")?#.EMJ4MU(8;.6;*)<OW\E,;Y5'.7^5!C[Y) /=Z*NIKHUK
M_;,D#ZDR;KC[.NV-6)SM7))P,XR3SC/>J.A^$]/T2YEO@9;S5)UVS:A=$-*X
MSG:, !$'9$ 7@<5NT <YIP_M'QMJ]Y*,KIB1V%N#_ SHLTK#_>#PC_MG[FNC
MKB]2OI?!_BR[U2XM+F70=4B1[FXMXS+]DN(QMW.JC.QD"#<,X*<]<TW6?BKX
M5TRQCEL]0CU>ZG.VWL].82RR-V! ^[^/X GB@#M)98X8GEE=8XT4L[L<!0.I
M)["N"U>34_B$#I>DO+8>&)/EO-4QMDO4[QVX/.PYP9",'/R[AG.5;IX_\7QR
M76HZ)8:=!NWVUMJ$S21HO4%H% ,D@..9& ! (0$9.!;^ /B+JJ7.N:Y?C^U8
MT8V=NUU\ZN1CY2G[N(<YRGS'D!DSNH ]KL;.VTZQ@L;.)8;:WC6**->B*!@#
M\JY_QEXWLO"5O%"(GOM7NOEL].@YDF8\ X&2%SWQ] 3Q7DL/@'Q[:Z.\*0II
MFEV@>[EM8+AIYKR8+DL0A_>R$JN%)5>!P><Z/AOPSXNBM;G6KN*73=0N4+WV
ML7B_:;YE[16T SLZ;>?F)(PH 4  74K34;&XAUWQ9XASXN+"?3](M+47B6B#
M);$.X*.!S(6 &W[['FL:7QGXR\2:0EWK>L#1=$F<Q)_9T'^D7[]/+MUR6<YP
M-P(49Y)Y%;,/@RZBM);_ %G3;S[-<R*+?0DG\R\U6;.5>]G[CC<5SL0<X&"&
M[KPGX(DLM0_X2'Q%)!>:\Z>7$L2XM]/BZ"*!>P XSUZ^K%@#G?AU\+[?3KZ#
MQ#J6FBSFB7_0K%Y3+)'D?ZV9ONF0]E4*J^F[IW/B'Q98Z!)!9A)+W5[OBTTV
MVP9ICZ^BH,$EVP  ?3%5_$UQXO>Y73O#FGV<<<Z#=JUS."+8Y.[]SC+-C!7D
MC)YX'/#:A\(O$%GJRZGX;\77,=[<1>7?W-Y(PED.>6#*.G PIZ;1SZ %W7M,
MNM6U2RTS7+J*75]44M/%"Y$&EZ<I!F"=]TF!&9",G><8"XK3U/XD+)J8T3P9
MI9UZ\3"RS1/MM+4=M\@!'&.@XZC.1BG:-\)M%MI%O/$,T_B74]H5KG4V,J@#
M/"HQ(QS_ !%L<X(S7'>*?"NA:9INIZ)H=UJ4D:[I+I9M0:+3].W8P9=H^=N5
MVQ_.Y&.@QD ZK7/C)X>TO4(]-T\/J]XSK&6MW1(%8G&#*Y"]^HR!W(Q6AXA^
M*GA3PXH2>_%Y=GK;6!$SCUR<A5^A(->?^"?@C'=-_:'B5YQ9DDV]C@PR2)V:
M7!)3(YV Y'&2#D5Z)IOPO\)Z7+J<D.FASJ"212!VP(HG&UHX]N-BD$C(YYZ]
M* .:USXF7/B.VL]#\"PO+K>I6XE9W95^PQD9)8Y*[P#TR<>YP"S3]%L-.N[6
MRN5'B+6[ ;K71K1LVE@V"?,E=N/,)W,9)/F8DE$XQ71'X5>&H[V*>S6]L(DM
M_LSV]E<M"DR;BQ\QE^=B21G+<[1Z5U6E:1IVAV"6.EV4%G:ITCA0*,^I]3ZD
M\F@#R*P\.:IX[^*-\/%MU#>6.A"/?:P!A;"5U#") >6 ZLQP20 1MP*]I551
M0JJ%4#  & !7-:/HVIZ-XHUB6**QDTG4[G[69#,ZW$<GE(A7;L*LN4R/F!&X
M]:Z:@ HHHH YG6M-\2:Y=-:V^J+HNE#AY;4;[N<=P&(VQ#T(W-T^[TJQX>\&
MZ%X75FTVR47,F?-NY29)Y2>26D;DY/..F>U%% &]1110 4444 %%%% !1110
M!SWCG4-2TSP;J%QHZ;M28)!;<@8>1UC!&[C(WY&>..:Q/!_@>YM+>QNO$+Q2
M3VN'M-/B),%H_>1B?];.223(W=CMQU)10!WE%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img_005.jpg
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K )8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BLW6]=L
M?#^G_:[UW.YA'##$A>6>0_=CC0<LQ]![DX )KFA;>-_$S>9<7D?A?3B?EM[=
M5GO'7_;D;*1GH<*"1TS0!V]%<:GPZME7]YXF\5RR?\]&UB4'\EP/TJK?_P!M
M^ U@U!M:N-8T'SHH;J'4 IN(%=P@D250-^&9<JP/&>: .\HHHH **** "BHT
MGBDEDB25&DBP)$5@2F1D9';(J2@ JO:7]I?FX%I<Q3_9YC!-Y;!MD@QE3CN,
MC([5S_CSQ$^@>'72R8'6-086>FP@_,\[_*#]%SN)/''N*T?"^@0>&/#5AHUN
M=RVT85G[R.>7<_5B3^- &O1110 445YOXC\8W.J6MPVDZBND^'86,5SKQ3>\
M[@X,5HO\;$@KOY&<[<D4 =GJ7B71=(NX+2^U&"*[N'5(;8'?+(6.!A%RQ&>^
M,5H7-U;V5M)<W4\4%O$NZ265PJH/4D\ 5Y/H^GZ1X*6/Q3J]A)%J5R&BTO3G
M/FWCEOO/(Q/S3/GYB3M13MXYR1V/B'Q]<)>RF!D#%HI)5\S3[+L##&?^/R8
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M;<9SM09P>6;*9]0\(^!I;>YB\0>)A!<:V$"VUM$H%MID7:*%.@(& 6]N#U+
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M-.1P9#G'(7J6;ICH^G'6O[9:SA;4A"+<7++EUC!8[0>W+'..O?H*O4 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1A Z<# 2(  A$! Q$!_\0
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M,/$U[X,E@N/$IM5U+-U<V$FG*Q\UL-AG+!@<@?2O9J*5E:WR_7\]1W=[_/\
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MH'4BCK;YBZ7/I:BO"O\ B^7_ $U_\E*]'^'O_"6_V+<?\)AN^W?:#Y6[R_\
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M^S^4F,&,,1NQNZ^]>Q4+6*EW!Z-H**** "BBB@ HHHH **** "BBB@ HHHH
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M2M!+U);O-OT"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT3R?LOF9VDG.[>/7TKT>BELT^P=+$4]O#=6TEO<1I+#(I1T<9# ]017DFN?
M/3KNZ:;1]4DL48Y,$L?FJ/\ =.00/KFO8**5M;C3LK'C&D_L_P!I#<K)JVM/
M<Q Y,-O#Y>[ZL2>/H/QKU[3]/M-*L(;&Q@2"VA7;'&@P *LT55]+"MK<\]N?
MA?\ :/B0OB_^V-N)TF^R_9L_=4+C?O\ ;TKOYH8[B"2&9%>*12KHPR&!X(-/
MHI=.7H'7FZGE>A_!:#0?%]OK=MK3&"WG,L=JUKR%YPN_?VSUQ7JE%%'2P=;A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4C,J(SL0%49)/84M<[XYAUB
MZ\(7]GH5L9[ZY3R5 D5-JMPS98CMFD[VT&E=ZGFVE>*=97QE:^*[F\G/AS5=
M0DT^*!I&*1J  CA<X&2#SCL?6O4;SQ)!9^*].\/M!(TU]%)*DH(VJ$'(/>N"
MU#X-1_\ "*-9VFNZW+<PP[X+66[7[/YP&1A-O SGOQGK5NZT[Q:-3\)^(VT7
M[5?65J]M?6@N8U<,PQO#9VD'KUJM-%V_*S_7\R7=WDNO^?\ E^1T;>.]-A_X
M2)KF*6&+0V59W.#YA8<;1[].>YK.3XD>7+I,=_X=U*R_M6=(K5I2A5@W\1P>
M,9'!YYKG;GPIJUQHOCJ37A:Z4-3DAGAF:X5HE*\@%NH&< D@>HJEK&H:_J<_
M@8:G96-O"FIP>6;:[6<W.,?O%V\*F/<]>U$%=I/R_&]QO9OU_"UCTFQ\5V]]
M>Z_:I;2JVC,%E)(Q)\I;Y?R[UGR?$/3X_!MAXB-I<%;^40V]L"N]G+$ $D[1
M]TG)-8ITCQ1I/B7Q4+#1XKRUUO#PW372QK"=A4AE^\>O8?\ UEM_#&L0?"?3
M-%FT.QOKN YN+"[D'*[V)V.K85\'@Y[U*^&_I^;N/[5O7\M#>A\6ZA/8ZF9/
M#6I6EW:0>;&CA72;/3;(IVD^V:K?##Q!J?B+PC%=ZI%,9]S?Z2^T+/EV^Z!T
M Z=NE8O@SPEJVFZOJ$L-C<Z/HLMHT,>G7-Z+C=*?XQ@D*!TZYK:^&-AK.C>%
M8]&UC2S9M9LRQR^>D@G#,S$@+TQD=:I6U]%^;_X!+Z>OZ%GQ3H.IZUJ$#-K\
M^E:'!"SW'V.8Q3._J7Q@*!7.>$;75/&/@R:&Y\0ZM!!;ZC(MGJ%M-Y<UQ O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[5(K9=8S'=W;& 1S+YC&<E2LFUE.5((W#8<GD$'';^*;BZ@T,M:I<EVEC5C
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M2YA?RHW++L$9QMY"\;<Y YYIVL[ G='8KX0T2..-8;62$QHB1R17$B.BJ&
M8-D<,P]\\TX>'-!<M;K:QAHUB!1)6#($W;.AR."P]P3G-<]+J-_>7]Q+(=8B
MT9KL /#;2I)L\@8P-N_;YF<D#KCL:8L.LWGB.TA9M7AL9HH?.E*>6YQ%*3O9
M1@'=LS@\$@=Z6XF['1:9X<@T[69M041#%M'9VR(I!CA3)P222Q)/7T J:]\-
M:7J%XUU<Q3%W*%U2XD1'*'*%E5@"0>F1_*N*EU/5K>WA.H7.JQW:K9I"8XF"
M'<X$GFX&U6/^UCC&WG-=;XEDG0V(+WT=BTC?:7LD9I!\IV_<!8#=Z>V>*&^O
M]=QVMI_78>_A+1GD=VMY<DEDQ<2 0DL&)C&[]V2P!^7%-7PGHL+I((94P07_
M -)DQ,VXL#(-WSG<2?FSUK NKC6?,&U]8%SY5N;!&A.V0D_O/.V H&]0Q&!T
MP:R;]=7NY)HKA-8N(H[R&=W2.9=@6X7CR]IR0F2#&Q!"Y('%-+6P,[E?"VD*
M9R8)6$J-'AKB0A%8[F"9;Y,D _+CH/05/%I$=AIUU!I^!-.2[273/-O<@#+D
MMEN !UZ"N:T+4KVTUF[_ +2?47MB2/-EBE54=I0J*4*D _,,%&*X!) X-=!X
MD>YCTQ#;FX5#/&+AK92TBQ;OF*@9/3TYQG%)[>H=2E9^$M&ATVTTL[F>R@\I
MC%.T3,K<L'"$95B"<'BK,GAC1#??:6A97#"01BX=8PVWRPVP-MSM^7.*Y.SG
MU"P\3?;Q'K3:8Y1'DGM7:21 L^W*JI8@$IC(SRN>369)I^IW'EW=_!K!N)(-
M-EE*12DG9.WF9"C[R@@[>O)('6JMS/7J"TOY'HFJ:%%>^%Y]#MV\B%[?[/&>
M6V*!@=\G@>M%OX;TNW9'$#RR(Y?S)IGD8DIL.2Q)(VG&#P*X=KGQ8T>H[9+\
M77E7&]$AD(4[OW>S*[<XQC9G(SGFNVU-;C3?"UT+0WEQ<10G80^Z9CZY(;G\
M#[ U-].;N*VMAL7A31X5V_9Y)%!3 EN)'"JARJC<Q^4'G;TZ<<5!>>'+)9=*
MRT$&G:=<&X2-\D^:<A0&9L*N6^[CJ% QTKF]*_MV^O8[6:;58[!KUOW@$JGR
MOL^?]8ZA]OF=SCGIQ4-VNKWEC;PZG_:[W'^AF!(X'*/MD!D,FU< \9.[&  1
MWIK=#[GI=%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML%,;AQSTZ<UE7/CVR$Y@LH'N)/M@M0S$I&P\OS"X8*>,=/7V'-5AX#G$,_\
MI]J99K@3\V\F$/EA/E;S?,!XSD,,\@]>+5MX-GAE+2ZL9U\\7!:2#]XS_9C
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M %W.GCO+>9[A(Y59K=MLN/X#@-@_@0?QK.'BK1&A>8:A'L0H"2&&=QPI''S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP&3@9/4U%=7=M8VSW-Y<16]O&,O+,X15^I/ KQA-3UOQ+=^![JYU4PW#7MQ
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M;X[OM<FM98;Y+&VT_2GN=6>2$.JS\J%88W#!5FPI!(IOR]?Z^ZWW K_U\O\
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M/EQIT)SGELFGV>LZ]=Z3XHTV36(8=0T67;'JGDHJ2#;N^=2"H]#@=^*;TO\
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M$VAO#+'K$>E/&]R,@L,E^%QQZ=_45;UGXA1:+?Z[;2Z;)(NE0P2;TE_UAE.
M",?*!GDY/THZ?UY/_(-;_P!>AD:MX>\?ZY9Q6NH6O@R6.$AHF#W:/&1W5E(8
M'Z&JP\'>-5T*315L/!JZ?(^^6-9;T&5LYR[ [FZ<Y)S701>,=2O_  OJ^H6N
MG6AFM(#)#);Z@D\,AP2?F !!7&2"O/3-:'@+4]2U?P9I]]JB 7,L8;>'#>:/
M[YP!MSZ=J+;_ "_K\!7T7]?UN<M#X=\?6FHW&HVUEX,CN;B%8)3&UV%= , %
M,[>!QG&<5'X8\,?$3PEHXTW3O^$2,/F-(6E-P69CZD #T'3M4GB9-:TK6;62
M#Q+>3ZW>WZBSTZ$X@%MD;@\?/ &<N:=K>C:C_P )CI^E:=XKUWS[MWN[E#<K
MY<%N#S@!<\DA1S1'6WGI^O\ 7F#T^6OZ"7GASQ[J&HR7]U:>#9+F2U:S=R]X
M,PL<E< X_'&?>H;3PEXWL&T\VUAX,3^SXGAM?WEX0B/]X8)^;/OFO4AP*\Y\
M?1ZEIRW6J?\ "2WL%PY2+1]/LSM#R]PZ\^9D^O %+;3^OZU_,>_]?UV,FT\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0KHVTX4_?W>8>3Z8_&H[&9EM9;+4_#OBVYLC:-:1QP>'(X6VD8WN^\EF [C
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MM)(K%I6!!R=O(^8GUSWH7GY"?EY_K_P#G[OQMK$-W?VL<EAYVF!8Y4^Q3O\
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MW*<'KRN#R:JVO@*UT[R1INK:E9JMLMI-Y;1DS1J25!+(2I^8\K@T2ZV_K?\
MX!*V5_ZT7ZW,W3-9;Q!KW@W57C6)[G3[MV1<X!_=@XSVR*[^L#2_".GZ0=)^
MSS7+?V7#+# )&4Y60@G=QR1@8Z?C6_3=NGF'J%%%%( HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+FUSQ#=^*]8TS
M3[K1;6WL/)VF\@D=WWIN/(D4<?2NTKAW\#66L>*O$=WKFDP3VUTL"VLS[2P
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MI7C:;[+, ,+E2OR88$D<] .>G-='J>JV6CVGVF^F\J,L$7",[.QZ*JJ"6/L
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MK-CK,,DEE*S>4_ERQR1M&\;=<,C ,I^HJGJ7B[1=)NI;>[N)0\ #3M%;2RI
M#T,C*I"?B1Z]*I>$M+GM;G4K^>RN[4W;1A1>W7G3.J @%\$JO4@ $\=:Y[Q/
MH_B+4[C7K06FHRI=(5LC:744%MMV8_>\AV;.>""",#I0]!QUW.[CUC3YKJYM
MDN5,UM$DTH(( C8$JP.,$<'IGI62_CSPZD2S"\F>$QK*TD=I,ZQ(PRK2$)A,
MCGYL<'/2L37/#.LW-CH_]GQ[)Y;)=,U+,B@I P4LV<\E2& QG[U4O$.@Z]=_
MVUIL-EJ#P31>7IXL[F*"V"",+^]Y#LV<\$$$8'2B6E_ZV_I?B*.J5_+^OS_
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M^IS"&>/4);-3';R&,8<J@=\%58\=2/I56?XCP1Z)KM^EI*7TZ[^SQH8)0''
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M:^#(EJ+QVBC>0+">CDJ#C/Y\'T-<_<#7M2O],O1X<FMVTB*5C%+/#_I$K1[
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M** "BBB@ HHHH **** "BBB@"*"V@M5=;>".%7<R,(T"AF)R6..Y/4U+110
M5%<VT-Y;2VUS$DL$JE)(W&593U!%2T4 16MK;V5M';6L,<$$2[4CC4*JCT '
M2I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'S-_F;LXQC&/?\*Z6BFG;\?Q5AWTM_6]PHHHI""BBB@ HHHH **** "BBB@
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MA):W6GZE: --9W:A7"GHP()!7W%9@^(7VUIWT3P[JVJVD+E#=P(BQNPZ[-S
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MC(-5=2U.RTBQDOM0N$M[:/&^5^@R<#]2*!+R,WPYX2TSPM)??V7YL<-Y()#
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M*R*.D:18Z%I<.G:; L%K",(@Y^I)[D^M7J**&[@%%%% !1110 4444 %%%%
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M-X]J;B.XO$MW"GYE4@DD#')XZ5BZGXX\1Z#;QZIK'A>.#1VD59&CO \T"L<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL/Q)XB_X1[^R/\
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M _*I&>UT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!G:SH]OKEE':W.=D=Q#<# [QN'Q^.,'V)K1HHH C%O MRUR(8Q.RA&E"C<
M5!) )ZX!)X]S5:]T?3-265;W3[6Y$H42>;"K;@N2N<CMDX],FKM% &;+X>T6
M>&VAETFQ>*U&($:!2L8]%&.!0_AW1))K:9](L3):@+;L;=,Q = O' ';'2M*
MB@"C%HNE0ZF^I1:=:)?2##W*PJ)&]<MC-.U#2=.U5(TU&PMKM8VW()XE<*?4
M9'%7** ,T>']&6\@O%TFQ%S;J$AE%NH:-0, *<< #IZ43^'M%N4E2?2;*199
M?/D#0*=\F,;CQRV.,UI44 99\-Z&SV[G1M/W6[%H3]F3]V2<DCCCGGZ\U;?3
M[*0.'M+=A)*LSYC!W2+C#'CEAM7!Z\#TJS10!2OM'TW5'B>_L+:Z:$YC,T2N
M5^F1]/RH.C:6;9[;^S;3R)(EA>/R%VLBYVJ1CD#)P.V35VB@"E9Z/IFGHB6>
MG6MNL:LB"*%5VJQ!8# Z$@$^N*Q-:\#V&LM'&YACM$A$"P"TB;RD'41,1F/(
MX./08Q7444=;@9NLZ+;ZUIR6-QCR%FBE*%0P8(X;:0>QQ@T'P_HQTL:8=*LO
ML .[[-Y"^7GUVXQGWK2HH I1:1ID-N]O%IUHD+Q"%XUA4*T8SA",<K\QXZ<G
MUIMWHFE7T]O/=Z;9SRV_^I>6%6,?I@D<5?HH J7&E:?=03P7%C;2Q7#!YD>(
M$2,  &;CD\#GV'I4,&@:-;/$\&DV,3PMOC9+= 4;&W(('!P ,UHT4 9]KH6D
M6,MQ+::79P/<Y$S1P*ID!ZAL#FG:=HVF:0KC3=.M;,/C?]GA5-V,XS@<]3^=
M7J* *;:3IS(R-I]J5970@PK@JYW..G1CR?4]:;>:+I>HK(M[IUI<"555_-A5
MMP7)4'([9./3)J]10!#;VEO:6J6MM!%#;HNU(HT"JH] !Q5&#PUH5L)!!HVG
MQB161]ML@W*W53QT.!QTXK4HH\P*L^F6%T)Q<65O+Y\8BFWQ*?,09PK9'(&3
MP?4TEEIEAIML;>QLK>VA8Y:.&((I.,9( Y. !5NB@"JNFV"JJK96P58?LZ@1
M+@1?W!Q]W@<=*KMX=T5[O[6VD6+7'R_O#;J6^7&WG'; Q]!6E11Y@5XK"S@D
M62&T@C=0X5DC (W-N;!'J>3ZGFC[!9B;SA:0>;YGF[_+&[?MV[L^NWC/7'%6
M** (%LK1+:2V6UA6"0L7B$8"MN)+9'0Y).?7-0II&F1VSVZ:=:+ \0@>,0J%
M:,9PA&.5&3QTY-7:* *$FB:5+J4>HR:;:->Q !+AH5+J!TPV,\4[4=(TW6(D
MCU*PMKQ$;<JSQ*X4^HR*NT4 56TVQ=)4>RMF26(0R*8E(>,9PIXY49/'3DU(
M+2V%R+D6\7GK'Y8EV#<$SG;GKC/:IJ* ,V#P]HML;HP:38Q_:@1<;;=1YH/4
M-QR/8TJZ%I4=Y/>PZ=:17LRE7N4A42$$<Y;&?_U5HT4=+!<QM#\,:5H.GI:V
MME;!O)6&:80JK3@#&7P.<_UJYIVD:;H\;QZ;86UFCMN=8(E0,?4X%7:*;=W<
M#%M_"VEPZQ>:K+:6]Q>7$WFK-)"I>+Y%3:K=<?+^IJU=Z%I%_:P6MWI=G/;V
M^/)BD@5ECP, *", 8XXK0HI 0M9VS202-;0E[?/DL4&8\C!VGMQQQ56YT+2+
MV".&ZTNRFBCD,J)) K*KDY+ $=2223WS6A10!FW'A_1KHVIN-)L93:@+;[[=
M3Y0'0+QP!@<#TI\^AZ3<Z@M_/IEG+>)C;.\"LXP<CYB,\'IZ5?HH CM[>&U@
M2"WACAA086.-0JJ/8#I532=(M='BN8[5=HN+F6ZD]W=MQ_P_"K]% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\
MH;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H
M_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9
M_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+
M4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_
M ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG
M_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK
M#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[
M]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^
MALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@
M#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;
M-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L
M+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__
M !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U
M'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\
M8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_O
MU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_
M +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_
M5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^AL
MUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<
MHK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9
M_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4
M?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#Q
MB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\
MH;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H
M_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9
M_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+
M4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_
M ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG
M_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK
M#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[
M]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^
MALUG_OU9_P#QB@#<HK#_ +"U'_H;-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@
M#<HK#_L+4?\ H;-9_P"_5G_\8H_L+4?^ALUG_OU9_P#QB@#<HK#_ +"U'_H;
M-9_[]6?_ ,8H_L+4?^ALUG_OU9__ !B@#<HK@/'C:YX7\%ZAK-EXHU.2XM_+
MV+/!:E#ND53D"$'HQ[T4 ='X+_Y$7P]_V#+;_P!%+6Y6'X+_ .1%\/?]@RV_
M]%+6Y0 4444 %%%% !1110 4444 %%%% !117%?$"WN4AT^\M=6U*S>2]M[1
MDMI]B%'DPQQC[V#UHZI =K17FNKZGKFB^(-4T[3EN]1@@T19-TUX%:)MTG[S
M)'S-P.GI6-_:>MW^I:;$MYJ,JG0[6X=8=32US(V[<Q+ [B<4+7;^M_\ (-OZ
M]/\ ,]CHK@_'MW?VFF>'H;&ZNE:>\2*0PW8B>1?+8X,AXZ@'-<_9>(-4FTZS
MTNZU:ZM5DUM[.YN6F1Y(8]F](Q,!M8MP-W7G%"5]$'2_]?UH>N45Y+J7BB\T
M>VUW1+;5[FZ'VJ"ULKTYFEB,B[I1E1ERB@GN>0*CG\3:KJGA'0(K:XU"34$U
M,V-VMM+]GFGVHY!R^-NX!6YHWV\OQ!Z;GKU%>-:+J.I:OJ6FVE]XCU&SLY6O
M2%^U!9X?+,85)6V@%@2QZ="*ZFP\1ZM_PJ>]U@/]HOK>*<0SE?\ 6A&95DP.
M#P,^AH>BN"5W8[RBO.;*]GTW7=$@LO$-UJT>IV<TMTL\PEV;4#+*N!\@SQCI
MS[5-\-%U:\TVUU349M5D$]MD27-\LL4A)ZB,<J>.].W]?.PKZ7/0**\IUW4[
MZVO?%VHQ^(+RWN-+N(A9VGG#RI,QH=AC(^;))''K6,->U^\-@//UFYS-J+2P
M6-T(I"L<B[>6ZA02,=?2I3TN-JS_ *_KJ>WT5XY)JVNW=IX33^U+JY-W:W,L
MAM;];8N R[-SL,%E!P>.N:UOM%S>:H^F7_B"_P!)MK+2TN8Y%O%9W<LVYGD
M_>!< 8'%4U;^NP'IM%>=:O;W-SJWA=K?Q+JK0ZJQ25[>;RD=5A+!E7'RY(!/
MUK(DUC4(_#U[X@_X2&[&K6NHFVCTXR@QD+*$$1CQDEEYW=><T):V_K=+]0_K
M\W^C/7**\9TW6=>?Q';;KW4H4N-;F@2XN+I6M'C1SF()@D-@8&<9/2M+3=9U
M*'QI;R7FJW-Q:7>H2VT4MM=+) WWML30$!HRN/O#/3DTEK;S_P"!_F#TO_7]
M;'JE%>>?$&^U.#Q#I%O8G59(6M;F::#3;E89&V;,')ZXR>.O/%<II^J^(-2O
M;2-]5O;Q3ID<^;75$M<;I9 -Q9<,P4!3@#D4+4'H>W45YFU[)=W^M2W_ (IN
M](72988K95E4KL**=[KC][N)(_E3=3U*YN[CQ5=7'B.YTV;1\"S@BE$:8\L,
M'9"/GW,2,'Z"AZ:_U_7D-*^AZ=17C6O>-->TK7+34G>9;>31H?-LUSM6XF23
M8=O^^H'XUS^F^,_$^C3"XOM1NKQ(;>6VEC9RP,[/.L;?]]1J,^].SO;^NO\
M7S0O/^OZ_P CZ%HKP^QU7Q'/:>'[2XU'4)[AC?+<>5J MV=HY%49=@1QSQ6I
MJ/B'6] U9YQ<74VEV^DQ_:XWN!.\32-(!*&7ABK* 2.WTI/17!:GKE%>217]
MY?O&]WXEOK#R/#EM>*R7(0/,0V68,"&S@9J#5_$&NW-K9:G)J$\:QZ5#=7-O
M972V\MNYR3*8W&)5(_AS^%-JSL_ZW_R!:_UZ?YGL5%<9XT\1O8^#K9[.YECN
MM3,4,$R1,70,,M($4$Y"Y.!WJ7P5JTOB/P8T4]S-]N@WV<\V&23<O ?!P02I
M5N>>:3OKY NC[G745X]'XL\07&GS+#/-]M\.:?/]OZXEN QC0M_>^56>M:$3
M#6=#TVT\4:E?0ZO;2/=,+D,\>U0RRH0/D!/RXZ<T[=OZW_R#;?\ K^KGI=%>
M+-/K$7AW2+M-;UB>>\U>6UD0WXCRB&4 !B,*?E&2?2O2_#,5P?#QCFFN1.[.
M"T]XMTZ>GSK@>^*72_\ 73_,-G;^OZT-ZBO,?$6G:_H<&D6J^(-3U"6]OHH2
M(I1 Y"PMN 8D@;F&[G]:?#]LGUZ71M4UW5-*AM-/6YC#7J^;(S,VYFDQA@N
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MP2IZ D<?2K'B+X;W^L_VO>6]S:VNHW5PKQ,KMM,)C1'C<[>F5R.#T'2JTO\
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MUZ'KVKIM2\'0C0[+3-&CBMXX-1AO'\V1F+[9 SDL<DL<=_SHLE_7I_P0O?\
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M>4OIL*37$10;BCJ""HSS]X9JQK>I:1X>TFTLIM+>>TNW^RPV5K;*X;*D[=G
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M=C_9%I9J]VFFW)2RC6-V=-P#8ZICUJWX6\)7/A/4&BL98CH]Q AG@>1BZ7(
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M^=9_\'5Y_P#':/\ A$]._P"?G6?_  =7G_QVMRB@##_X1/3O^?G6?_!U>?\
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M3O\ GYUG_P '5Y_\=K<HH P_^$3T[_GYUG_P=7G_ ,=H_P"$3T[_ )^=9_\
M!U>?_':W** ,/_A$]._Y^=9_\'5Y_P#':/\ A$]._P"?G6?_  =7G_QVMRB@
M##_X1/3O^?G6?_!U>?\ QVC_ (1/3O\ GYUG_P '5Y_\=K<HH P_^$3T[_GY
MUG_P=7G_ ,=H_P"$3T[_ )^=9_\ !U>?_':W** ,/_A$]._Y^=9_\'5Y_P#'
M:/\ A$]._P"?G6?_  =7G_QVMRB@##_X1/3O^?G6?_!U>?\ QVC_ (1/3O\
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M^TM@G'SA=O7/&WVJ>1=#/C'Q"=5G\*1RB^3 U>%&FV^3']TLPPO7MUS32O\
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MVGZGJDJR#D^1.+L@-[*P&#Z$#U-"5[?+\;?Y@]+_ -=_\CU875N6"B>(L3C
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MPG_R![C_ +"=_P#^E<U;E !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_C];E% &/X8M[JVT9A>6SVTTMY=S^3(RLR+)<22*"5)7.UAT)K8HHH ****
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M:&V>]LY?-AA9W4+M9I4'/F,",_Q<]0>E;7A>&=-&U(.L\BR7,KQ3SQ&.6X#
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M!969MS@MOR-_("G..#SQ323=OZ_K\K M=&;8U3P_</KEGBW=K4;]2A,.=P*
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MR5WJ&.20& .3ZFM#4M'2_%J\5Q-9W%HQ:": *2F5VD88$$$'TI=/Z_K<.O\
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M-,L/#$FF2'[)K^J);M</<&V*VY0EW+L,F+=@DG^+/O35NO\ 6W_!$_+^M_\
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MJB227%W+.Q5"Q49D9B "[<#UK1HHH P(?!NDVT$<$$FK10Q*$CCCUB[544#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1=7M?$5S>RZ_97#RK$MW FGE"0H;;@^:=O![@]*I3^!IX]5U?4K?5+&V:_\
M,+3G3MT\*LH! E\P< #/2H[7P-,+H3W5OII86OE[T7YA($*J<;0/E!&",=\
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MQX8_[";_ /I)<5N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEAALC$\IC(*;V,C9 (!P ,XKKJ*+_P!?B'2W]=@HHHI %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!AZ[_R&/#'_83?_P!)+BMRL/7?^0QX8_["
M;_\ I)<5N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &'KO_(8\,?\ 83?_ -)+BMRL/7?^0QX8_P"PF_\
MZ27%;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!AZ[_P ACPQ_V$W_ /22XK<K#UW_ )#'AC_L)O\ ^DEQ
M6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 8>N_P#(8\,?]A-__22XK<K#UW_D,>&/^PF__I)<5N4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &'KO_(8\,?]A-__ $DN*W*P]=_Y#'AC_L)O_P"DEQ6Y0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBMRL/7?^0QX8_P"PF_\ Z27%;E( HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L[4/$&BZ3.L&HZO86<S+O$=Q<I&Q7)&<,0<9!Y]JT:* ,/_ (33PK_T
M,NC?^!\7_P 51_PFGA7_ *&71O\ P/B_^*K<HH P_P#A-/"O_0RZ-_X'Q?\
MQ5'_  FGA7_H9=&_\#XO_BJW** ,/_A-/"O_ $,NC?\ @?%_\51_PFGA7_H9
M=&_\#XO_ (JMRB@##_X33PK_ -#+HW_@?%_\51_PFGA7_H9=&_\  ^+_ .*K
M<HH PQXR\*#IXET89Y_X_HO_ (JC_A,_"N<_\)+HV?7[=%_\56Y10!A_\)IX
M5_Z&71O_  /B_P#BJ/\ A-/"O_0RZ-_X'Q?_ !5;E% &'_PFGA7_ *&71O\
MP/B_^*I#XR\*,"#XET8@]0;Z+_XJMVB@#"/C+PH1@^)-%(][Z+_XJE_X3/PK
M_P!#+HW_ ('Q?_%5N44 87_"8^$]H7_A)-%VCH/MT6!_X]2_\)IX5_Z&71O_
M  /B_P#BJW** ,(>,O"@)(\2:,">3_IT7/\ X]2_\)IX5_Z&71O_  /B_P#B
MJW** ,+_ (3+PIN+?\))HV3QG[=%_P#%4?\ "8^%"2?^$DT7)&#_ *=%R/\
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M_P"$DT7;C&/MT6/_ $*MVB@# 7Q=X269YAXCT42. K-]OBR0,X'WO<_G3O\
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M27%;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!AZ[_ ,ACPQ_V$W_])+BMRL/7?^0QX8_[";_^DEQ6Y0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 8>N_\ACPQ_V$W_\ 22XK<K#UW_D,>&/^PF__ *27%;E !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!AZ[_R&/#'_ &$W_P#22XK<K#UW_D,>&/\ L)O_ .DEQ6Y0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8>
MN_\ (8\,?]A-_P#TDN*W*P]=_P"0QX8_[";_ /I)<5N4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'KO\
MR&/#'_83?_TDN*W*P]=_Y#'AC_L)O_Z27%;E !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZT/VE5BD?9]G\SJOR9W C(SZ=:Z:]\5V5A8+=W%I?+'M=I T&#$$.&W9('X
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M!(/Y\=\4Y;NW]7(CM=G)CQCJAL[D?VE;A8;ORQ,9(=[IY0? ;_5$[L\9&0"
M<BKFE>+M5O\ 7[:%GC6.29(_LTBK&[1F,-YFS)<'//\ = XZ\UNMXQTM/+CD
MMKN-/-6"3?" L,A;:%;GDYQ]W.,@]#FI_P#A*=-5+BYDCN8[:%'8730G9($.
M&VD<]>@.,]LT+N4S,\0:U-!J=Y:-JD-BL<4?DV[P[VNM^0V/XCCI\O0\GBL2
M#7-:T;P[91B[2=7L;*3S7C5/LZN2K')XQ@#ENA.3D<5W&EZW9ZO'.\*R+);-
MMDCD4;TR,CH2#D>A]NM8MYXWMUCVVUG<-.LUNKP2Q?.T<K[00 >O!X.".XI+
ML'F9</BF_EMXOM>KVMA&$F>.Z,:R"Y*. J\<,<'D)R?X<5:T+5+M?%VHV<S^
M39RWLAB<C/G2"*,F/G[F!EL=3STP<ZS>+=-$0VVUV\D8=IH$AR]N$.&+#/&/
M;.>V:LQ^)M,E*A)6.Z5HON]-J>86/HNW!S[CUIIVU$T<<SWUQXWEM(]8DCE7
M5GVJ0K&*,VF1A3V)SC/'RGOF@>,=;:XLU9[=&,-NPC;:HNF=B'P#ECZ +T/7
M(KL='\2Z?KDKQ6ID5Q&LRB10"\9Z,.3Q['!'<5J3D)$\NT%D4D9^E)OE2;Z?
MU^@]V[=3C?%>H/I_B>"9-5BL&73)V02*&$SAT(3!ZY]!R>U1IXGU![U/M%Y#
M:3FY$,FFE%WQ1&/<9LGGC[V?NX&.O-4H/B#=RZ5%=I)I&H.]F;F2&T9BUHP4
M,!+\QQS\O8Y[5TT/C#29[B5(_.9D20HRQ;O.\LX<(!DG!]0,]1D4[-:?U_7]
M(5]2'P?K5[K$=T=0=%FC*B.)8RF^,CY9N></R0.V,=0:Y'5O%FI7L&K6UOJ!
M"/97CJ%$:R0F(@+@*2RY&[[YSQD 5V/_  F^F;#^ZNO/$_V<V^U=^_9O_O;3
M\ISP<]NM377BO2K&\6WE\U&98WE8Q[1%YG"[P<$$^F#COBCJAIV*>NZA>+9Z
M/#I^H(4O%??<!%D\Q%A9P1VYP.1V-88\47=M96"'4;>R?[-8^1:M&I-T)-H<
MKGGC...F,GK77ZMXCM-'G$,T-U*_D/<,((]VV-2 S'GMD<=?3-8^H7VAW6HF
M>2&_F"R+'N1W%O),@WHA&[!;W(QG )R,4KK<23V.;FO-7M?"-XL6I/Y=Q;ZB
MZ*J -$8Y3@JW7H2#GVQC%=1X@UU]/TK2VMM14?:C@70\K:ZA"V=[D(,\'H<]
MAW!8^/-/GLK"6ZBE@EN((9I5P"L'F?=R<\@GT!XY.*O^(-<;2)M.A6S-Q]KE
M=-W&(]L;.#[_ '?RS1+16?\ 5E_P!K5G+Z?XGUN_LEOC=0QB&WLI'A6$$2-*
MY5P2>1P.,=#^56-)U2?4O&&FO<:E&\XAO!+8*H!ML.@ ..>@_BZ\D<5K:7XQ
MAO=)CN)[*\CN3;0SF%83\XDX!3G[N0>6(QU/%.T_Q;!J>M6=G:6DIBN(9W>9
M@ 8WB=4*D9YY)Y!/;&<U5O>_KS%>ZO\ UT.DHHHJ1C)IHK:"2>>5(H8E+R22
M,%5% R22>  .]8W_  FGA7_H9=&_\#XO_BJ/&G_(B^(?^P9<_P#HIJW* ,/_
M (33PK_T,NC?^!\7_P 55O3_ !!HNK3M!IVKV%Y,J[S';W*2,%R!G"DG&2.?
M>M&L.Z_Y'K2?^P9>_P#HVUH -=_Y#'AC_L)O_P"DEQ6Y6'KO_(8\,?\ 83?_
M -)+BMR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,[4/#^BZM.L^HZ187DRKL$EQ;)(P7).,L"<9)X]ZJ?\(7X5_Z
M%K1O_ "+_P")K<HH SM/\/Z+I,[3Z=I%A9S,NPR6]LD;%<@XRH!QD#CVK1HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&K:3!K-HEM</(J+*DH,
M9 .5.1U!XJ_61XDM;B[TQ(X(7N%$\;S0(X5I8PWS*"2!^!(ST[TF!1'A[2YI
MDLH;RY2[T^VMXT92NZ((6,;\K@D_,#V([4@\$V8>.8ZA?M=QL[I<%DW!VD$A
M;&W'48QC&"1BL2#PM=/<WM\FE2VDF;8V2M=AVC"S,6&0V%^4].F#M!-4;CP_
MXDN+F_DCL9H7FM[J-RDRJ'9G4Q_.92S< \D+C. !T%;L5E;^NAT^H^"+35$C
M%WJ-])((I(7ED\MV99#EL;D(0]AM P./3"S^"+&:9YA=W2R&59E++$X1A&(S
M@,A!W*JY!SR 1BL35[%-$OLW%OOT>2Z+)9_:4C$A\D?,-[JO#!B02,\D9(K.
MT_1M=O(-*ND2Z9'M;8V\@=2;?!R^YF8,,@Y)"MN'!I+4;V.UU30W;PC)HM@
M[-%Y*232;2A_YZ9 Z@_-@ <CM4*>'=/O+*W&GZA/"D-NU@\ELR'S(U.&5MRG
MD$'D8(.>:I^&=+U*Q\07DD]G(EO(KEIIG4LS%\@ JV'&,\LBL.!D\UC0^&M0
MM;>>!]%GEB+78@2&>-0DKREDF^^.-I49^\NT\<T=+OK_ %_7^0_+L;-[X?T3
M3;C?/JMQ;6\9-X+0,FT%8Q$7^Z7P%91UQDUNR:':S>&QH9DF^RBW6WW@C?M
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M$@DE'E0;&^0)CR_+V8P!CC@C.>N6CPIHTNJ"&"ZG6:UA@2>(!6+HN?+)9E+
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M+6C?^ $7_P 31_PA?A7_ *%K1O\ P B_^)K<HH P_P#A"_"O_0M:-_X 1?\
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M)H_X0OPK_P!"UHW_ ( 1?_$UN44 8?\ PA?A7_H6M&_\ (O_ (FC_A"_"O\
MT+6C?^ $7_Q-;E% &'_PA?A7_H6M&_\  "+_ .)H_P"$+\*_]"UHW_@!%_\
M$UN44 8?_"%^%?\ H6M&_P# "+_XFC_A"_"O_0M:-_X 1?\ Q-;E% '.>%K*
MUTZ^\26ME;0VUNFIKLAAC"(N;6W)P!P.23^-='6'H7_(8\3_ /833_TDMZW*
M "BBB@ HHHH **** "JM_9?;K81"YGMG5@Z2P, RD?4$$>Q!%6J* .5NO")A
MA$^GW$CZBLOFB6618\L3DGY8RJG''W"/;)S3[#P?%%HZ6MW=3M.S)++)$X!W
MJS,,':.['G _"NGHH"QS-AX(T_3Y?,AN+@,6#/M6) ^$9#D*@ZASD]<]ZEM?
M!]I!*TD]Y>7;-'Y)\XH!L"% ORJ.Q/XUS_C[7=:T;6(9--=VM8]-N)KF%.I
M**'7W4L&^@-8]]X^UQ='N(+5[5+F.T/52UQ%MA5_/89QL;) XZD<GI1N%K,[
MO1_".EZ+87=G;QKY5T@27$4<>Y0",'RU7)P3R>>:=:>&+>VOH+V2\N[BY@*[
M'E*#Y51D"D*H& '8^N3UQQ7,6/CK4KK6-1L7&FQP6ML\BW;N-H*JI$K*)"QC
M;=D<#C&&;MZ"AW1JV0<@'(Z&GKN+1JW]=#&N_#,-]=&2:^O&@,OG"VRA17QC
M*DKN [X#8_#(-6_\%:=J&!+-<!?+2(H1&ZD*I4':RD9YSG'!Z8KG$OM>@BM-
M4WW#6_VN5)$-SO-QAVVJJ8^7A2.OX'LI^(&IC0GNS!:).')7(C974('*_+.5
M!Y ^_GN$[5.EOZ_KJ/K_ %YG33>#M,GT,:5+OE@659E,JI)\R@ 9#*5(P.A'
M>DC\&:5'IQL!Y@MR8RRJ$0'82>BJ  =QR ![8K OO'>HV]U<PQ06SG*B+:%;
MR@2H+.6F4?Q#AO+ZC!;K6CJ/BR]M/#^DZD(K:)KH;IE<A\ #.$ < Y_V2Q]%
M:JW^8DE96+K>#;.;+7%[>SS;51969 RA00F % X))Z<GKD<56G^'VE7=U]JO
M));JX:1G>6>&%RV2#@93Y?N]5P>3SZ9NJ^,;[3/MQCEL8O)F;RUNPQ,_SA=B
M?,,$9R>O4<#K6YI&MW\^G:A+>10S7%JBR*MLC('#1"0+@EN><9SSZ"IYOM#M
MT_KL-U^R%AX7BAMHKB=(+^TF*QQ-+)M6[CD<A4&3@!CP.@JQ_P )9IW_ #[:
MS_X);S_XU7-:1XZU2_O;:">&R2.:15>48(B!VD9V2..=VP98'<0<=@U/'E]+
MJL]IYVFV\(4RQW$Z':%!;]V0)"VX[>"0I'/R'N_(#I_^$LT[_GVUG_P2WG_Q
MJC_A+-._Y]M9_P#!+>?_ !JN:7Q/J=CKVKRW5PEQ96<F7A2,@Q1$J,@9R2-P
M.2.1GBM7Q'XDU#0]!L[DI;+?2QF22-URN57<RC+H/;[Q/HK=*.EP6KLC0_X2
MS3O^?;6?_!+>?_&J/^$LT[_GVUG_ ,$MY_\ &JH:9XDOM2UB_L%%J&2 R6ZA
M=V" OWR'SU8<%4]BW45F\7WLVG17B"TLHI6DV/=HV/W:#<A^8?,7W@'T4G!H
M>@+4V/\ A+-._P"?;6?_  2WG_QJC_A+-._Y]M9_\$MY_P#&JP;;QGJ&H&U@
MM?L*74HB6575G\AV=U*LH8'("CC(-:7B3Q!?Z/='R!:FW@@2>821LS.#($PI
M#?+USG!Z=.:3=M6"UV+G_"6:=_S[:S_X);S_ .-4?\)9IW_/MK/_ ();S_XU
M7+)XYUB:RN'B6P,EOYLA<QY5T2(2  )*V"<XSN]RHZ58N/&>KVNJ0V+VEM*P
MF"R2(%19 2F%4/*"" XS@/GC@9XI(.ESH?\ A+-._P"?;6?_  2WG_QJC_A+
M-._Y]M9_\$MY_P#&JI^*/$=WHLK"W:T7RX/."7"L6N#NV[(\,,$<$]>HX'6I
MY]2U6/0M-F5[+[=>RQH7,+&- X)^[OR<#'\0S[=IOI<'H2_\)9IW_/MK/_@E
MO/\ XU1_PEFG?\^VL_\ @EO/_C5<I;_$#4KAB$BLB6@+*-GW9%* Y_>;B#N/
M&U?9FJQ<^,=;LH&\V*RFD:62%7BBV+&8YO++L'E (/& 77!XR<TQM6.C_P"$
MLT[_ )]M9_\ !+>?_&J/^$LT[_GVUG_P2WG_ ,:K*TGQ;>WVM:?:W$5M%'=6
MZOY:$.^XJ6SD.<#CCY2O^WGBJNJ>-[RRU>_MH_L?D01OM:1<;&1D!+GS-Q'S
M$_<4<<%J!&__ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_^"6\_P#C5<]:^-=0
M:^N(3+IMY]G?RQ%:HPDN1M8^8GSG"C;C&&[\\<U3\0-3&A/=F"T2<.2N1&RN
MH0.5^6<J#R!]_/<)VHN'D=7_ ,)9IW_/MK/_ ();S_XU1_PEFG?\^VL_^"6\
M_P#C55(?$%^^CZGJ3K:B.&7RX5"-\@R,NYW<@;L\ <*>>>*'_"5:KYH"-I\L
M,)'FRI$VVX!F$>8_G^4<]]W*D<]:.M@OI<VO^$LT[_GVUG_P2WG_ ,:H_P"$
MLT[_ )]M9_\ !+>?_&JR-7U+5U\17%G:ZA!$/.M!#&\).T/OW%@&!8$CVZ=:
MH:3XUU"XFL!,MLL=U<%)!@LW+*H"@N"!D]@_N%'-"UT!Z'3?\)9IW_/MK/\
MX);S_P"-4?\ "6:=_P ^VL_^"6\_^-5FWPUB\\57<%C+*B0+;,'^T;4C!+%\
MI@[\@?\ UQUJG+XMU6&S2XFFTN'>AF19(G'F+OV;%._[PQN)]P,#K2N!O?\
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M#SQEOE_B,7<8..2X(Z;_ (2S3O\ GVUG_P $MY_\:H_X2S3O^?;6?_!+>?\
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M[CRDAETUI+AT&X1L1:[F92L@W\M\N>J]",=ZT?%?B:31=*M[JP>VE:96D1F
M99%5=WRDN@Y]=Q/HK=*.EP6KL6_^$LT[_GVUG_P2WG_QJC_A+-._Y]M9_P#!
M+>?_ !JN;O/%NH_VB)(+BR79'*%L2K;P08P'D^;D'=D8 Z]Z6?Q7K$.P7'V-
MR)I4!AC>/)BD*$G+G(;@X[>IHO97 Z/_ (2S3O\ GVUG_P $MY_\:H_X2S3O
M^?;6?_!+>?\ QJN6D\8ZS!<7*RFQ\V.&%@P4J@$@5ONO* 2-V.77/Z&SIOBG
M5+@L_P!ILW22XDD(>!\Q0K"D@4 -G)R>2.^<'I0%_P"OZ]3H/^$LT[_GVUG_
M ,$MY_\ &J/^$LT[_GVUG_P2WG_QJN1L/&^K7.IW9EFLO)@MF*H(P%8EH_WA
M*ROPH<D\] <A>@Z'P_X@O-0OKY+VZT[[+:R+ LT*%1/(QP"I+D 'IMY.3UXY
M+"NB[_PEFG?\^VL_^"6\_P#C5'_"6:=_S[:S_P""6\_^-5EZ[XIO;+Q"NF6A
MM]KJ4)9 75S&S*W+@D<#@(0?[P/%8F@^,=7:(K=:A87+J8W ,15YPRQCRX\/
MPPW9S@]1QSD"U&]-SK_^$LT[_GVUG_P2WG_QJC_A+-._Y]M9_P#!+>?_ !JL
M1/%&MXAF?^S_ "6596187W%#,(MH._ /.<X]L=ZIV_CS5I+J96TZ(1%S#$OR
MEDE8LL:OMD8X++@EE0\].,D6NP/0Z?\ X2S3O^?;6?\ P2WG_P :H_X2S3O^
M?;6?_!+>?_&JK>*M8N;'0(;[3KRW!2ZC21RN]&&[#+P1CD8Z^U4%\6W\#PVU
MTVGM=RF)U10R;D>)W) +$X!4#/UX[4K@;'_"6:=_S[:S_P""6\_^-4?\)9IW
M_/MK/_@EO/\ XU7*6_C;57,UVSVTJPV<K?9XHU4/(&C^8-YK*0%?G#8QG)7D
M"QHOCC5=1UNUL9[&!8W?RW96BR_WOG7$[' VXPH<=?F&,55M;!?2YT?_  EF
MG?\ /MK/_@EO/_C597B?Q!:ZCX3UFRM;/69+BXL9X8D_L>[&YV0@#)CP.2.M
M'B/Q3?Z5>SQ6IL<QM'&MO.K&23>,^8"&'RCD$8/0\C&#=\2:W>:'I]NQN;"*
M4Q.\EQ<1L(F9%SL4;@06.<<G&#UJ;Z7';6Q8U#PS'J%[<SMJ5]##=QK%<VT7
ME>7*JY&"2A<9#$':PJG;^!=/MKMKJ*YN5F)4[PL0/RR!QD[,L<C&6R<?G63?
M>.[JW:.W1K%+IY)$*,,E  A0E3(H&=Q^\R@\<^LEKXNU2]M$NMVGVD#K K23
M1LRQ-(N2S$.!MXP!GJPYXY=[">J]39TGP=INB7DUU8$P22'EDAB4[=VXJ6"9
M8'IEB3CH0>:BUK4]/TGQGH\^HWUM9PMI]Z@DN)5C4MYEL<98@9P#Q[5S">--
M1L-$$PG@N)_)CD#R#<)!Y99L;I$ S]<^BM72>'/$EUJ#*=3>SC2>!)H?+!3;
MND9 A+,=Q)48QCKC%"UT!Z.Y=_X33PK_ -#+HW_@?%_\51_PFGA7_H9=&_\
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M2WT[3K6PEAELUG+7$;LVXNZX^5P,84=J]7KYT^/G_(]6/_8,C_\ 1LM (/\
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MZ@K:8X:19)(XUCE/ 5B90A.,D$DJ,9SG&89?B3I5M(7N(9([5XHI8)6EB7S
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MO"FC7D*136TGEH&&Q)Y%# OO(;##<-W//2D[VT!;ZE./Q-,/"M[JXL1(]LQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >(?M#_\ ,N?]O/\ [2KP^BB@:-SP7_R/7A[_ +"=
4M_Z-6OL.BB@&%%%% @HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$ Z<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M R4P.2.M=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<_XZ_Y$+7O^O&;_P!!-=!574]/
M@U;2[K3KH-Y%S$T4FTX.UA@X-*2NK#B[-,X;4M+T^RE\#S6MC:P2O?1AGBA5
M6;]PYY('->AUREIX%@M[[3[FXUW6KY;!_,@@NIHS&K!2H.%0'@$]ZZNK;O\
M>R$K6]$%%%%24%%%% !1110 4444 %%%% !1110!XA^T/_S+G_;S_P"TJ\/K
MZ9^*G@'5?'']D_V9<6<7V/SO,^TNRYW[,8VJ?[I_2O.O^%!^*O\ H(:-_P!_
MI?\ XW0,X?P7_P CUX>_["=M_P"C5K[#KP7P_P#!+Q)I/B32]1GOM):&TO(I
MY%CED+%4<,0,Q@9P/6O>J 84444""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX(\.66J2.[Z'K]K)#<9Y$%P-P1OH0,?GZ"II],BUGX=?#S3)F98[J]>)F7J
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M= >..<"JDOCCQ)ILNA+JV@VD2:O=1PQO#<EO*#=F!4?-SGC(Z]*HW?@RXL]
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MJTZI"Q,*A!N+ #Y0.^:],HHJG*]_5O[Q)6MY*P4445(PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '->*]*O=2O\
MPY+:0^8EGJ:7$YW*-D81@3R>>2.!S2>,M)O=631!90>:;;5K>YF^=5VQJ3N;
MDC.,]!S7344+2WK?^ON#K?RM^?\ F<O>:+>7/Q"AU'R?] _LF6U>4.O#LX(&
M,YZ9YQBN&M? ]S8Z4-%;P='>WJ,8TU&2\(M9$W<.Z"0,#CJH'45[#10M/Z\[
MC;O_ %Y6([>(6]M%"  (T" #..!COS7GIT[Q'I2>*-*L]%-V-6N9KBVO1<1K
M$@D0 AP3N!&.P.:]&HI/6]^H1?+M_5CA;;P]JL=WX"=K7"Z5:R1WA\Q?W3&$
M*!U^;D8XS3[WPK>ZGK7C!94\FUU6PAM[><L#E@K \ Y&"1U%=O152?->_G^(
M)V_#\#SB[A\4ZM:>']-D\.O;_P!G7UM+=W#7,11EC/+1C=DCOR >V":CU?PD
MUMXMU34IO#<NN6NHE)(VM[H1/ X7:58%U!4X!R,XKTNBAN^OK^/_  PEHK'G
MM]X5U)OA1=Z-;:9:P:A<,)!9VTIV*3(K8W.W)P.3D G.*W_%UC=7VBPP1:/:
MZM )5-S9SD!G3')C8D .#@\^]='12>O]?(%I;Y_B>;Z/X<U:+2_$<%K87EAI
MEU8-#9:;>78F<2E6!(.Y@BG(&"WO4C:=J&COX.N8889]4LM/:UETUKA$DE78
MF\QL3M)4@9YQ@]:]$K-UC0=,U^".'4[19UC;=&VYD9#ZJRD$?@:+O^OG_F'2
MW]=/\C@M/&JZWKGCU)K%8+J;3X;>*V697*DQR;59A\N[G)YP,]:UK_P]JDW@
MGPMI\=KFZL;BR>XC\Q?D$>-YSG!Q[9SVKJM)T73M#M3;:;:I;Q,V]L$DNWJS
M')8^Y-7Z=[6MY?A?_,+M_C^*L>::OX2:V\6ZIJ4WAN77+742DD;6]T(G@<+M
M*L"Z@J< Y&<59_X174[3PUHT]IIMG#J.FWYOCI]O*VQ@<AD#NQ^;:>N<$CM7
MH5%):+0'KN<7I<6MZC\0!K=YHTFGV"Z:UL@FFC:0N9%;D*QQTX^E:WC&UU>\
M\,74&B2,EZVW 23RW9-PW*K?PL5R :WJ*'JK?UO<+ZW/,-.\,W2^,=!U6P\,
M7&GVEL\HNIKV]66=MT9 /+L=H/OGGI5BWU34].^)/BS[#HLNIQLEIN$,J(R-
MY9QG>0"#S]/2O1ZJ0:99VVH75_# J75V$$\@)R^T87/T%._Z_C8.C^7X'F>M
M:7J7AWPGH6^**75)_$4=V\*OA/,D9VV!OQ S^-=);Z?J?B+Q5%J^HZ9+I=K9
MV<MM%%-*CR2/)C<WR$@* .,GDFNHOM,L]3%N+R!91;S+<19)&V1>C<>E6Z6E
MK?ULE^0/^OON>9KIOB>'P2_@I=$+L8FM%U+SX_(\HG&\C._.T_=QUK>M= O+
M/QY:WB1%M/@T060F++S() 0,9ST&<XQ77447_KY6#^OQO^AYQ'X7UE?@Q/H!
ML_\ B:,L@$'FISF8L/FSMZ<]:V-1T_4X/&^AZK;Z>]U;)9O9SE)$4PEF4[B&
M(R!@],FNOHIWUO\ UM8;=_Q_%W/*]=\-ZI=ZA?2P^&7AUQY6^R:SIEV((RI/
MRM*-^20/O#:<XXZUZ?;K*EM$D[B254 =P,;FQR?SJ6BDM%83U=SAX[77/".M
MZI)IVCMJVDZE.;L+!,B2V\I #@AR RG&<@\5/;V_B^_L-<OII%TZ[NH#'IUC
MYBN+<@'#LPXW$^F0*[&BE;2WR'?6YY$?"FI7!T2>W\+WD5]9WL$U[=ZAJ"S.
M^UAO\O,C<=_X>G -=9X]T36+Z"SU#PZJG5K8O$-S!08I5*OR2.AVM_P&NQHI
MO702T.)\0>']1L_">CZ5HJ7$MI9R1K>6]K.(9IX0#N"OD8).">1GUJAX9\-W
M=CXZ_M2W\//IFF2:>\'[ZZ668OO4@R?.QY XY;ISBO1:*+ZM][_CH'2QYQ'X
M7UE?@Q/H!L_^)HRR 0>:G.9BP^;.WISUKT.!2D$:L,$* 1^%244[[_UTL-N_
MX_B[G*:%X==-0\3-JEA$]O?WQDB\S:XDC,:CISCD'@XK.L_#&KQZ/KWA*<N^
MCRPLNFWKR!C&K#_5,,[OE/0XQBN\HJ;:6\K!?6_G<\HT_P (SL-.LG\%16]S
M!)']IOKB]+P;5ZM&JR;BQQD @8SS71?9]:\.>)=9N;'1Y-4M=6=)D:*9$,,H
M4*0^XCY3@'(SWXKM:*;=_P"NXK'FQ\,:X_P:ET*2R7^UW9F,"RIC)N-_#9QT
MYZUT6H:3?3^._#^I1P;K2TMKF.>3>HV,X7:,9R<X/05T]%.^M_ZVL#U5G_6M
MSSR\\(ZM>V/BF-8TBFN=4COK(R."LNP(1G!. 2I'-7)H=;\4ZYHCWFB2Z5::
M9<?:IGGFC<R2!2JJ@0GC))).*[>BDM+>7Z: ];G&:/H6I6NC^+H)K;;+J%]=
M2VJ[U/F(Z *>#QD^N*H0Z%K.CV?A+5(-/-U=Z78FTN[%)4#E65<E6)VD@KTS
MS7H5%'_ _!6&W??S_&W^1R'A:TUAO%.OZOJ>FFPAO4MQ;HTJ.V$5@=VTG!Y'
MY]ZG\<66K7VFVB:8EQ+"MTK7MO:S^3+-#@Y57R,<X.,C/K7444/IY"ZMGG7A
MGPW=V/CK^U+?P\^F:9)I[P?OKI99B^]2#)\['D#CENG.*;'X7UE?@Q/H!L_^
M)HRR 0>:G.9BP^;.WISUKT>BG?2W];W&G9W_ *VL<CKVFZE;:UHNOZ?9&^>Q
MADM[BT1U5V1P/F4L0,@KT)YI/"UIK#>*=?U?4]--A#>I;BW1I4=L(K [MI.#
MR/S[UU]%"?Z_B*VEO3\#)\3:4=<\,ZCIJXWW$#+'GL^,J?S KF=(\*:C<_#S
M5;#68UCU?53--.-P8+(W"<@D<!5[UWE%3;1KO_7]>@[[>1PNA>']8A^'6K6^
MHP#^W=32XDFC#J<R,I51NSCH%[XHMO#VJQW?@)VM<+I5K)'>'S%_=,80H'7Y
MN1CC-=U157UO_6B:_42T5O7\?^&/-;[PKK4W@WQ?81V6;K4-5>XM4\U/WD9>
M,@YS@<*>#@\5=\3Z3J=WXEAENM,U#5=%%J$CM;*\$&R?/)D&]-P(QSD@<\5W
MM%+^OPL-N_\ 7G<\IB\'ZXGP]\3Z0FD16\]Y?B>TMHIT*^63&<!B1T"GKCI7
M7ZAI-]/X[\/ZE'!NM+2VN8YY-ZC8SA=HQG)S@]!73T4[_P!?*PGJK?UNG^AS
M?AC2KW3M6\23W4/EQWFH>= =P.]-BC/!XY!ZU5\4>'KGQ/XBTBTNK=_["M=]
MS/(LVPO-C;&HVL'&,ELC\ZZZBEV\@[^9PMUX-.A^)M'UKPY:W$C+(;>_26\>
M0M P^]F5S]T@' ZU/H^A:E:Z/XN@FMMLNH7UU+:KO4^8CH IX/&3ZXKLZ*35
MTX_UJ-.SOZ?@<#8>'-6AG\ M):8&E6TD=[^\3]TQA"@=?FY&.,U/>>%;W4];
M\8+*GDVFJV$-O;S[@<L%8'@'(P2.M=O152?->_G^()V_#\#RC3_",[#3K)_!
M45O<P21_:;ZXO2\&U>K1JLFXL<9 (&,\UU<%CJ5E\2;V^%@\NGW]I%%]I210
M(6CW$AE)SSD8P#UKK**+ZW]?Q)MT.&\.G5O"OA;6H[O2"7LI9[F%C<HJ7*L[
M.,-D[>,?>'>NRLIVNK&WN&B,32QJYC)R5)&<?A4KHLB%'4,IZAAD&G4NGW#>
M]SSK6=$U*[\4ZC)J>B7NM6<H3^SEBOA%;Q#;AED3>O?))PV:@3PKK@^#$WAU
MK!!J8=@L"2IM(\_>"&SC&WUQ7IE%"T5O3\'<=];_ -=CF-<TF^O/$_A:\@@W
MP6,TS7#[U&P-$5'!.3SZ9K!^P>(M$TS7-!L=$:^CO9;B6TO%GC2-1+DD2!B"
M""3T!SQ7HM%)JZMZ_B"=K>5OP,OPU9SZ?X6TFSND\NX@M(HI$R#M8* 1D<'G
MTKB-7\)-;>+=4U*;PW+KEKJ)22-K>Z$3P.%VE6!=05. <C.*]+HJI/FES?UJ
M):*QYS<^'=;M/!>G6EGIZVX^V>?J&GZ9=-&SQ$G*+(S?>^[G!&><4GAWPQ=6
MWC5M0A\/OI>E3::]L?-NEEF+EU.7^=CDCIRW3G%>CT4N_P#72P?U^-SS_2(_
M%NAZ#;>&;32!YULPBCU1I8S;^3NSO*YW[MO&W'7O6SHVDWUIXW\2ZC/#MM;U
M;402;E.\HA#< Y&">^*Z>BG?O_7]6#I9?UK<YKP)I5[HWA6*RU"'R;A9YW*;
M@W#2,PY!(Z$5%XDT_4HO$6D^(=-LS?-9QRP3VJR*CM&^/F0L0,@KT)YKJJ*7
M6_\ 78._G_PYQFEZ9JNH:YK'B"_L#8M<V2V=K:/(K2;1N)9RI*@DG@9K9\(6
M%SI?@_2;"\B\JYM[5(Y4W!MK <C()!_"MJBCR_KK_F']?E_D<GJ]CJ47C_1]
M8M;![NT6VDM)BDB*8M[*0Y#$9& >F34&CZ%J5KH_BZ":VVRZA?74MJN]3YB.
M@"G@\9/KBNSHI6]UQ]?Q=QJ5G?T_ \POO!=ZVC^$KFXTG^T)-+L_LUYIXG".
M054$HX8 E2O3.#5S3?#-Q_9GB.2V\.1:4;RR:WM87N#)<2$J?OMO* 9(P.W.
M37H=%.7O7OUO^(HZ-/M;\#AI?#VJ-HW@>W%KF73+BW>\7S%_=!8BK'KS@GMF
MM6PTJ]@\?ZSJ<D.VSN+2WCBDW [F4MN&,Y&,CJ*Z2BFW=W]?Q$E96]/P,K0=
M6FUBVN99K/[*T-U+;A1*) X0XW9 QSZ=NE8OQ!T75=3TJUNM!C#ZM9RDP@L%
MRCJ4<9) Z-G\*ZU$6-=J*%7T48%.J6K_ -?U_3*3LSS:'P+?V?C/2UMXT_X1
M^*&":X.X9-Q C(G&<\Y4YQ_#6W:Z'J \3^+[IX0EOJ,$$=M(7!#E8V5N <C!
M(ZBNNHIO56?G^(D[;>7X'FUOH6NW/@[PMITNDO!<Z3J=L9U::,@Q1YW2 ANG
M/3K[5TDVE7K_ !)M=66'-BFER6[2[EXD,BD#&<] ><8KI:*;=W?U_%6#I;^M
M[A1112 **** "BBB@ HHHH **** "BBB@ HHHH *\ST?4+UO$WBC7=4L[T#2
M]_EI]NS'$JQ*WEB,'!)R3NQWKTRN1MO#]](GC*"9!"NJS-]FD+ AE:%4W8!R
M.0>OI2=U=KL_T*5G9/:Z^XO2^*H8M#T;5#;2%-4EMXD3<,H9>A/KC-<Y<WMV
M-9^(B"ZF"V]A"T($AQ$3 Y)7T.>>*JK8>*+W1_#6COX?>V72;NU:ZGDN8BLB
MQ'&8P#DC'S<X/;FM6?P_JCZKXYF6US'J=E%%9GS%_>L(64CKQR0.<4YI>];^
M];\+!3>JOY?^E?Y'0>$I9)_!VBRRR-)(]C"S.YR6)09)/<U2U;Q7+8>)8M L
MM(GO[V6V^TKLE5$"[BIW%NG3WZBM'PU9SZ?X6TFSND\NX@M(HI$R#M8* 1D<
M'GTKDM8O[_3_ (MPR6.FR:AG13YL,3JKA?.ZKN(!YQQFJG9U';:[_4B"]SY?
MY&U%XWL5\/W^IWMO/:2Z?*8+JT8!I%EXPHP<-NR,$=<T6?BRY_M6TT_6-#N-
M+>^S]DD>9)5=@,E&VGY6QS@_G6#-X1U?5-!UR[FBCM=5U&]BO8;9Y PC$6W8
MC,.,D+R1ZU>FAUOQ3KFB/>:)+I5IIEQ]JF>>:-S)(%*JJ!">,DDDXI+?7R_+
M7\0>SMY_GH27WQ%L=.\+'6[BTF!6\:R>V# NLBL0WY!2WTK7F\46<&K7%FX/
MDVUA]NN+G/R1H2<#ZD G\*Y>X\%7UWXZOO.A4^'ITEN@=R_\?,D0B8;<YZ9;
M.,<TWPUX,U>3P9K=EKS+%J>HQ?90X8,%BCC$<9X)]"Q^M3]F_6W_  /SN_0K
M2_\ 7K^6GJ;%OXWE)LKF^T*[LM*OI%CM[R25&Y?[A= <H&[=>HSBI)O&%PWB
MNYT"PT*YO)+1HC<3K*B)&C@'=R<G&>@YX-<EI_A&=AIUD_@J*WN8)(_M-]<7
MI>#:O5HU63<6.,@$#&>:['1M)O;3QQXEU&>#9:7JVHMY-ZG?L0AN <C!/?%7
M97^_]+"Z/Y?F=*S!5+,< #))KBS\0&^Q-K":#>-X?5RIU$2)G:#M,@CSN*9[
M]<<XKL9XA/;R0L<!U*DCW&*\W73?$\/@E_!2Z(78Q-:+J7GQ^1Y1.-Y&=^=I
M^[CK4=?Z[CT+/B26]U;X@:+IGV>[?3#;O<#[-?>2)>4^<X()"Y/'?-=SJ5_!
MI6F76H7)806T32R;1D[5&3@5@KH=U;^+]$N(HR]C9:9+:O*6 PQ,>T8SGD*>
MU;NIQW,NEW4=FMN]RT3"-;E2T3-C@,!S@]Z<M(V7G^8HZR3?E^6IAZ1XIOM1
MNK-+GP]=VMK?(7M[I94F3&,_/L^YD>O&>,U9L?%$-]8ZW=+;2*-)N)H'4L/W
MAC4$D>F<UQ^A>'+^V\1:=<Z9X>NO#R1N6U(?;%>VG&TC:D8<]3@@X&,58.G>
M(]*3Q1I5GHINQJUS-<6UZ+B-8D$B $."=P(QV!S1+9V[.PXVOKY?\$F\9>()
MG\+^&-9LTND%UJ-I*8(7P[JP+>7U .>F#Q6[IGBF2XU=])U72IM+O?(-Q$KR
MK*LL8."0R]P>HK$U70]<'@KPI;6-BLVH:9/:2S0-,J@>6A##=G'7CC-7;*UU
M?6_%T.MWFF/I<%C:20017$B.\DCD98["0% 7UR:J5DVEM=_EH+HK]OU_R':9
MXWN-4%I=P^'KUM)NYO*BO(Y$D8<D!FC4EE7CD]N^*CT[6M7G^)FKZ9-;R?8(
M+6(I^]7;'G=\^.IW8QZC%<VGAG5CJ5M+9>&WT761<JUUJ-E=A+.1 V6/E[R6
MW#^$KG)Y-=7%8ZG9_$B]OA8/-I^H6D47VE)$ A9-Q(92<\Y&, ]:G_@_E_78
M'U^7YG-77B.\M_AUH]YH27S)<:@L3/<7*M+CSR"I8]=QR >PKMXO$ ?Q-%H4
MMH\5R]A]M9MX(7YMI3CJ<]ZXV/POK=O\+M-T[[!OU&SOENFM1*F659R^ V=N
M2I]:U=1AUFU\7V'B>VT2>[2733:3VD<T:RP,7#C.6"D=C@T]+OU_]M7ZCEN[
M>?\ Z5_D-\3>+;L^#O$EUI4$D5SIL[VADWKE2 "9!G_>Z=:LMJ>[5_"*7\-[
M!>W23[8TN08\B/)\P#A\CD>A-947AO7[KP3XNL[NSCAU#5+J:>"(3*RD,J8&
M[\".<=/2M Z?JVI:WX.U*32Y+5+$7 NTDEC+19CVKT;G)';/OBB.^OE^3O\
MB#MT\_TL3W'C6<RW[Z7H%WJ-CI\C17-U'*B?,OWPBDY?;WZ>V:DU'QQ;6RZ(
M=/L;C4CK*LUJL+*I.%#<[B .O/I@UE6D'B+PS;ZKI-GH3ZC'<W,T]G=1SQJB
M^8<XD#$$;2>P.13K+PC?Z7=^!X8T$\.D1W"W<RL %9X\# )R06ST%*.MK^7Y
M.X/=_/\ X!T&@>(VUB[O["[T^73]0L6030/(L@VN,JRLO!!P:W:Y>PTR^L_&
M_B+57M_]%N;:W6!O,7]XR*VX=<CJ.2*UM U236M"M-1EM?LLDZ;C#Y@?;R1]
MX 9Z=:-U_7F)Z/\ KR(M;UJ;2VM8+33+G4+NZ8K'%$0JC R2[GA1^I["L^R\
M91O;ZR=4TZ?3KG1T$MU"667Y"I8,K+P<@&JGC73M4OK_ $MH[6]OM'3S/MEG
M8W7D2NQ V-G<NY1SQN'6LSPSX<U?3+WQ--;Z':Z=#?V\7V."XE$R%E5@5EVM
MDDYR>HYZFET?S_0>FGR-[2/%-]J-U9I<^'KNUM;Y"]O=+*DR8QGY]GW,CUXS
MQFMC6[FXL]$O;FTB,MQ%"S(H8#D#KD\<=?PK@-"\.7]MXBTZYTSP]=>'DC<M
MJ0^V*]M.-I&U(PYZG!!P,8KT:_@:YTZZMTQOEB=%STR0114^!V\PA\2OY'F%
MYXAU<_#SPEJ=PMW]IDU*UWB*4%[I2"3T('S?W37::3XIFN]<ET?4])FTR]6W
M^U1J\R2+)'G!.Y> 0>HKF;?0M=N?!WA;3I=)>"YTG4[8SJTT9!BCSND!#=.>
MG7VKH;S1;RY^(4.H^3_H']DRVKRAUX=G! QG/3/.,5<MW;N_R5OQ$ME?M^O^
M14/CXFU?5DT.[?P^CE6U$2)]T':9!'G<4SWZXYQ79(ZR(KH0RL,@CN*\?M?
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MK1(65"<*&YW8 Z\^F#7-:!J>N0/XLM-.T)[Y9=7N5BG6:-%C<XSY@8@X'!R
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M_P"$TT;_ (1NXUWS)A:VS^7.AB(EB?<%*LAY!!(K1NM7M;/4=/L92_G7Y=8
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MU0.>"VW'09->JT4T[._];6!ZW^?XNYQW@[3KJ%/%*3P36YN=7N'B:1"N]"%
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M[5-)U2:.VE<V=U9VK3I/$S%E&5^ZPS@@T[5K;Q+XE\$W\UU8>5,UY'<V>GL
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M' R*62WO-<N_%>N6^GWD-K<:0;*VCFA9)+AP')8(1N[@#(YKT>BB?O7OUO\
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M?Y&AXB\7QVW@"Y\1:*WVH&(F!UC+!3TRPX(P<YST-6Y/%=G9:+87EY%=B>\
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M,>_Z''6L6/3=3U2W\6>(KK3Y[:34-/:UL;)US,(U1L%E&<,S'[O6EU#3;YO
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M-E!VKSC)J30;.YB^(/BN[DMIHX)TM/)E>,A9,1G.TG@X/7'2E';[_P!+#?\
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MIEY%<Q*Q1BAY5O0@\@^QH O45Q7BKXA:5I6E:BNG:I9R:K;#"0L2REP0"N>
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M+V[U'0(;N\O[:]DE)82VT)B0#^[@DG@YYJI>^,+6S\<67AQC&#/ TC.<Y#Y
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M%'6P>9T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6;K>AVFOV26UV9D,<BS0S02%)(I!T93V/)K2HH Q-&\
M,6FCW<UZ;J\OK^9!&]U>RAY-@.0HP  ,\X %;=%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5YOH,$3:#\06:-29-1O5<D?>
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M$C_&F!V4%DT)BI(Z'SL<?@33_ @"WWBQ% "C6I< =!E$)KLJ*2T^[];C;O\
MA^"L<3XZNX-.USPG?WDJPVD-^_FS/]U,Q,!D]N:/#\<3_$[QC*45F\JS4-CG
M!C.1^@KM64,,, 1Z&EH6B^_\;?Y W^GX,\4$%R?AGH%Q%*T%G9:S)+<R+")1
M#&)9 '*=U4D''X]JZ7PW+#J?CV.]A\1/K4D%D\<D]O9HD"JS A&=6Y;(R!@]
M^E>C4U$2-=J(JKZ*,4T]?Z[)?H*6O]>=S*\5_P#(GZU_UXS_ /H!KSK^U-)U
MGP1X8T+1W5]72:T9;=%/F6Y0J7=A_",;N>^?>O7*:$4.7"C<1@G')I+1_=^
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M&!!_$4 /HKFO%_B^#PSH%QJ,"0WLL$B1O LP4C<P7G ..OI72*=R@^HS1TN
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M(MH< G+'C(!Z4 =%14<T\-O%YL\L<2#JSL% _$TJ312PB:.5'B(R'5@1CZT
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M23U[UC6'P_\ #&F:FFH6FEJD\;%X@979(F/4JA.U3]!57]^_3^OS$E[EGO\
MU^1S%S:CQ7\3]9TG5KV[BL].M(FM;>"X:$,6 +2':1D@G%87BK2]/O+#P6L6
MNW.K1?VJEG]K\\@E2>>1_$.F[K7I6O>"O#_B:>.XU73UFGC78LJR/&VW^Z2I
M!(Y/!]:+[P7X>U'1+;1KC38_L%LP>&*-F3RV&>05(.>3WYS4QT2\K?F_\RGJ
MW_70Y7Q%$VI_$/1?"=S?75MHZV!GV13M&URX) 4L.3@#-5]#N;K3[WQQH$%_
M<7>FZ?;;[:264N\+-&24WGG@_EBNUU7PAH6M:?:V.H:>LT-JH6 [V#Q@  8<
M'=V'?G%2Z9X8T;1](ETO3[!(+28$2HI.9,C!W,3N)QWS2:NFO7\=ON!-73]/
MPW^\X?P+HTQ\ +X@DUFY&JW5A+&MS=7!,4 R0IP>!C .>O)KG] EG\/ZMH<V
MMV>K6[3S+$FJ6>J_:K>^9NF]22-IZ\5[#8Z-I^G:/'I%M;*MA'&8U@8EQM/4
M'<23U/6L?3_A]X8TR_BO;73,2PL6A#S2.D1/=49BJGZ"KO[]^G]?U^9*7N6>
MYT8FB,IB$B&0#)3<,@>N*Y7XAWUI:^'HH;NXU*(W=S'!%'ISA)9G)X3<>@..
M3D5IP:!'%XPNM?(19);5;8!2Q+ ')+9.!V P/7/M9UO0=,\1:>;'5;5;BWW!
MPI8J58=""""#]*AZI?UU*3L_Z['G?@G[9IGQ/U#2##<V5FVFK.+*:^-UM;>
M&+$G!P3P"?K6%;Z=+J7P]\3ZU<:IJ7VRPO+DVA2[=5BV$'@ X.>G/3MBO5=+
M\&Z#HNHC4+"Q\J\\HPF;SG9G4G)W98[CD#DY/%20^%=%M]'O=)BLMMC>N[W$
M7FN=Y?[QSG(S[$4WMIO:WXW_ "$M_G^ECSTSW'BKQ1X4TG5KZYCL9M%6]=(9
MFB^T3$<Y*D$XZ\>]7_AO;QVGC?QM;Q74ES'%/ BRRR;V( 88+=R.F3Z5UNI>
M"O#VK:=96-YIP>"Q4);8D=7B4   .#NZ =ZL:-X7T7P]-<RZ38I:M<A!+L9B
M&VC"\$X'4].O>JNKM^OXN_\ P!=$O3\#D_C3D_#R7!P?M4.#_P "K9T+3/%]
MM=B35_$%I>VGE$"&*S$;;L<'=[5M:UH>G>(=/-AJEO\ :+8NKE-[)R.0<J0:
MO@   =!4I:-=_P#*PWK;^NIYM\'+BW@\/:CI\[K'JEO?RF\1SA\Y^\?;C&?8
MU3\-R1WGB[XAWU@0VFO$$$B?<>4(=Q![\Y_.NOUSX>^%?$5[]LU+28Y+D_>E
MC=XR_P#O;2,_C6O8:'IFEZ4=+L;**WLBI4Q1C&<C!R>I)]>M*6J?>UOPM^@[
MV?SO^-SQ#3+OQ?I7PBLKRSO;<:&_F1W"Q6V^X@C:1@S#)PW.?3&1]:]B\&6.
MFZ=X0TRVTB=KBQ$(:*9NK[CN)/H<D\=JMZ?H.EZ7HBZ-9VBIIP5D\AF9QM8D
ML"6))SDTNB:%IWAW3ET_2H&@M58LL9E=P">N"Q)'TJV[M^9-M$<)XO1K[XL:
M!I4NHW5K9W5E*)4@G,?F?>^7(/?'UKG[^YN]%L/B!H=EJ%U+8V$4,ML[S,SP
M,Q&Y0Q.?_P!7UKLO$O@M_$7C[2K^[M8;C2(+22*<.^&#'.TC'.02.1TK:MO!
M'AVST*ZT6#356QNSFX3S'W2G.>7SN_6L[>Y;U_,NZYON_(Y"]M[OPE\++[7;
M*]O+C5KNS@>:>:4OL9L LH/"X#'IZ"L_4;$>$8/"NKZ+K-]<WE_=0PSI-=-*
MMXCC+':21^(Z9KU<6-K_ &>+ P(UH(O)\IQN!3&,'/7CUK"TGX?^%]$U(:A8
M:5''<KG8S2.XCSUVAB0O4]*TO[[?2_X:Z$)>XD][?CW^1R5S9+KOQDU;2+W4
M;R.R_L^.06T-RT8D8;?0]LYXK-L_$6KZ3\-_%ZVEY-='2KY[6SNY&WNL98#.
M3UV@YS727G@!-:^(FIZIJ]G%/I<]G''"PE*R+(,9(VD%>,\YKKM/\/Z3I>C?
MV19V,,>G[2K0$;@P/7=G.<^]0E[EO+]7^GYEW7-?S_3^ON/,M1L1X1@\*ZOH
MNLWUS>7]U##.DUTTJWB.,L=I)'XCIFG^,;'5KGQAJ$XMY=<L$AC"VUAJI@FL
M..6,8/))R1D'-=OI/P_\+Z)J0U"PTJ..Y7.QFD=Q'GKM#$A>IZ5)K'@CP]KM
M\;V^L";EDV/+%,\3.OHVQAN'UIRUV\_Q_K_(F.F_E_7]?,XBYUO2M;\+>%[.
M&Y\17KWCNL-JMPD4MSY?#":3Y>!Z@\TO@B6\AD\<Z5<>='!9JOE6TET;CR=T
M;Y <]>@KN+[P5X>U#3[.QFTU%@LCFV$+M$T1_P!EE(//?GFI--\(Z%H[7C:?
MIZV_VV,1W 61\2  CD$]>3R.3GDT2U4O._XVL-:6\K?F><64.H7/P1\/PZ;?
M0V\S3#=%)=?9S=+YC9B5\C!)QT-:WP_O([/Q/>:/<V&L:5?O;";[!=7GVFWV
M@XWHQ^8$_7%=BWA#07\.QZ ^G(^F1?ZN%G8[#DG(8G<#DGG.:71/">B^'II9
M].LRD\P"O-)*\LA [;G)./:JO[S??_(FWNI=O\S:HHHJ1A1110 4444 %%%%
M !1110 4444 %%%% !7%ZK\3-(TO4KJT%CJEY'9,%O+JTMM\-L?1VR.G>NTK
MS7Q9J::MJ%YX*\-PVL5Q=#.JWI"JD"-US_><C^?Y+6]D-6MJ>B6EU!?6<-W;
M2"2"9!)&Z]&4C(-350TVVL]'TFQT^"5!##$L,.YQEP!@?4U?JG:^A*O;4XW5
M?B7H^DZC<VKVFI7$-FXCO+RWMM\-NQ[,V?Y UU\,T=Q!'-"X>*10Z,.C C(-
M>?>/F@UKPKJYTG6;>*'3RYU*U6,?Z05P?+9^"O0CCKFNL\.ZE;7GAG2+I8TM
M$N+:,Q0%ONY484>M*.L?ZZ_UH.6C-BBBO+?%8MM;\4ZK:VL6KZA=6%JOF1K?
MBUM;0D$AA@AF8]3PW^";L-*YZE17BUUJVIW'P$TF]:_N!>-<I']H#G?@2LHR
M>_ '6MPV#>&?BMX?M[*^OI(=3MI_M:7%R\HD95R&^8\'..GX5?+[W+YV_"Y-
M]+_/\;'I4TH@@DF8$K&I8@=< 9K-\-Z_;>)]!MM8LXI8X+C=M28 ,,,5YP2.
MWK7G-E:#Q+J?C34=6U6]@N--N)(+98[IHUMHU4X;:#@YQSG@\UTGPB_Y)CI'
MTE_]&M2CJF_)/[[CEH[>;7W';USV@^,=,\1ZQJNG:=YKMIK*DDQ V.3D?*<Y
M."I'05G?$?5M0T[08K;3K:\=[Z7R)9[2$R/!%_&P [XX'UKCOAA?:=:>/]>L
M-/TV_MK:=(%A66W*F()&<^9_=)ZC/7-*.K?S_0):*Y['13(YHIE+12(X!P2K
M X/I3Z *&L:C+I=@;F#3KJ_<,!Y%J 7.>_) XKE;;XBS7EW<VL'A'77FM65)
MT"1YC)&1GY_3FNYKCO"G_([>-/\ K[M__1(H6_\ 7D#>G]>9N6.NP7^NZGI*
M12K-IXB,C-C:WF*6&.>V*LZI?/IVG2W<=G<7CQXQ!;J"[Y(' /US^%<%!X<T
M_P 0?$OQ:NHB>2*..T"Q).\:DF,_,=I&2,<9Z9-9\VH7DGP&N9I+J9YX7,*S
M%SO*K<;1D]<X %-:I?+\78KE]ZW];7/6 <@'&*6O._%NG7E_XDADCLX]=M8;
M-1)I4>HFWE@8L?WH&0&R..<=.*Z+P1>6UYX7@^RRWTBPN\+B_(,T;*Q!1B.N
M.@//&*2U(OM_72YT5%<5\2 TEAHD NY;5)]8MXGEBD*,%.X$9'2HK:SB\.?$
M2RTW23*EG?6$LES;-*SJC(5VR#<3@G)!]:/^#^"N-Z?UYV.ZHKR3PO:G3?AE
M>^+89;F?6A:W0266=W"A78 !"=O&W/3UJUJ6E6WASPSHWB+2[NZ;57FM=\SW
M3O\ ;/,90ZL"2#D$GIQCBG;6WI^(2TO\_P #U&BO+/'E]<:#XC9=+U*2!-4@
M U,*K/\ 8XPP7[0,?=."1^O:MO7H8O#$GAS6+.9QIUI(+.ZS(65H9> ['OAM
MIS[FDM5?Y?U^']('H[?/^OQ_IG<45RG@EI=2BU+Q!,SE=3NF-NK$X6!/D3 [
M9P6_&KGC2]AL?"E[)/=7=LKA8E>S ,Q9F "IGH3G&>V>HH>@+<WZR]%UV#6V
MU$0121_8;Q[-]^/F9<9(P>G->>Z;!-H_C[PZD.C7.BQ7HGCECFU'SVN L98%
MD!8 @X.<YYI]I%<7'AGQI!::A#8W$NO3(DLTWE*Q)3Y-PY!;[O'/-.W7^MTO
MU';3[OU_R/4Z*\V\,NFC>(9+.71M0T6_FLY'CLS>?:;6XV$$NK9)#=/3@\UF
M)I\,WPO?QD]_=#7_ "&O!>_:7&V0,<1A<[=O\.W%+SZ?\&PEJ[?UM<]<HJMI
M\\ESIMK/,FR66%'=?0D D5Q?BS[/J?BJ'318:CK$T-KYC:?#<""",,V!([%E
MRW! '/TH:L[!%IJYWM%>9>&KBZ7X>^+[=VDC-E-=PPQ&Y,Q@41@A!(>2 2<&
MI[V\D3P+X&;[0XEGN]/4G><OD D'U]Z=M?N_$=OU_ [>+6+2;6;G2HV8W5M"
MDTHV\!6SMY[G@U%X>UR#Q'HD&J6T4D44Q<!),;AM8J>GN*Y;2M+LT^+>OW"Q
M,)4LX)%/F-PS[PQQG'^%<98:);6GP=;Q)#+=)JML[S03K<.!%B<C:JYVX/.1
MCG)I1U5WY?FT.W1=_P!+GN%%<'>6Z>)?'YTK57E:PMM,CN8[5)6C661V(+MM
M(W8P /3-<YJUU=67@GQMI=O>7#6VF7D4=G,TI9XU8QL4W=3M)(Y.>:/Z_&Q*
MU:_K=7/4]0OGL1;%+*XNO.G6$^0H/E@_QM_LCO5RO.O$&CVWAK3?#\.G27*_
M:-=M6F>2X=VD)R#DL3UQR.E,\8:'INKZ^=*TN&=M<N\27-R+R<1V<73S"@<+
MN.,*N.3R>*=NW?\ R#HGY?J>D45YIXJM[FQO_#'A6RM[F]T]XI6E@-Z87N2@
M& TAY/4L1WIVCQ:G8+XDT\S0Z':?8Q);QSZDLYLI"""Y.=R(>#SQD'%+HVO/
M\ [7\OQ/2:*\K\.PC0O$&CIJ>E7^F7-P3"EY;:A]IMK]RF?G#$D9P2.,Y[XK
MU2FT),**\=CCU/Q'+KVH7&D7%W/#>SP072ZO]F%FL9PH5,C&/O$GKFMC4;V3
M4M&\+V6HB\U34;B%I9+'3;E%BN]JX+O*& V@D'@X)/2DM5]WXE/1_?\ @>E4
M5YUX$DN;+7/%&G?97M(K98)8K W9N!"S(Q(#'IG ..@JIH>DZ=J'@NT\5ZEJ
M]U:ZI(XN)=2^T/\ NV\S'E[2=NW^';C%.WZ?B+^OPN=Y8Z[!?:]JFD1Q2+-I
MPB,CMC:WF*6&.<]JU*\UM_#NG^(/B5XL&HB:2*.*TVQI.\:DF,_,0I&2,<9Z
M9-;_ ,.+JXN_!%FUS-)-)')-"))#EBJ2,JY/<X H6J^2_4<M'I_6B9U=%<AX
M[FF8:'I@N);>UU'44M[F2)RC%-K-L##D;B .*H1Z;;:%X^M-$TXS#3=3L)VN
MK0SNZH5( <9)*DY(X(I+7^NRN)Z?UYV.AT/Q*->O;Q+?3KJ.SMY'B6\EVA)7
M1MK!1G=USR1VK1U34[71M+N=1O7*6UNADD*J2<#V%<I\,M-M++0KR:",J[W]
MS&Q+LV565PO!/I5KXFVT5S\.]8\U2WEPF1,,1AAT/%*6B5O+]/\ ,<5>5O/_
M #_R-:Z\0VUKJVCZ>T4K2:J)#$P PFQ-QW<^A[5KUYGKVB6<^N^ M+'G16A6
MYW+',ZL1Y08C=G=@]^>AI(YYO"MQXZM-):7[/8V45W:PR.T@B=D8MC<2<9 .
M*J5E?Y_@P2O;T7XGIM%>/6=IJUE9:-J]KISVEW)+"TVI7.MJRW:OC<K(QP=V
M>!V.,5[#0U8E.X45YY!HMGX@^(WBB'4YIYH;=+;RK87#HJEH^7PI'/'![<UA
M3ZUJ\G@C2[".6>Y2?6I-.,PN/*DN($9MJ^9V+;0N[KQ[TEJE\OQ=BFK/^NUS
MV"BO._#=KJ&D^,$MDTX:5I]Q:.TEE)JBW!9U(Q(BD[AZ$CCD9JAX*T:)OA_/
MKS:G-;ZK/;W,0OKFZ?9 N]@IP3M & <XSR:'M?\ K>P)?G^ESU.BO*_#L(T+
MQ!HZ:GI5_IES<$PI>6VH?:;:_<IGYPQ)&<$CC.>^*UK?2[;Q;XP\1Q:T\\L>
MGR106MNL[QK$I0,7 4CYB3U]J;7Z_A_PY-_T_$[ZBO'Y[R^U'P5HUK+J%T0O
MB06"7:2D22PAW4'<.IQQGVKH["Q@\.?$@Z;ITDL%C=:2]Q+'),TBB19  _SD
MX.#S2\_ZVN5;^OG8[VBO';"%]$ET_4-8MKQP;I"/$>FZEYT=SN? $D;'A#D
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MNK2X8QWW]K6XV)QD2(0/EYXQTP:M>$XM4UCQ#K5_=Z[?_9[#5I[>"R1E$10
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M;Q>2MU:LNYH_[K!@0PSSTX-6M"T"UT"VFC@DGGFN)3-<7%P^Z29SW8@ =@,
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M$'_H K/OO =I>37XAU34K.SU LUW9VTBB.5B,%N5)4GO@\UT.F6$6E:7::?
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M8XZ5/37^M?\ +_(?73^M/\SE](U:\M?&NB6UO=^(Y+*_$R3#68@JN50L&C!
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M>321F\BNK5?LKQMC?L Y7 .01Z<YIK5V]/Q$]-_/\#UBBD/W3]*\@M[K7O\
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MIHMQJ[W:M8V[F.26,%P&#;2..OS<<5J@@@$=#7BWV-K?X(:\XNKB4O>.H$K
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MIXATU+=/%%S:7#&.^_M:W&Q..)$('R\\8Z8-0:-!-ID?Q"O(-0O&F@EF";Y
M1N$(8/T^\.F?2DW9-^3_  M_F.*NTO-?B>D6=W%?64%W 6,,\:R(64J=I&1D
M'D5/7FMQJ&L:@O@&TBU>YM3JEJ[7<T6W>^(58GD$9Z\XXS4L>M:CX:;QE:->
MW&HII5K'=VKW9#."Z,2K, ,@$54ERM^5_P !)-I?+\3T6BO,]3M]:T;2] U1
M/%&H3RWE]:I=QRLACD$C#(0!?E'L#TKTRAJWY"O>WF%%%%(84444 %%%% !1
M110 4444 %%%% !1110 5SO_  A]H+W69EO;U(=7C9+FV#KY89E"EURN0V!Z
MD>U=%118:;1A1>%+"*;09%EN=VB1-%;99?G!0(=_')P.V.:F@\.6=O=:S<))
M.7U<@S@L,+A-GR\<<>N>:UZ*'KOY_CN+M_6QS4W@G3WT?2K&"ZO+>;2E"V=[
M$ZB:/C!R=NT@CJ,8-6]#\-P:+<75VUW=7U_=;1-=73 NP7[J@* %49/ %:=S
M>6UDL9N9XX1+(L2%VQN=NBCW-3T[O<+=#-\0:':^)-$N=)O7E2WN H<PL W#
M!N"0?2L[3O!\%GJD%_=:GJ&HO:*5M$NY%9;<$8)&%&3CC+9.*W6N[=+R.T:9
M1<2(SI'GYBHQDX].1^=4F\1Z(NJ#3&U>Q%^3M^SFX7S,^FW.<^U);Z ]M3(N
M_ UO-=7LEGJ^IZ=!?L7N[:UD01RL1AF&5)4GN5(S6DWAG3MNC)$)(8M(??;1
MQD;?N%,-D$D8)].:TC=VXO!9F9!<M&9!&3R5!P2/;)'YU-0M >ISFH^$8[O5
M9M2L=5U#2[FX54N6LV3$P7@$AE(W < C!I?^$+TI=)TS38O/B@TZ[2\C*N"S
MR*2<N2#G)))Z?A7144+38#'UWPY;:[]EE:>XM+RT<O;7=LP62,D8(Y!!!'4$
M<TW0_#<&BW%U=M=W5]?W6T375TP+L%^ZH"@!5&3P!6U37ECC*AW52YVKN.-Q
M]![T+0'J9OB#0K?Q%I9L;F6:$"1)4E@8!T=3E2,@CJ/2H[;P[!!KD&L/=74]
M[%8BQ+2,N'7=NW$!1\Q/IQ[5K>;&93%O7S -Q3/./7'I3J%IM_70# _X0_2G
MLM8LYQ+/!JUPUQ<+(P^5R /E( QC:".ISWJ#3_!L=MJ5K?7VKZEJDEF"+5;Q
MT*Q$C&["J-S8XR<UTU%"T!Z[@1D8KFAX(TU?"47AL3W?V..42A]Z^9D2>9UV
MXQGVZ5TM5_MUK_: L/M$?VLQ>=Y.X;]F<;L>F>,T+^OEJ'2W]=BG<:#:76O0
MZQ*TIGBMGM1'D;"CD$Y&,YX]:YV3X:V4^CMHLVM:NVD#_4V8E0+%SD?-LW,
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M7Y_-%YIZLL05@$;(/WAC)QDXY'6DT/PGIGA^^U6[LED\W4Y_/GWD$ \\+@#
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M9Y]JTM*T;68]3;4-9UPW;B+RH[:VB,,"Y.2Q7<=S>YZ=J;W?]=%^HG_7WO\
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MNFQPR([VHE=F=,[>2!C(.3UZ8KND4(BJ"2 ,9)R?SK$L_#OV3Q!KFJ_:M_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1H6OR21:5JMK=R1C+)&^6 ]<=<>]0^,]9N?#_A#4M5LUC:XMHPZ"4$J3D#D
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M>4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445G:AX@T729U@U'5["SF9=XCN+E
M(V*Y(SAB#C(//M0!HT5A_P#":>%?^AET;_P/B_\ BJGL_$^@:C=):V6N:9<W
M#YV0PW<;NV!DX .3P"?PH U:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *R-9T&/5KK3+L3&"ZT^X$T4@7=D$89"/1
M@<?E6O10 A4,,, 1Z&EHHH 0* 20 ">OO2T44 (0&&" 1Z&EHHH *0@'J ?K
M2T4 %(%"YP ,]<4M% "8&<X&?6EHHH 3 SG STS2T44 %( !T 'TI:* "D
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M** "BJ.HZUI6D>7_ &GJ=G9>;GR_M,ZQ[\8SC<1G&1^8JC_PFGA7_H9=&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
